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Summary 
The 28 amino acid hormone, ghrelin, has been found to have various effects on 
metabolism. This thesis focuses on the pathways integrated into ghrelin’s effect 
within adipocytes and adipose tissue depots of those with and without Type 2 
diabetes. To determine whether acyl-ghrelin plays a role in mediating the metabolic 
state in an in vitro and ex vivo setting this thesis investigates cellular mechanisms 
via the analysis of: lipid staining, lipid retention gene expression pathway, 
inflammatory marker levels and determination of oxidative burden. This project 
confirms and translates previous murine model findings that establishes a 
mediatory role for acyl-ghrelin within lipid retention.  Furthermore, this mechanism 
is influenced and magnified within the presence of hyperglycaemia, indicating that 
the impact of glucose metabolism on acyl-ghrelin and lipid homeostasis may result 
in the deterioration of dyslipidaemia. In addition to novel findings relating to lipid 
retention, results indicate that acyl-ghrelin also impacts the inflammatory state. 
Acyl-ghrelin exposure resulted in a marked decrease in pro-inflammatory marker IL-
6, and ghrelin mRNA expression was associated with an increase in IL-10 and total 
antioxidant status. The promotion of the inflammatory state in the presence of 
acyl-ghrelin may yield novel therapeutic avenues for acyl-ghrelin combination 
treatment in the amelioration of the low-grade inflammation present within Type 2 
diabetes. 
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Chapter 1 
General Introduction 
 
  
2 
 
1.1 Diabetes Mellitus  
Diabetes Mellitus (DM) is a multifactorial complex carbohydrate metabolic disorder. 
Individuals that have DM normally exhibit abnormal blood glucose levels due to 
insufficient insulin levels or activity. DM is separated into four main groups: 
1) Type 1 diabetes mellitus (T1D) - accounts for 5-10% of all diabetes diagnosis 
(American Diabetes Association, 2016) and is due to cellular mediated auto-
immune destruction of the pancreatic β-cells. 
2) Type 2 diabetes mellitus (T2D) - accounts for 90-95% of all diabetes and this 
form encompasses individuals with insulin resistance and relative insulin 
deficiency.  
3) Gestational diabetes - diabetes diagnosed within the second or third 
trimester of pregnancy and is not clearly overt diabetes. 
4) Other specific types of diabetes - condition caused by other factors i.e. 
monogenic factors, such as neonatal diabetes and maturity onset diabetes 
of the young (MODY) (American Diabetes Association, 2016). 
 
1.1.1 Glucose and insulin homeostasis 
Serum glucose levels, in a healthy state, remain relatively steady throughout the 
course of the day. To allow for this plateau, glucoregulatory factors, derived from 
many tissues, are responsible for glucose homeostasis (Plum et al., 2006). The 
circulation of glucose is dependent upon the rate in which it enters the circulation 
and the balance of its removal. Circulating glucose is derived from various processes 
3 
 
i.e. intestinal absorption and hepatic processes involving glycogen breakdown 
(glycogenolysis) and glucose formation (gluconeogenesis) (Aronoff et al., 2004, 
Plum et al., 2006). The pancreas plays a fundamental role in glucose homeostasis. In 
a fasting state, pancreatic α-cells secrete glucagon at an increased rate, whilst β-
cells secrete insulin in the presence of elevated glucose levels. This allows for a 
decrease in glucose levels by promoting glucose uptake within peripheral tissues 
(predominantly adipose, skeletal muscle and liver), promoting liver glycogenesis 
and inhibiting glucagon secretion from α-cells. In addition to glucose, insulin 
stimulus can be in the form of increased plasma concentrations of certain incretins 
i.e. amino acids (arginine) and gut hormones (gastric inhibitory polypeptide (GIP) 
and glucagon-like protein (GLP)-1) (Aronoff et al., 2004).  However in DM, this 
highly regulated balance of circulating glucose is hindered due to an insulin 
response deficiency (Aronoff et al., 2004).  
 
1.2 Type 2 diabetes 
Research has shown that patients with T2D are highly likely to be overweight or 
obese. The LEADER 5 study demonstrated within nearly 10,000 individuals with T2D 
there was a high prevalence of overweight (29%) and obesity (62%) (Masmiquel et 
al., 2016). An excess of abdominal fat is thought to result in the release of pro-
inflammatory cytokines leading to insulin resistance. Obesity is a global epidemic 
which will result in an increase in the number of people with T2D rising from 415 
million in 2015 to 642 million in 2040 globally (International Diabetes Federation, 
2016).  T2D is a progressive condition linked to both environmental and genetic 
4 
 
factors that prevent the maintenance of normal glucose homeostasis due to insulin 
resistance and β-cell dysfunction (Popa and Mota, 2013). T2D is the combination of 
three main aetiologies: insulin resistance, β-cell dysfunction and β-cell destruction. 
 
1.2.1 Insulin resistance 
Insulin producing β-cells are situated in the Islet of Langherans in the pancreas, and 
predominantly respond to blood glucose levels by the synthesis and secretion of 
insulin. Insulin is initially synthesised as a single chain precursor, preproinsulin. A 
signal peptide is removed when it enters the endoplasmic reticulum generating 
proinsulin; and finally the C-peptide molecule is excised to produce the mature 
form of insulin. Secreted along with insulin is a neuroendocrine hormone, amylin, 
complementing insulin’s action. Obese individuals classically display the onset of 
insulin resistance which is counteracted by increased insulin secretion and β-cell 
mass, avoiding the onset of T2D (Popa and Mota, 2013). Insulin resistance develops 
due to the body’s inability to utilise insulin efficiency. Individuals at risk of T2D 
display an initial state of insulin resistance that is often counteracted by pancreatic 
β-cell overproduction of insulin. The early stages of insulin resistance can occur up 
to 15 years before T2D onset. Ultimately an increase in hepatic glucose production 
becomes too great for insulin reserves to cope with, resulting in an increased need 
of insulin secretion. The combination of insufficient insulin levels and insulin 
resistance leads to the development of hyperglycaemia. The molecular 
mechanism(s) that underpin insulin resistance have not been clearly defined. 
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However, it is associated with body mass and inversely correlated with physical 
activity (Tangvarasittichai, 2015).  
 
1.2.2 β-cell dysfunction and destruction  
In genetically predisposed individuals, β-cells can develop a change in insulin 
secretion threshold, with a reduction in insulin gene expression and a decrease in β-
cell mass.  It is a combination of insulin resistance and genetic predisposition that 
results in an increase in glucose and free fatty acid levels. Chronic exposure of β-
cells to high glucose levels can result in apoptosis via the increase of pro-apoptotic 
gene expression (Popa and Mota, 2013), as well as glucolipotoxicity causing β-cell 
dysfunction and destruction via the production of islet amyloid polypeptides (Kahn 
et al., 1999). In a high glucose environment, there is an increase of toxic amyloid 
fibrils, resulting in amyloid fibril accumulations and ultimately β-cell dysfunction 
and destruction (Popa and Mota, 2013, Kahn et al., 1999). 
 
1.2.3 Related complications 
T2D is a heterogeneous disorder that results in a vast array of related 
complications. T2D can result in insulin resistance, inflammation and dyslipidaemia, 
which when combined add to the risk of further related complications. 
Complications can be grouped as either; macrovascular (e.g. cardiovascular disease 
(CVD)); or microvascular (e.g. diabetic nephropathy, retinopathy and neuropathy). 
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The level of glucose that can result in endothelial dysfunction is relatively low, 
therefore, patients that are yet to be diagnosed with T2D are still at an increased 
risk of developing macrovascular and microvascular complications (American 
Diabetes Association, 2016).   
Previous findings report a linear correlation between exposure to high 
glucose levels and the risks of vascular complications and mortality (Zoungas et al., 
2012). The association results in approximately 80% of individuals with T2D being at 
risk of death from associated cardiovascular complications (Martín-Timón et al., 
2014). CVD encompasses coronary heart disease (CHD), stroke and peripheral 
vascular disease (PVD), all of which are the result of atherosclerosis and 
inflammation within arteries. This increased risk results from hyperglycaemia 
triggering dyslipidaemia and increasing oxidative stress (Stephens et al., 2009), 
activating numerous biochemical pathways linked with diabetes-associated vascular 
disease (Johansen et al., 2005). 
Microvascular complications develop as a result of increased glucose levels 
having a detrimental effect on small blood vessels within the eye (retinopathy), 
kidney (nephropathy) and nerves (neuropathy). Diabetic retinopathy is one of the 
leading causes of visual impairment in the Western world (Marques‐Neves, 2015). 
The hyperglycaemic environment associated with T2D results in changes in retina 
cell metabolism and alterations in biochemical balance that lead to retinal cell 
death (Madsen-Bouterse and Kowluru, 2008). Diabetic nephropathy effects 
approximately 20-40% of people with T2D (Gross et al., 2005), with vascular 
damage to capillaries within the glomeruli, altering the efficacy of waste filtration, 
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resulting in mircroaluminuria and eventually proteinuria. Diabetic neuropathy arises 
as a result of peripheral nerve dysfunction caused by an increase in reactive oxygen 
species and the production of advanced glycation end products (AGEs) (Fowler, 
2008). The disease can affect approximately up to 32% of people with T1D and T2D 
and it results in numbness, tingling or pain and isolated or multiple nerve palsies 
(Stratton et al., 2000, Fedele et al., 1997).  
As with all microvascular and macrovascular complications, the risk of 
developing the disease is increased with prolonged exposure to hyperglycaemia, 
with this also influencing severity. Furthermore, as well as the length of 
hyperglycaemic exposure, some individuals may hold a genetic predisposition to 
develop the disorder.  
 
1.3  Obesity 
Obesity is often defined as an excess of body fat that adversely affects health. As a 
multifactorial disease, it has many causes but predominantly a chronic excess in 
energy intake compared to energy expenditure. Obesity is often classified by body 
mass index (BMI) (Table 1.1, Figure 1.1). BMI is the same for both genders and 
adults of all ages, however it does not take into consideration an individual’s 
configuration, therefore leading to a rise in the use of alternatives such as body fat 
percentage indicators.  
 The prevalence of obesity has more than doubled since 1980; with 
predictions over the next 20 years for numbers to increase by 73% to approximately 
8 
 
26 million people (World Health Organization, 2016). This increase in the 
prevalence of obesity is seen in both developed and developing countries; with the 
rate of childhood obesity reported to result in a global increase to 70 million 
overweight or obese children by 2025 (World Health Organization, 2016). 
BMI (kg/m2) WHO class 
<18.5 Underweight 
18.5-24.9 Healthy 
25-29.9 Overweight (Pre-obese) 
30-34.9 Obese class I 
35-39.9 Obese class II  
>40 Obese class III (severely obese) 
Table 1.1 BMI classifications, as given in (Wass and Owen, 2014). 
 
 
 
 
 
 
 
Figure 1.1 BMI Graph. http://www.nhs.uk/Livewell/healthy-living/PublishingImages/weight-chart-
377.jpg, accessed 30/08/2016. 
9 
 
1.3.1 Environmental and genetic causes of obesity 
Obesity is a multifactorial disease that encompasses both environmental and 
genetic factors. Environmental factors are often highlighted within developed 
countries, where a higher caloric diet including refined sugars and a high fat 
content, alongside a sedentary lifestyle have become common place.  
Obesity can be inherited with strong association of genetic factors, both 
monogenic and polygenic factors, for example, resulting in leptin deficiency or 
ghrelin abnormalities. Prader- Willi syndrome (PWS) is a key example of genetic 
obesity and results from a loss of paternal genes in the q11-13 region of 
chromosome 15. Patients with PWS experience excessive appetite (hyperphagia) 
which is linked to hyperghrelinaemia (DelParigi et al., 2002).  
 
1.3.2 Comorbidities linked to obesity  
The hypercaloric state associated with obese individuals has a detrimental effect on 
the individual’s health and predisposes them to many diseases, including an 
increase risk in CVD, hyperlipidemia and T2D (Scerif et al., 2011). These 
comorbidities present a great challenge to the National Health Service (NHS) and 
healthcare providers, and has resulted in the practice of various bariatric surgeries 
to allow a reduction in adipose mass. Abdominal obesity causes a chronic low grade 
inflammatory state, activating the immune system and playing a vital role in 
obesity-related insulin resistance and T2D (Cooke et al., 2016). In an obese state, 
the make-up of adipose tissue changes, resulting in the infiltration of macrophages 
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and the enlargement of adipocytes. Macrophages are responsible for the release of 
free fatty acids (FFA) and the subsequent release of tumour necrosis factor α 
(TNFα) (Bastard et al., 2006). FFA activate nuclear factor kappa B (NFκB) by binding 
to toll like receptor-4 on macrophages.  Macrophage-derived TNFα activates 
adipocytes, inducing the expression of various genes and the release of adipokines 
(i.e. interleukin-6). The overproduction of adipokines produced by the infiltration of 
macrophages in the obese state is involved in the pathophysiology of insulin 
resistance (Bastard et al., 2006). 
 
1.4 Oxidative Stress 
Oxidative stress is the result of free radical mediated damage that often has severe 
pathological consequences. Free radicals are atoms or molecules which have one or 
more free electrons within the outer shell of the atomic structure, causing it to 
become unstable and reactive. The most common form of free radical mediated 
damage results from reactive oxygen species (ROS) (Stephens et al., 2009). 
Oxidative stress is often underpinned by a disturbance in the balance of pro- and 
anti-oxidants, resulting in a shift towards a pro-oxidant state. For instance, ROS are 
produced naturally in the body, but when over production occurs, together with 
insufficient anti-oxidant defences, it can be associated with pathological disorders 
i.e. diabetes and cancer (Stephens et al., 2009). 
 The development of ROS can result from the electron transport chain 
‘leaking’ electrons, that combine with oxygen causing the formation of superoxide 
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molecules (Evans et al., 1997, Cooke et al., 2003). As well as electron leaking, ROS 
formation can result from ionisation, ultraviolet radiation and certain exogenous 
chemicals. Due to the unstable nature of ROS they can potentially target all 
molecules in the body, especially DNA, attacking the double bonds present 
between bases, resulting in a direct effect on replication and transcription (Cooke 
et al., 2003).    
 
1.4.1  Lipid peroxidation 
Lipid peroxidation is the degradation of lipids within an environment of high 
oxidative burden. It is the main molecular mechanism that is involved in oxidative 
damage of cell structure resulting in the destruction of membrane lipids. Oxidative 
damage results from a free radical chain reaction composed of three stages; 
initiation, propagation and termination (Ayala et al., 2014). Initiation involves the 
formation of lipid radicals via the hydrogen abstraction or addition of an oxygen 
radical. Polyunsaturated fatty acids undergo peroxidation forming a conjugated 
diene which binds an oxygen molecule to produce a peroxyl radical. Thus, allowing 
for the propagation of the free radical chain reaction; peroxyl radicals producing 
hydroperoxides, capable of hydrogen abstraction of another polyunsaturated fatty 
acid. The free radical chain reaction is terminated when two free radicals conjugate 
or in the presence of a chain breaking anti-oxidant (Repetto et al., 2012, Ayala et 
al., 2014).  
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 The anti-oxidant effect can either be enzymatic or non-enzymatic. Enzymatic 
routes are often underpinned by anti-oxidant systems like superoxide dismutase 
(SOD), catalase or glutathione peroxidase (Valko et al., 2007). Non-enzymatic anti-
oxidants consist of vitamin C, vitamin E and glutathione (GSH) (Valko et al., 2007). 
All anti-oxidant systems demonstrate a potent role in either the prevention, repair 
and/or termination and neutralization of ROS through reduction (Valko et al., 
2007).  Furthermore, increased lipid peroxidation within inflammatory diseases is a 
result of the promotion of ROS production (Repetto et al., 2012). 
 
1.4.2  Inflammation and ROS production 
Inflammation is the body’s immune reaction in response to a pathogen, allowing it 
to eradicate the imposing threat. The process of inflammation is regulated by a 
variety of factors and is characterised by the production of pro-inflammatory 
cytokines and inflammatory cell activation. The activation of inflammatory cells 
results in an increase in superoxide and other ROS production, via the pro-oxidant 
action of the phagocytic isoform of nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase (Valko et al., 2007). Increased level of ROS can result in the 
alteration of inflammatory cell signalling pathways; activating c-Jun N-terminal 
kinase (JNK), mitogen-activated protein kinase (MAPK), extracellular signal-
regulated kinase (ERK) and NFκB signalling pathways. The production of hydrogen 
peroxide acts as a secondary messenger that activates NFκB via TNFα and 
interleukin 1 (IL-1) (Valko et al., 2007). The generation of ROS within the immune 
system acts as a defence mechanism, however, as previously mentioned, if the rate 
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of ROS production overwhelms the anti-oxidant system then there will be an 
increase in oxidative stress and lipid peroxidation.    
 
1.4.3  Oxidative stress in T2D  
Oxidative stress is implicated in the pathophysiology of comorbidities linked to T2D, 
due to increases in ROS and decreases in free radical quenching enzymes 
(Tangvarasittichai, 2015, Martín-Gallán et al., 2003). Hyperglycaemia activates 
detrimental pathways including the hexosamine pathway and AGE pathway, both of 
which cause an increase in oxidative stress (Figure 1.2).  As previously mentioned, 
pancreatic β-cell function plays a vital role in the development of T2D. Chronic 
hyperglycaemia is reported to be a causative factor in β-cell apoptosis via oxidative 
stress, with a resultant decrease in β-cell mass (Valko et al., 2007). Anti-oxidant 
treatment is beneficial in the treatment of diabetes, resulting in the suppression of 
β-cell apoptosis and theorised protection against the loss of insulin mRNA and 
insulin concentration (Valko et al., 2007).  
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Figure 1.2. Overview of oxidative stress within Type 2 diabetes. Type 2 diabetes encompasses a raise 
in circulating blood glucose and free fatty acids. Both of which result in an increase of oxidative 
stress i.e. activation of auto oxidation, polyol and advanced glycation end product pathway in 
hyperglycaemia. An increase in oxidative stress can result in increased inflammation and insulin 
resistance triggering β-cell dysfunction.  
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1.5 Adipose tissue 
Adipose tissue is a highly complex and metabolically active organ. This endocrine 
organ has demonstrated a role in central nervous system (CNS) communication, 
fasting FFA source and regulation of nutrient homeostatic mechanisms (Trayhurn 
and Wood, 2004). Traditionally grouped into two simple classifications; white 
adipose tissue (WAT) and brown adipose tissue (BAT), a third classification has 
recently been discovered, ‘beige’ or ‘brite’ (Rosen and Spiegelman, 2014). All three 
classifications store energy in the form of lipid droplets, yet are distinct and contain 
differing gene expression patterns, allowing for specific differences in their 
functions and depots. WAT, beige adipose tissue and BAT all require peroxisome 
proliferator-activated receptor γ (PPARγ) for development and functionality (Rosen 
and Spiegelman, 2014, Harms and Seale, 2013). However, they differ in cell lineage 
(Figure 1.3) with embryonic stem cells that express key developmental and 
transcriptional factors Myf5 and Pax7 being the precursor for BAT and two distinct 
lineages Pax7 and Myf5 negative as the precursors for WAT and beige adipose 
tissue (Wu et al., 2013, Rosen and Spiegelman, 2014).   
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Figure 1.3. Different cell lineages that produce brown, beige and white adipocytes. Taken from 
Rosen and Spiegelman (2014) 
 
1.5.1 Brown adipose tissue  
BAT is a group of highly specialised cells that has vast vascularisation and 
cytochromes, with a main function of thermoregulation. BAT has the ability to 
transform stored energy into heat through the action of uncoupling protein 1 
(UCP1). Located in the mitochondrial membrane, UCP1 catalyses a proton leak 
across the inner mitochondrial membrane, uncoupling fuel oxidation for ATP 
synthesis (Rosen and Spiegelman, 2014).  BAT develops during gestation in humans, 
allowing for protection against cold present at birth and atmospheric life. 
Significant BAT depots present in gestation are depleted in adult humans, who 
instead are dependent upon shivering thermogenesis to maintain 
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thermoregulation. Acute cold exposure results in sympathetic nervous system 
release of noradrenaline and the induction of BAT thermogenesis via the 
stimulation of intracellular lipolysis  (Cypess et al., 2015). 
 As well as thermoregulation, chronic BAT stimulation has been highlighted 
to play a beneficial role in the regulation of metabolism (Harms and Seale, 2013). 
The activation of BAT is negatively associated with obesity and insulin resistance, 
hence a negative association with T2D (Orava et al., 2011). High levels of the 
glucose transporter 4 (GLUT4) are present within BAT, resulting in an increase in 
insulin sensitivity and glucose uptake (Cypess et al., 2015, Stanford et al., 2013, 
Orava et al., 2011) 
 
1.5.2 White adipose tissue  
WAT is an abundant reservoir of triglycerides which accounts for 85% of tissue 
mass. Spanning the human body, this heterogenous tissue is composed of mature 
adipocytes, fibroblasts, macrophages, endothelial cells and pre-adipocytes. The 
classical functions of WAT are lipid synthesis (lipogenesis), lipid storage and 
triglyceride breakdown. WAT also allows for the subsequent release of fatty acids 
under certain metabolic stressors i.e. exercise or caloric restriction.  
WAT is linked to primary roles within the endocrine system, namely the 
secretion of adipokines. Adipokines are a group of diverse protein signals and 
factors that allow WAT to communicate throughout the body, having an effect on 
endocrine, paracrine and autocrine systems (Figure 1.4). This ability for adipokines 
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to act either locally or distally allows for WAT to play an intrinsic role in the 
regulation of whole body energy homeostasis. However, not all regions of WAT 
produce the same amounts of adipokines resulting in various functions for 
anatomical fat depots. 
 
 
Figure 1.4. An example of adipokines secreted by white adipose tissue. Monocyte chemotactic 
protein (MCP), tumour necrosis factor (TNF), interleukin (IL), insulin-like growth factor (IGF), vascular 
endothelial cell growth factor (VEGF) and transforming growth factor (TGF). 
 
1.5.3 Beige adipose tissue  
Originally, WAT and BAT were thought to be located in anatomically separate 
regions, however over 30 years ago UCP1 positive cells were located in WAT depots 
(Cousin et al., 1992, Young et al., 1984). Beige adipose tissue originates from a 
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different source to BAT and is the product of WAT differentiation, which can occur 
due to cold exposure or in the presence of key peptides e.g. neuropeptide Y. Often 
termed ‘inducible BAT’, beige adipose tissue and BAT share functionality and 
cellular morphology, however they exhibit differing gene expression. Basal UCP1 
levels in beige adipose tissue is low and comparable to WAT, however cyclic 
adenosine monophosphate (cAMP) stimulation in vivo results in a rise of UCP1 
expression equivalent to that of interscapular BAT (Wu et al., 2013). This indicates 
beige adipose tissue is unique in functionality, allowing energy to be stored as lipid 
droplets, as well as responding to cAMP, resulting in heat production and energy 
dissipation (Rosen and Spiegelman, 2014). Beige adipose tissue is inversely 
associated with age and obesity, and is increased after weight loss from bariatric 
surgery (Wu et al., 2013). 
 
1.5.4 Adipose depots 
Commonly, the location of WAT spans the inguinal, retroperitoneal and gonadal 
regions of the body whilst BAT is located in the interscapular, perirenal, axillary and 
paravertebral regions. Interscapular BAT has been identified in human adults using 
[18F]-2-fluoro-D-2-deoxy-D-glucose (FDG) and positron emission tomography (PET); 
further analysis of a biopsy section confirmed the tissue to have BAT morphology 
and characteristics, including UCP1 positivity (Rosen and Spiegelman, 2014, Cypess 
et al., 2009, van Marken Lichtenbelt et al., 2009, Virtanen et al., 2009). 
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A large accumulation of WAT has been observed in two depots; 
subcutaneous located under the skin and visceral, largely in the omentum. The 
storage of adipose tissue in these depots plays a vital role in metabolic disease, an 
increase of visceral fat in obesity is associated with related diseases including T2D, 
however subcutaneous fat does not share this association.  
 
1.5.5 Adipogenesis 
Pre-adipocytes have the ability to proliferate and undergo differentiation into 
mature adipocytes, a process intensely regulated by specific transcription factors 
and cell cycle proteins. During adipogenesis, pre-adipocytes undergo a 
morphological change, resulting in a change from a fibroblastic to a spherical shape.  
As a result of the morphological changes, cellular make up is also altered, including 
quantitative changes in extracellular matrix and cytoskeletal components (Moreno-
Navarrete and Fernández-Real, 2012). Due to a key part of adipose tissues ability to 
have homeostatic system control, adipose differentiation and understanding of the 
transcriptional basis of adipogenesis has gained great importance.       
PPARγ and sterol-regulatory element binding protein-1 (SREBP-1) are key 
transcriptional factor in adipognesis. PPARγ is a subfamily of nuclear hormone 
receptors and exists in two protein isoforms; PPARγ1 and PPARγ2, which are 
produced via alternative promoter usage and alternative splicing at the 5′ end of 
the gene (Wu et al., 1995). Present in high levels in pre-adipocytes, PPARγ has a role 
as the master regulator of adipogenesis, inducing fat cell differentiation. PPARγ 
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adipogenic effect is reliant upon its transcriptional activity, where it is shown to 
increase transcription via the DNA recognition site DR-1 (Spiegelman and Flier, 
1996).   
SREBP-1 is encoded by the SREBF1 gene which is transcribed into two splice 
variants, SREBP-1a and SREBP-1c (Knebel et al., 2012). The sterol response binding 
protein exhibits two main functions in adipocytes characteristics.  Firstly, it is shown 
to control de novo lipogenesis via the induction of key genes of fatty acid 
metabolism; whilst on the other hand, under conditions favouring adipogenesis 
SREBP-1 has shown to promote and increase the overall percentage of pre-
adipocytes that undergo differentiation (Kim and Spiegelman, 1996, Knebel et al., 
2012).  
 
1.5.6 Lipogenesis 
De novo lipogenesis (DNL) is the enzymatic process by which lipid synthesis occurs 
from acetyl CoA, predominantly within the liver but also within adipose tissue 
(Knebel et al., 2012, Kersten, 2001). The rate at which DNL occurs is diet 
dependent, with an increase in dietary carbohydrates resulting in increased 
lipogenesis and a subsequent rise in plasma triglycerides. Alternatively, fasting can 
cause a decrease in DNL within WAT; which when combined with an increase in 
lipolysis results in a loss of triglycerides. The radicalised triglycerides from WAT are 
transported to the liver where triglyceride synthesis is increased to overcome the 
influx, resulting in hepatosteatosis (fatty liver) (Kersten, 2001).  
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 DNL is a highly regulated process, induced from a variety of mechanisms 
including the increase in lipogenic enzymes and several transcription factors 
(Knebel et al., 2012). As previously mentioned, SREBP-1c is a key inducer of DNL 
due to its regulatory role in the expression of genes that encode vital lipogenic 
enzymes. Two central enzymes for DNL are acetyl CoA carboxylase and fatty acid 
synthase, and are responsible for the generation of fatty acids from the products of 
glycolysis (Figure 1.5). Insulin stimulates SREBP-1c levels in the liver, therefore in a 
high insulin environment i.e. obesity and T2D, there will be an increase in DNL that 
may result in dyslipidaemia. Liver X receptor (LXR) response elements within the 
SREBP-1c promoter are identified as mediators of insulin induced SREBP-1c 
transcription (Howell et al., 2009). As well as DNL, SREBP-1c and LXR have 
demonstrated a role within other lipid-mediated pathways i.e. cholesterol 
metabolism (Wagner et al., 2003, Vaughan and Oram, 2005).  
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Figure 1.5. Pathway of fatty acid production. Glycolysis (GREEN), TCA cycle (BLUE) and de no 
lipogenesis (PINK) with key lipogenic enzymes in bold. 
 
1.5.7 Reverse cholesterol transport 
The reverse cholesterol transport pathway (Figure 1.6), the removal of excess 
cholesterol from peripheral tissues back to the liver for excretion and catabolism, is 
critical in the defence against atherosclerosis (Kennedy et al., 2005, Fielding and 
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Fielding, 2001, Vaughan and Oram, 2005). Cholesterol efflux is dependent upon ATP 
binding cassette (ABC)A1 and ABCG1 (Kennedy et al., 2005, Ma et al., 2014). ABCA1 
and ABCG1 are members of a superfamily of transporters that function to mediate 
the transfer of cellular cholesterol to the cell surface for removal by high density 
lipoproteins (HDL) (Kennedy et al., 2005, Vaughan and Oram, 2005). PPARγ induces 
the expression of ABCA1/G1 via nuclear cholesterol sensors, LXRα and LXRβ 
(Vaughan and Oram, 2005). LXR acts as a transcription regulator for the genes 
associated with cholesterol efflux, which is activated when total cellular cholesterol 
levels are high (Wagner et al., 2003). However, when total cellular cholesterol levels 
are low, SREBP induces cholesterol biosynthesis (Wagner et al., 2003).   
 
 
Figure 1.6. Reverse cholesterol transport within humans. Diagram illustrates key steps within the 
reverse cholesterol transport system in human macrophages. PPAR-LXR-ABC pathway exports 
intracellular cholesterol to the cellular membrane, mature HDL then transport free cholesterol to 
the liver where is undergoes cholesterol secretion or bile acid production.  
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1.6 Ghrelin 
1.6.1 Discovery and structure 
In 1997, Kojima attempted to identify the unknown endogenous ligand responsible 
for growth hormone secretion via the stimulation of the growth hormone secreting 
receptor (GHS-R). However, initial studies proved unsuccessful despite the 
development of several hundred assays (Kojima et al., 1999). It was not until 1998, 
when Kojima and Hiroshi combined their findings with the recently described 
orphan G protein-coupled receptor GPR38  that progress was made (Kojima and 
Kangawa, 2008, Kojima, 2008). Through the use of a stable cell line, which 
expressed GHS-R, Kojima and co-workers were able to establish a calcium 
increasing activity (Kojima et al., 1999). The monitored activity was focused to a  
stomach extract, showing a ligand with a molecular weight ranging between 3-4 
kDa (Kojima and Kangawa, 2008, Kojima, 2008). Final characterization of a 3 kDa 
endogenous ligand was deemed to be ghrelin (Peino et al., 2000). 
Ghrelin was finally isolated from the gut of humans and rats via cloning 
(Shiiya et al., 2002, Peino et al., 2000). The research produced a novel 28 residue 
peptide hormone that was an endogenous ligand of GHS-R (Kojima et al., 1999). An 
anomaly was identified in the peptide structure and explained by the presence of a 
hydroxyl group in the serine 3 molecule undergoing acetylation (Tokunaga et al., 
2005). Kojima originally proposed this hypothesis of hydroxylation, through the use 
of high performance liquid chromatography (HPLC) experimental data. He 
discovered that natural ghrelin was eluted 10 minutes after the synthetic desacyl-
ghrelin, concluding the modification occurred via a hydrophobic moiety. Electron 
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ionization mass spectroscopy (EI-MS) analysis concluded the moiety mass was 
C7H15CO (Kojima et al., 1999) (Figure 1.7). 
 
Figure 1.7 Amino acid sequence of ghrelin and the acetylation of the serine 3 residue. 
The unique characteristics of ghrelin occur from the post translational state, 
where the peptide is originally synthesised as a pre-pro-hormone and 
proteolytically processed into the 28 amino acid sequence (Meier and Gressner, 
2004). Pre-pro-ghrelin contains 117 amino acids. In addition to ghrelin, this gene 
encodes for a small signal peptide and obestatin. The cleavage of the pre-pro 
ghrelin gene produces a 23 amino acid signal and pro-ghrelin. Further proteolytic 
processing results in the cleaving of the 28 amino acid peptide by prohormone 
convertase 1/3 (PC1/3) (Yang et al., 2008). As well as ghrelin, the presence of a 
second endogenous ligand has been reported in rat stomachs. This ligand is termed 
des-GLN 14-ghrelin and is a 27 residue peptide that is not processed from the 
ghrelin gene but a product of alternative splicing of the ghrelin gene mRNA, 
resulting in the loss of the 14th glutamine (GLN) residue (Figure 1.8) (Wang et al., 
2002). The second endogenous ligand for GHS-R exists in the stomachs of all rats 
observed to date, suggesting that the endogenous ligands for GHS-R are two 
homologous peptides, des-GLN 14-ghrelin and ghrelin (Hosoda et al., 2000).  
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Figure 1.8. Ghrelin structure with a cross indicating the loss of an amino acid residue to produce des-
GLN 14-ghrelin via mRNA splicing.  
Ghrelin is the first natural peptide to be reported containing the elusive 
post-translational modification of N-octanoylation (Kojima et al., 1999, Wang et al., 
2002). In 2008, it was shown that a membrane bound O-acyltransferase 4 
(mBOAT4) was vital in the activation of ghrelin (Kirchner et al., 2012). The human 
gene mBOAT4 is located on chromosome 8 (8p12), containing 6 exons. It was later 
termed ghrelin O-acyltransferase (GOAT) due to it being the only enzyme that 
acylates ghrelin (Figure 1.9) (Kirchner et al., 2012). This acyl modification occurs at 
the pro-ghrelin maturation stage of ghrelin.  
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Figure 1.9. Ghrelin synthesis and maturation within a stomach cell. Amino acid (AA) length and 
name for each peptide given in bold and process undergoing or enzyme in italics. Medium chain 
fatty acids and acetly coA (MCFA + CoA) are the substrates used in the octanoylation of ghrelin by 
GOAT.  Ghrelin also circulates in des acyl forms but only the acyl form is secreted to bind to GHS-R. 
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1.6.2 Function 
The peptide was named ghrelin, from the Latin word ‘Ghre’ which means ‘grow’ 
due to its role as a growth hormone releasing peptide (Meier and Gressner, 2004, 
Kojima and Kangawa, 2005). The novel peptide was isolated from the gut of both 
human and rat as the endogenous ligand of GHS-R (Kojima et al., 1999). GHS-R is 
transcribed in humans from the growth hormone receptor 1 (GHR1) gene, which 
encodes the full length functional receptor (GHS-R1α) and a splice variant truncated 
non-functional isoform (GHS-R1β) (Gnanapavan et al., 2002, Müller et al., 2015). 
GHS-R1α mRNA is expressed at low levels over a wide tissue distribution but is 
predominantly expressed in the anterior pituitary gland (Gnanapavan et al., 2002). 
The highest levels of ghrelin are secreted from the X/A-like cells of the oxyntic 
glands located in the gastric fundus, with lower levels widely distributed throughout 
the body (Garin et al., 2013, Dixit et al., 2004). Ghrelin is secreted directly into the local 
gastric circulation and transported to the brain directly, requiring it to either cross 
the blood-brain barrier via a saturated transport system or via the blood stream to 
enter areas of the brain that are not protected by the blood brain barrier (Angelidis 
et al., 2010).  
Ghrelin also reaches its main active site, the hypothalamic arcuate nucleus 
(ARC), in an indirect manner, activating the vagus nerve and brain stem nuclei 
(Angelidis et al., 2010, Date et al., 2002). Ghrelin circulates in two major forms; 
acylated (approximately 5% of total ghrelin) and desacyl (95% of total ghrelin) 
(Rodriguez et al., 2009). GOAT is vital in the activation of ghrelin (Yang et al., 2008). 
Both forms of ghrelin are observed to cross the barrier in a blood to brain direction, 
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however desacyl-ghrelin lacks the ability to cross the barrier in a brain to blood 
direction (Banks et al., 2002). Ghrelin’s ability to cross the blood brain barrier is the 
result of non-saturable, saturable blood-brain transport and saturable brain-blood 
transport that is highly dependent on the unique post-translational acylation and 
primary structure (Serby et al., 2006, Banks et al., 2002, Banks et al., 2008). Ghrelin 
has a homeostatic role that encompasses multiple areas of the body, with actions 
that include; down regulation of BAT thermogenesis (Tsubone et al., 2005, Yasuda 
et al., 2003), modulation of non-hypothalamic brain regions producing an increased 
taste sensation (Cai et al., 2013) and stimulation of gastric emptying and motility 
(Masuda et al., 2000, Asakawa et al., 2003). In the last 16 years the peptide has 
generated considerable attention due to its role within these various peripheral 
effects (Müller et al., 2015)(Figure 1.10).  
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Figure 1.10 Cognitive and peripheral effect of ghrelin- taken from (Müller et al., 2015). Schematic 
indicates the effact of ghrelin administration on key areas of the body, importantly the effect on key 
tissues involveld in glucose homeostasis. Ghrelin is shown to alter glucose metabolism, increase 
insulin sensitivity and decrease insulin secretion in the pancreas, increase insulin-like growth factor 1 
(IGF1) levels in the liver, decrease inflammation and increase lipogenesis in adipose tissue.   
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1.6.3 Acylation of ghrelin 
1.6.3.1 GOAT acylation 
GOAT is responsible for the post-translational modification of ghrelin; the fatty acid 
modification of the amino acid structure in the peptide chain which is vital to 
determining functionality. As previously mentioned, ghrelin undergoes the 
attachment of an acyl moiety, octanoic acid, within the endoplasmic recticulum at 
the third serine residue following pre-pro-ghrelin cleavage into pro-ghrelin. GOAT is 
part of a 16 member family of membrane bound acyltransferases. This family, 
mBOATs, results in the transfer of long fatty acids to membrane-associated 
hydroxyl acceptors, however only one is responsible for ghrelin octanoylation, 
GOAT. GOAT expression is found widespread in human tissues, corresponding with 
that of ghrelin secreting tissues, thus GOAT expression levels are high in the 
stomach, gut and pituitary (Lim et al., 2011). The origin of the octanoyl (eight 
carbon) fatty acid, alternatively named medium chain fatty acid (MCFA), used in 
ghrelin activation is associated to orally ingested MCFAs. The location of the vast 
majority of ghrelin secreting cells are in the stomach lumen, allowing direct access 
to dietary MCFAs or medium chain triglycerols (Sato et al., 2012). Evidence shows 
the utilization of dietary MCFAs as a substrate, establishing GOAT as a dietary lipid 
sensor, however little is known about the comparison of de novo synthesised fatty 
acids used (Müller et al., 2015).  
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1.6.3.2 APT1 des-acylation 
In 2010, it was reported that acyl-ghrelin levels can be affected by acyl-protein 
thioesterase 1 (APT1). APT1 is encoded by the LYPLA1 gene, comprising of a 230 
amino acid sequence homodimer. Originally APT1 was purified as a cytosolic 
lysophospholipid hydrolysing enzyme, the recombinant APT1 exhibits both 
deacylation and lysophospholipase activity (Satou et al., 2010). In contrast to GOAT, 
APT1 has been demonstrated to act as a ghrelin des-acylation enzyme (Shanado et 
al., 2004), thus suggesting that the levels of acyl-ghrelin present are dependent on 
the bioavailability of APT1 and GOAT (Satou et al., 2010).   
 
1.6.4 Ghrelin and adipogenesis  
Ghrelin is involved in the regulation of metabolic hormones with GHS-Rs present 
within adipose tissue (Korbonits et al., 2004, Kojima et al., 1999).  In addition to 
stimulating GH secretion, ghrelin has been shown to play a role in adiposity. Upon 
the addition of acyl-ghrelin and desacyl-ghrelin, PPARγ and SREBF1 mRNA 
expression levels increase in human visceral adipocytes during differentiation 
(Rodriguez et al., 2009). Therefore, in the presence of ghrelin, in vitro and in vivo 
studies have demonstrated that the mRNA levels of PPARγ expression are 
increased, resulting in the differentiation of pre-adipocytes (Rodriguez et al., 2009). 
PPARγ activity can be influenced by key components that play a role in the 
mammalian insulin pathway, such as mammalian target of rapamycin complex 1 
(mTORC1) and Akt/protein kinase B (Akt/PKB) (Chabot et al., 2014). In the presence 
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of ghrelin, mTORC1 and Akt/PKB can enhance PPARγ activation promoting 
adipogenesis; demonstrating that ghrelin exhibits inter-relationships between 
adipogenesis and the insulin pathway (Chabot et al., 2014). The elevation of SREBF1 
gene expression was accompanied by a significant increase in lipid accumulation  in 
visceral adipocytes (Rodriguez et al., 2009). This administration of ghrelin directly 
stimulated the intra-cytoplasmic lipid accumulation via the increased production of 
various fat storage promoting enzymes including carboxylase, acetyl CoA, fatty acid 
synthase and lipoprotein lipase (Rodriguez et al., 2009). 
 
1.6.5 Ghrelin and lipogenesis  
Centrally acting ghrelin following chronic intra-cerebrovascular infusion, has also 
been shown to increase mRNA expression of genes which promote the retention of 
cholesterol (Davies et al., 2009). So in the presence of ghrelin, SREBP1-c expression 
is increased, with ABCG1 and LXRβ expression decreased (Davies et al., 2009). Even 
though these results indicate that ghrelin has a role in increasing lipid retention 
within adipocyte cells, the relationship between cholesterol efflux, biosynthesis 
genes and ghrelin is disputed among studies. Sirtuin 1 and SIRT1 and tumour 
suppressor gene p53 activates AMP-activated protein kinase (AMPK) via 
phosphorylation, however in the presence of ghrelin there is the deacyetylation of 
p53 via SIRT1 impinging on AMPK activation (Velásquez et al., 2011, Kola et al., 
2005). Phosphorylated AMPK inactivates fatty acid biosynthesis and activates fatty 
acid oxidation (Winder and Hardie, 1999).  In vivo, the administration of ghrelin 
within p53 null mice demonstrates a decrease in lipid metabolism modulating gene 
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expression, indicating that p53 is essential for the action of ghrelin on adipose 
tissue (Porteiro et al., 2013).  Ghrelin administration has also been reported to 
activate the PPARγ-LXR-ABC pathway in a dose-dependent manner, resulting in an 
increase in LXR and ABC expression in human THP-1 macrophages (Demers et al., 
2009). An increase within cellular fat mass could result in an increase in lipogenesis 
and substrate uptake, and a decrease in lipolysis and cellular export (Mishra et al., 
2016). These processes could alter the intrinsic regulation of FFA and cholesterol 
biosynthesis pathways that could lead to hypertriglyceridemia and other 
complications (Schultz et al., 2000). Due to the diversity of published data and 
various doses of acyl-ghrelin administered, further research into ghrelin-mediated 
lipid retention especially within humans is needed. 
 
1.6.6 Ghrelin and Type 2 diabetes 
An important contributor to the pathophysiology of T2D is the failure of glucose 
uptake into peripheral tissues such as adipose, skeletal muscle and liver. Decreased 
total ghrelin levels in patients with T2D are associated with an increase in 
abdominal adiposity and insulin resistance (Katsuki et al., 2004). As previously 
mentioned, ghrelin has a demonstrated role in fat metabolism and glucose 
homeostasis; and cross-talk between lipid and glucose metabolism may result in a 
physiological role of ghrelin in insulin resistance. Cellular lipid accumulation that is 
observed upon ghrelin administration can have a knock on effect on glucose 
homeostasis. There are two hypotheses relating to lipid-mediated insulin 
resistance. The first is that an excess of visceral adiposity triggers release of FFA into 
36 
 
the circulation. An increase in hepatic FFA oxidation triggers insulin resistance and 
an increase in glucose output from the liver (Lam et al., 2003, Boden, 1999). Acyl-
ghrelin infusion in humans has been associated with a rise in circulating FFA levels 
(Huda et al., 2009), and a subsequent decrease in insulin sensitivity (Boden, 1999). 
These findings demonstrate possible causation of insulin resistance that can occur 
in healthy volunteers when given an acyl-ghrelin infusion (Vestergaard et al., 2010, 
Vestergaard et al., 2007). The second hypothesis is that enlarged lipid-containing 
adipocytes are associated with the release of FFA, physical stress and ROS 
production (Maumus et al., 2008, Gustafson, 2010). Prolonged elevation of ghrelin 
increases visceral adiposity in mice and attenuates the transcription of LXRβ and 
ABCG1 which increases adipocyte volume due to a reduction in lipid export (Davies 
et al., 2009). This could alter immune function, as a result of increased ROS 
production and the release of damaging inflammatory agents such as TNFα. This 
indirect immuno-modulatory response may lead to insulin resistance and T2D due 
to TNFα’s ability to induce the inhibitory phosphorylation of insulin receptor 
substrate (IRS)-1, leading to systemic insulin resistance (Gustafson, 2010) . The 
association between obesity and T2D is well documented, allowing ghrelin to play a 
potential pharmacological role in its prevention and/or treatment. 
1.7 Aims 
I hypothesise that acyl-ghrelin will be shown to mediate lipid retention within 
human adipocytes, thus causing an increase in inflammation and oxidative stress. 
Upon translation from a single cell type to a depot, I propose that acyl-ghrelin 
would still be deemed detrimental to lipid homeostasis and thus would highlight 
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key associations of acyl-ghrelin and inflammatory markers within the circulation of 
those with and without T2D. This thesis proposes to explore this hypothesis via the 
following aims: 
1. Investigate the effect of acyl-ghrelin exposure on the lipid retention 
pathway and consequent inflammatory response, in an established human 
adipocyte cell line  
2. Translate cell specific findings into a depot specific effect via analysis of the 
lipid retention pathway in human visceral adipose tissue biopsies 
3. Explore acyl-ghrelin within circulating plasma of individuals with and 
without T2D to establish any associations with indicators of the metabolic 
state 
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Chapter 2  
General Methodology 
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This chapter is split into three arms to allow for fluidity throughout the 
methodology, the sections are based on result chapter’s sample source and are as 
follows; (i) in vitro samples- cell lines, (ii) ex vivo samples- human visceral adipose 
tissue and (iii) cross over protocols, including data analysis. 
 
2.1 In vitro samples 
2.1.1 Human pre-adipocyte cell line 
Alternative methodologies including primary human adipocytes and the excising of 
adipocytes from adipose tissue biopsies were also considered for the in vitro aspect 
of this project. Upon investigation of these techniques, the use of an established 
cell line was considered to be of greatest benefit for the experimental design of this 
project, allowing for experimental repeats and minimal risk of addition cell type 
carry over. However, cell lines can undergo alterations during high passage culture, 
therefore to reduce the risk of phenotypical changes within cells undergoing 
experiment the sub-culturing protocol restricted cell passages to a maximum of 10.  
A human pre-adipocyte cell line was derived from a stromal vascular fraction from 
infants with Simpson Golabi Behmel syndrome (SGBS) (Fischer-Posovszky et al., 
2008). SGBS (MIM312870) is a rare X-linked congenital overgrowth syndrome to 
which the cause is not fully elucidative (Wabitsch et al., 2001). It has a clear genetic 
link with the glypican 3 gene, a gene involved in organ growth control, where often 
in cases of SGBS there is either a point mutation or deletion within the Glypican 3 
gene (DeBaun et al., 2001).  
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 The human pre-adipocyte cell line is well established as a unique tool for 
studying adipocyte biology, exhibiting a high capacity for adipose differentiation 
that results in mature adipocytes. In 2001, the SGBS cell line was induced achieving 
adipogenic differentiation at a rate of over 90% for up to 50 generations (Wabitsch 
et al., 2001). The cell line exhibits specific metabolic functions; insulin-stimulated 
glucose uptake, insulin-stimulated de novo lipogenesis, β-adrenergic-stimulated 
lipolysis and adipokine secretion (Wabitsch et al., 2001, Fischer-Posovszky et al., 
2008).  
 
2.1.2 Cell culture 
2.1.2.1 Revival 
Upon arrival, a cryovial containing 1 million cells per mL was placed in a water bath 
at 37°C for rapid defrosting and placed in a falcon tube containing 20 mL of media A 
(Table 2.1) and 10% foetal calf serum (FCS) (Invitrogen™) to dilute freezing medium. 
The falcon tube was then centrifuged for 4 minutes at 1500 rotations per minute 
(rpm)(200 x g), supernatant decanted off and cell pellet resuspended in media A 
plus 10% FCS and seeded into a T75 flask with 20 mL media A plus 10% FCS. Cells 
were incubated at 37°C in 5% CO2. After 24 hours, media was decanted and 
refreshed and cells were incubated at 37°C in 5% CO2. 
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Reagent Quantity Supplier 
DMEM F12 
 
500 mL Invitrogen™ 
Panthotenate 
 
1.7 mM Sigma-Aldrich™ 
Biotin 
 
3.3 mM Sigma-Aldrich™ 
Penicillin (10,000 U/mL)/ 
Streptomycin (10,000 µg/mL) 
solution 
 
5 mL Invitrogen™ 
Table 2.1. Media A components 
 
2.1.2.2 Subculturing 
Cells were grown in T75 flasks until 80% confluent, old media was removed and 
cells washed three times with 4mL phosphate buffered saline (PBS) (Corning™). 
Adhered cells were trypsinised using 2 mL of 0.05% Trypsin-EDTA (Gibco®, Life 
Technologies™) and incubated for 5 minutes at 37°C. Detached cells were 
suspended in 5 mL media and centrifuged for 10 minutes at 1500 rpm (200 x g) and 
the supernatant discarded. Cells were resuspended in 1 mL of media A and counted 
using a Scepter™ 2.0, an automated handheld cell counter (EMD Millipore) and split 
into four T75 flasks at approximately 2,000,000 cells in 20 mL media A containing 
10% FCS. The flasks were incubated at 37°C and 5% CO2 with a cell doubling time of 
38.4 ± 1 hour; cells were split every 4-5 days at 80% confluency. 
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2.1.3 Cell seeding  
SGBS cells at passage 5 were seeded into 6-well plates for differentiation and 
treatments. Confluent T75 flasks were washed and trypsinised as detailed in section 
2.1.2, 10 mL of media A was added to the T75 flask, transferred to a 50 mL falcon 
tube and centrifuged for 10 minutes at 1500 rpm (200 x g). Cells were counted and 
placed into 6 well plates at a seeding density of 0.2 x 106 with 1.5 mL media A 
containing 10% FCS. Cells were placed in a CO2 incubator at 37°C and 5% CO2 until 
90% confluent. 
 
2.1.4 Cell differentiation  
Media A was decanted from the 6 well plates and adhered cells were washed three 
times with PBS as described in section 2.1.2. Differentiation is induced under 
serum-free culture condition that contain a specific adipogenic cocktail made up of 
various components to aid in the differentiation of preadipocytes. Frequently found 
within adipogenic cocktails are insulin, dexamethasone and 3-isobutyl-1-
methylxanthine (IBMX) (Scott et al., 2011). Insulin acts to induce proliferation and 
differentiation of preadipocytes, as in high concentrations it is known to mimic 
insulin-like growth factor-1, activating mitogen-activated protein kinase pathways 
and in turn activating PPARγ and thus adipogenic gene expression (Ailhaud, 1982, 
Qiu et al., 2001, Kim et al., 2010). Dexamethasone is an anti-inflammatory steroid 
molecule and IBMX is a competitive non-selective phosphodiesterase inhibitor, 
both of which regulate PPARγ-promoting adipogenesis and induce transcription 
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factors for growth and differentiation (Salasznyk et al., 2005, Gurriarán‐Rodríguez 
et al., 2011). In addition, the adipogenic cocktail also contained rosiglitazone, a 
PPARγ agonist that aids in sensitizing adipocytes to insulin action, increasing the 
rate and degree of differentiation (Ninomiya et al., 2010, Scott et al., 2011); thyroid 
hormone (T3), which stimulates basal metabolic rate, transferrin to act as an iron 
source for adipogenesis and cortisol to promote adipogenesis (differentiation 
media B). 
Differentiation media B (2 mL)(Table 2.2) was introduced to each well for 
four days of incubation. On day 4, differentiation media B was removed via 
decanting and 2 mL of differentiation media C added (Table 2.3) for a further 10 day 
incubation. Fresh media was supplied every 4 days as previously published 
(Wabitsch et al., 2001) (Figure 2.1). 
Reagents 
 
Quantity 
 
Concentration 
 
Supplier 
 
Media A 
 
10 mL  See Table 2.1. 
Transferrin 
 
100 µL 0.01 mg/mL Sigma-Aldrich™ 
Insulin 
 
2 µL 20 nM Sigma-Aldrich™ 
Cortisol 
 
10 µL 100 nM Sigma-Aldrich™ 
Triiodothyronine 
(T3) 
 
10 µL 0.2 nM Sigma-Aldrich™ 
Dexamethasone 
 
10 µL 25 nM Sigma-Aldrich™ 
IBMX 
 
10 µL 250 µM Sigma-Aldrich™ 
Rosiglitazone 
 
2 µL 2 µM Cayman™ 
 Table 2.2. Differentiation media B components 
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Reagents 
 
Quantity 
 
Concentration 
 
Supplier 
 
Media A 
 
10 mL  See Table 2.2 
Transferrin 
 
100 µL 0.01 mg/mL Sigma-Aldrich™ 
Insulin 
 
2 µL 20 nM Sigma-Aldrich™ 
Cortisol 
 
10 µL 100 nM Sigma-Aldrich™ 
Triiodothyronine 
(T3) 
 
10 µL 0.2 nM Sigma-Aldrich™ 
Table 2.3. Differentiation media C components 
 
 
Figure 2.1. Media components for 14 day differentiation period 
 
2.1.5 Cell treatment 
Mature human adipocytes were exposed to various treatments as specified within 
each chapter. In Chapter 3, mature adipocytes were exposed to either an acute 
normo- or hyperglycaemic environment at day 12 of differentiation. The ranges of 
glucose added to the media were based on the physiological ranges present within 
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individuals with Type 2 diabetes (T2D) and healthy individuals, respectively. To 
exhibit a normoglycaemic and hyperglycaemic environment, media A was spiked 
with D-glucose (Sigma™) and set at glucose concentrations of 5.5mM and 25mM, 
respectively. On day 14, mature adipocytes were exposed to either acyl-ghrelin 
(100 nM), lipopolysaccharide (LPS) (1 µg/mL) or LPS and acyl-ghrelin (1 µg/mL, 100 
nM respectively), dependent on allocated well in plate layout (Figure 2.2). The 
collection of RNA and cell supernatant occurred at 17 and 34 hours post 
treatments.  
Within Chapter 5, mature adipocytes were also exposed to a hyperglycaemic 
(25mM glucose) environment at day 12. The cells were then dosed with metformin 
(SigmaAldrich™) on day 14. The cell dosage of metformin was determined by 
previously published literature (Section 5.3.1).  Vehicle of PBS was used as a control 
within both Chapter 3 and Chapter 5. Cell dosage concentrations were indicative of 
previous published work within similar cell types, as discussed in relevant chapter, 
to establish the effect of treatment and not representative of physiological level.   
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Figure 2.2 Plate layouts for cell treatments, replicated for high and low glucose  concentrations. 
Plate one represents the wells treated with 100 nM ghrelin (G) or 1 µg/mL LPS (L) or PBS (V). Plate 2 
is combined treatment with ghrelin (100 nM) and LPS (1 µg/mL) (GL) or PBS (V). Wells will be treated 
for the time indicated in hours for each well; 17 or 34 hours.  
 
2.1.6 Oil red O staining  
At the required time points (17 and 34 hours) mature adipocytes underwent oil red 
O staining to allow for the quantification of accumulated lipid area (Figure 2.3). All 
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reagents were purchased from Sigma Aldrich™ and staining undertaken as 
described by the manufacturer’s protocol and published by Kishore and colleagues 
(Kishore et al., 2012).   
Fixing adipogenic cultures 
Treatment media was aspirated from the wells and adhered cells washed with PBS 
and fixed by the addition of 2 mL 10% formalin. After one hour of incubation at 
room temperature, the 10% formalin was removed, cells washed with deionised 
water and placed in 2 mL 60% isopropanol for 4 minutes then aspirated off. 
Preparation of Oil red O stain  
Stock solution was prepared by adding 300 mg of Oil red O stain powder to 100 mL 
of 99% isopropanol, this stock solution was then diluted 3 parts solution in 2 parts 
deionised water and left to stand at room temperature for 10 minutes. The solution 
was then passed through a filter to remove any residual debris. Prepared oil red O 
solution is only stable for 2 hours so a fresh working concentration was required 
every use. 
Staining adipogenic cultures 
Prepared Oil Red O solution (500 µL) was added to each well whilst the plate was in 
oscillation, incubated at room temperature for 5 minutes and then washed with 
deionised water. Cells were then counterstained; 1 mL of Hematoxylin solution 
(Sigma™) was added to the cells, left for 1 minute, then rinsed with warm deionised 
water.  
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Figure 2.3. Mature SGBS cells imaged at magnification x50 before and after Oil red O staining and 
haematoxylin counterstain. N = nucleus, L = lipid droplet.  
 
2.1.7 Cell supernatant collection 
Cell supernatant was aspirated off all treatment wells and collected in 2 mL 
centrifuge tubes, the supernatant then centrifuged at 4000 rpm (500 x g) for 10 min 
at 4°C. To ensure all cell debris was removed, the supernatant was placed in a fresh 
2 mL centrifuge tube which was labelled with cell treatment, replicate identifier and 
time point for storage at -20°C until needed.   
 
2.1.8 RNA extraction  
At collection time points, RNA was collected from the mature adipocytes using the 
RNAeasy mini kit (Qiagen™). To the allocated well, 350 µL of buffer RLT was added 
and the cells dislodged using a cell scraper. Cell lysate was collected using a 1 mL 
pipette and placed into a 2 mL centrifuge tube. The sample was homogenised by 
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passing through a 20G needle, 7 times. One volume of 70% ethanol was added to 
the homogenised sample and mixed well via pipetting. The next stage of the 
extraction used an RNAeasy mini kit (Qiagen™) which contains all components and 
buffers. The lysate was transferred to an RNAeasy mini column with a 2 mL 
collection tube and centrifuged at 13,000 rpm (10,400 x g) for 15 seconds and the 
flow through discarded. The collection tube was replaced with a clean 2mL 
collection tube, 700 µL of buffer RW1 added and centrifuged for 15 seconds at 
13,000 rpm (10,400 x g). The collection tube was discarded with flow through and 
replaced with a fresh 2 mL tube, 500 µL of buffer RPE added and centrifuged for 15 
seconds at 13,000 rpm (10,400 x g). This step was repeated a further time. RNA was 
eluted by placing the spin column into a clean 1.5 mL collection tube and 40 µL of 
RNase-free water added and centrifuged for 1 minute at 13,000 rpm (10,400 x g). 
This step was repeated with a further 40 µL of RNase-free water and incubated for 
5 minutes to ensure all RNA was eluted. The column was centrifuged again for the 
final time for 1 minute at 13,000 rpm (10,400 x g).  
2.1.8.1 DNA free treatment  
In order to remove any genomic DNA contamination from the RNA, a DNA-Free Kit 
(Ambion™) was used according to manufacturers’ guidelines. DNase I buffer  (10X) 
of 0.1 volume and 1 µL DNase I was added to eluted RNA, vortexed and incubated 
at 37°C for 30 minutes. Then 0.1 volume of re-suspended DNase inactivation 
reagent was added to the mixture, vortexed and left to stand for 2 minutes’ whilst 
mixing occasionally. Samples were centrifuged at 13,000 rpm for 1 minute and 30 
seconds, when they were aliquotted into 20 µL for storage at -80°C until needed.  
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2.1.8.2 RNA quantification 
Extracted RNA was quantified using a NanoDrop spectrophotometer at 260 nm 
wavelength. The nanodrop allowed for the measurement of up to eight 1 µL 
samples to be measured simultaneously. When the sample is placed on the 
pedestal, the arm is closed which forms a sample column and is held into place by 
surface tension during measurement. Before each measurement, the NanoDrop 
was blanked using DNA and RNA free water, 1 µL sample was measured and RNA 
concentrations were recorded as ng/µL. As a measure of purity the RNA absorbance 
ratio at 260/280 nm was also recorded, a ratio of around 2.0 is generally accepted 
as ‘pure’ for RNA (Desjardins and Conklin, 2010). 
 
2.2 Ex vivo samples 
2.2.1 Sample collection 
The East of Scotland Research Ethics Committee granted ethical approval for the 
project proposal (14/ES/1073)(Appendix 1). Sampling criteria required 10 
participants as deduced from power calculation to achieve 80% power based on 
previous hVAT sample analysis with inflammatory marker IL-6 as a primary output, 
for each three groups: 
I. Non-obese (BMI <30 Kg/m2) 
II. Obese (BMI >30 Kg/m2) 
III. Obese with Type 2 diabetes (BMI >30 Kg/m2 & T2D)  
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The sample collections were carried out by myself at Morriston and Singleton 
Hospitals, Swansea. Eligibility inclusion criteria included between age 18-65 years, 
undergoing elective abdominal surgery and generally well at time of surgery, and 
exclusion criteria included unable to give informed consent and any participant 
undergoing surgery for an underlying malignancy. Informed consent was taken by 
myself after eligibility was checked by surgeon. Informed consent was given to 
collect human visceral adipose tissue (hVAT), two EDTA blood samples and 
additional clinical information. The participants’ demographic measures (weight, 
height, birth date, blood pressure, medications and previous medical history) were 
documented from the medical records. Participants with systolic blood pressure 
≥140 mmHg and/or diastolic blood pressure ≥90 mmHg or on antihypertensive 
medications were deemed hypertensive.  
  All participants information was anonymised with an unique study 
identification number. A GP letter was sent out and noted within the medical 
records that the participant had taken part within the ‘Ghrelin’ study. No further 
contact was required with the participant. 
 
2.2.2 Blood collection 
During the surgical procedure, two 4mL Vacutainer™ EDTA-plasma tubes of whole 
blood were collected. 350 µL of blood was transferred to cold sterile centrifuge 
tubes containing 4-(2-Aminoethyl)-benzenesulfonyl fluoreide (AEBSF) at a final 
concentration of 2mg/mL and gently mixed to inhibit the activity of proteinases 
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within 30 minutes of the blood being drawn. The blood containing AESBF was 
centrifuged at 6,000 rpm (2,000 x g) for 15 minutes at 4°C and the supernatant 
decanted into separate sterile tubes (50 µL aliquots) and stored at -80°C until 
needed. The remainder of the EDTA tube of whole blood was aliquoted into 1 mL 
centrifuge tubes and stored at -20°C. The second EDTA tube was centrifuged at 
6,000 rpm (2,000 x g) for 5 minutes at 4°C and the plasma aliquoted and stored at -
80°C for later use. 
 
2.2.3  Tissue collection 
Samples were collected from routine abdominal surgery. A 3 x 3 cm biopsy of hVAT 
was removed from the greater omentum via laproscopic scissors. No extra incision 
was required for the biopsy. Once removed, the tissue was sectioned into smaller 
pieces using a sterile blade and place into a 2 mL centrifuge tube containing 1.5 mL 
RNALater® (Ambion Inc) to preserve tissue stability. Samples were transported to 
the Institute of Life Science 1 in Swansea University for storage at 4°C overnight 
before storage at -20°C until required. 
 
2.2.4 RNA extraction 
RNA was extracted from hVAT samples. Samples were cut into pieces of ≤100 mg 
and placed in a 2 mL homogeniser tube (Lysing Matrix D, MP Biomedicals). At room 
temperature, 1 mL of QIAzol lysis buffer was added, centrifuged at 4 meters per 
second for 20 seconds and then placed immediately on ice, this was repeated until 
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the sample was completely homogenised. The lysate was transferred to a clean 1.5 
mL tube and left for 5 minutes at room temperature. Chloroform (200 µL) was 
added, shaken for 15 seconds and spun at 15,000 rpm (12,000 x g) for 15 minutes at 
4°C. This stage allows separation of the mixture into a lower red phenol/chloroform 
phase, a white interphase and a colourless upper aqueous phase which contains 
RNA. The upper aqueous layer was transferred into a clean 1.5 mL tube where 1 
volume of 70% ethanol was added and immediately vortexed to mix. The next stage 
of the extraction used an RNAeasy mini kit (Qiagen™) which contains all 
components and buffers, and is described in detail in section 2.1.8. 
 
2.2.4.1 DNA free treatment  
DNA free treatment was conducted as described in section 2.1.8.1.  
2.2.4.2 RNA quantification 
Extracted RNA was quantified as described in section 2.1.8.2. 
 
2.2.5 Analytical chemistries 
2.2.5.1 Randox Daytona Plus 
The Randox Daytona Plus is a system for immunoturbidimetry and clinical chemistry 
analysis, providing rapid measurement of glucose, cholesterol, high density 
lipoprotein (HDL), albumin, creatinine and triglycerides in serum and plasma. 
Samples were run alongside quality control samples (Multisera Levels 2 and 3) and 
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calibrated using saline and Calibration Serum Level 3 (Randox). The instrument uses 
direct photometry to measure a coloured endpoint to determine glucose 
concentration (mmol/L), total cholesterol (mmol/L), HDL cholesterol (mmol/L), 
triglycerides (mmol/L), creatinine (µmol/L) and albumin (g/L). Finally, LDL 
concentration (mmol/L) was calculated using values produced by the Randox 
Daytona Plus and utilizing the Friedewald equation, all concentrations are mmol/L: 
 
 
2.2.5.2 HbA1c analysis 
In humans, glucose binds to haemoglobin in the bloodstream which has a viability 
of 8-12 weeks. Therefore, measuring the glucose bound to haemoglobin gives an 
average blood glucose level for the past three months. Determination of the 
relative percentage of glycosylated haemoglobin in whole blood (HbA1c) was 
undertaken using the BioRad D-10 haemoglobin analyser, via high performance 
liquid chromatography (HPLC). Samples were pre-diluted (5 µL in 1500 µL buffer) 
aspirated and introduced into the analytical flow path. The sample probe was 
rinsed between samples to reduce the risk of carryover. A programmed buffer 
gradient of increasing ionic strength delivered the sample to the analytical 
cartridge, where the haemoglobins are separated based upon their ionic 
interactions with the cartridge material. The separated haemoglobins were then 
passed through the filter photometer flow cell, where changes in the absorbance 
𝐿𝐷𝐿 =   𝑇𝑜𝑡𝑎𝑙 𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 − 𝐻𝐷𝐿 − (
𝑇𝑟𝑖𝑔𝑙𝑦𝑐𝑒𝑟𝑖𝑑𝑒𝑠
2.2
) 
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were measured at 415nm. HbA1c levels were recorded in both mmol/mol and % 
units.   
 
2.2.6 Acyl-ghrelin mesurement 
2.2.6.1 ELISAs 
Enzyme linked immunosorbent assay (ELISA) is a quantitative analytical method 
that shows antigen-antibody reactions through a colour change. This colour change 
is achieved via an enzyme-linked conjugate and substrate that when compared to a 
known concentration, i.e. a standard curve, can determine the concentration of 
specific molecules. There are two types of ELISAs; homogeneous and 
heterogeneous (Aydin, 2015). Homogeneous methods requires the enzyme to 
become inactivated upon antibody binding resulting in continuous antigen binding 
to the medium causing low sensitivity, however it is often used to quantify 
therapeutic substances in small quantities (O'Kennedy et al., 1990). The ELISAs used 
within the project are heterogeneous and require a wash stage to separate the 
bound antigen from the free antigen after antigen-antibody interaction. 
Heterogeneous ELISAs are based on 4 distinct methods; direct, indirect, sandwich 
and competitive (Aydin, 2015). Within this project all ELISAs were based on a 
sandwich method (Figure 2.4). 
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Figure 2.4. Key steps involved in a sandwich ELISA. (AB)-Antibody, (HRP)-Horseradish Peroxidase, 
(TMB)-3, 3’, 5, 5’-tetramethylbenzidine. 
 
2.2.6.2 Acyl-ghrelin assay 
An acyl-ghrelin ELISA kit (Merck Millipore™) was used to determine fasting plasma 
acyl-ghrelin levels, the assay was completed as per manufacturer protocol using the 
reagents supplied within the kit. Assay is characterized with 100% specificity for 
human acyl-ghrelin and 0% desacyl-ghrelin specificity. The protocol required the 
addition of 20 µL of matrix solution to the blank, standards and quality control 
wells. Then, 30 µL of assay buffer was added to the blank and sample wells, with 
the addition of only 10 µL of assay buffer to the standards and quality control wells. 
In duplicate, 20 µL of standards were dispensed in ascending concentration order, 
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followed by both quality controls and the unknown samples (AESBF treated 
plasma). Antibody solution mixture (50 µL) of human active ghrelin detection and 
capture antibody was added to each well, and the plate incubated at room 
temperature, oscillating on a plate rocker for 2 hours. The plate was then washed 3 
times, aspirated and 100 µL of enzyme solution added per well for a further 30 
minutes incubation oscillating at room temperature. The plate was then washed 6 
times. 
The colorimetric reaction was initiated with the addition of 100 µL of substrate 
solution and the plate incubated for 5-20 minutes dependent on the rate of colour 
change. A blue colouration is formed in the wells of the standards, with intensity 
proportional to increasing concentrations of acyl-ghrelin. Stop solution (100 μL) was 
added causing the blue colouration to turn yellow. Absorbance was read at 450 nm 
and corrected at 590 nm in a plate reader within 5 minutes of addition of stop 
solution. Acyl-ghrelin concentration was determined via comparison of the 
absorbance of unknown samples against the standard curve.  
 
2.2.7  Oxidative stress measurement 
Plasma total antioxidant status (TAOS) is based on the method previously described 
by Sampson et al, 2002 and Stephens et al, 2009. Laights photometric microassay 
allows the determination of TAOS values via its capability to inhibit the peroxidase-
mediated formation of the 2,2-azino-bis-3-ethylbensthiazoline-6-sulfonic acid 
(ABTS+) radical.  Due to it being inversely related to oxidative stress, the inhibition 
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of ABTS+ formation is proportional to the samples antioxidant capacity and 
therefore a low level of oxidative stress will result in a high TAOS value. Hydrogen 
peroxide acts as a free radical donor that causes the formation of ABTS+ radicals, 
thus producing a colorimetric change. Phosphate buffer saline (PBS) is used as a 
control as it contains no antioxidant molecules allowing the reaction to proceed to 
completion. Upon the addition of a plasma sample, the reaction is retarded from 
going to completion and the degree of inhibition is dependent upon the level of 
antioxidants within the sample. The percentage inhibition of the reaction is 
represented by the difference in absorbance divided by the control absorbance: 
 
The protocol required the addition of 2.5 µL of plasma or PBS (control) to a clear 
96-well ELISA plate in triplicate. Then 20 µL ABTS (20 mmol/L), 20 µL HRP (30 
mU/mL) and 40 µL PBS was added to each well, the reaction was initiated by the 
addition of 20 µL hydrogen peroxide (0.1 mmol/L). The plate was incubated at 37°C 
for 12 minutes and read at 405 nm on a Crocodile ELISA miniWorkstation (Titertek-
Berthold™).  
 
  2.3 PCR 
Polymerase chain reaction (PCR) is a technique that is based on DNA polymerase’s 
ability to synthesise new DNA strands, thus allowing for the amplification of a 
specific region of template sequence. The most commonly used DNA polymerase 
𝑇𝐴𝑂𝑆 % =
(𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑏𝑠 − 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑏𝑠)
𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑏𝑠
 𝑥 100 
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and one used in this methodology is Taq polymerase (from Thermus aquaticus). 
Standard PCR works on the principle of three main stages where double stranded 
DNA is heat denatured, specific primers align to the single DNA strands and DNA 
polymerase extends the primers resulting in two copies of the original DNA. This 
amplification cycle consisting of denaturation, annealing and elongation occurs at 
specific temperatures for multiple repeats (20-40 cycles) (Figure 2.5) which are 
optimised for the primer set to ensure a maximum product yield.  
 
Figure 2.5. Polymerase Chain Reaction (PCR), three main stages and description. 
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2.3.1 Reverse transcription 
As previously mentioned, PCR utilises Taq polymerase which is unable to use RNA 
as a starting material, therefore the initial step of RT-PCR is to convert mRNA into a 
complementary strand of DNA (cDNA) using the enzyme reverse transcriptase. 
Reverse transcriptase is an RNA-dependent DNA polymerase that generates cDNA 
via the use of mRNA as a template in the presence of either oligo-dT or random 
decamer primers. Oligo-dT primers work by annealing to mRNA poly A tails, thus 
allowing for a reduction in background due to specific reverse transcription of 
mRNA. Contrary to this are random decamers, which consist of a pool of 6-10 
nucleotides with all base combinations present, this method enables the reverse 
transcription of mRNA molecules too large for oligo dTs, however, this can increase 
background due to nonspecific annealing of RNA. The genes of interest within this 
study contained a final intron-exon boundary at various Kb distance upstream from 
the polyA tail. Therefore to ensure efficient reverse transcription of mRNA each 
specific primer required the use of either oligo dTs, random decamers or a 
combination of the two (see Table 2.4).  
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Primer Set RT Primers 
β-actin 50:50 mix 
PPARγ 50:50 mix 
ABCG1 Oligo dTs 
LXRβ Oligo dTs 
Ghrelin Oligo dTs 
LYPLA1 Random Decamers 
mBOAT4 Oligo dTs 
SREBF1 Oligo dTs 
GHSR-1α Oligos dTs 
Table 2.4. Reverse transcription primers used for cDNA synthesis for each specific primer set. 
 
2.3.1.2 cDNA synthesis  
The mRNA within total RNA extracted from tissue and cells underwent reverse 
transcription using an Ambion™ RETROscript kit following the manufacturer’s 
protocol. A master mix for the desired amount of reaction was prepared containing 
the following components, ensuring each reaction compiled of the exact same 
quantities:  
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2 µL random decamers [50 µM] OR 2 µL oligo-dTs [50 µM] OR 
1 µL random decamers & 1 µL oligo-dTs 
2 µL 10 x RT Buffer 
4 µL dNTP mix [2.5 mM each dNTP] 
1 µL MMLV reverse transcriptase [100 U/µL] 
The master mix was vortexted and centrifuged and 9 µL placed into a 0.2 mL 
centrifuge tube. 1 µg of total RNA was then added and brought to a final volume of 
20 µL using RNase free water. The final reaction was mixed, briefly spun and 
incubated at 44°C for 1 hour then at 92°C for a further 20 minutes to inactivate the 
reverse transcriptase, and stored at -20 °C for future use.  
 
2.3.2 End point RT-PCR 
End point RT-PCR utilises the basic principle of standard PCR to confirm the 
expression of key genes related to this project. Standard PCR undergoes 3 phases. 
Initially the reaction has an exponential phase where the exact doubling of product 
is accumulating at every cycle. This leads into a linear phase, which is due to the 
reaction slowing and components being consumed. Finally, the PCR enters a 
plateau phase, where the reaction stops and no more PCR product is generated. At 
this point the PCR product can be visualised on a gel, known as end point detection. 
Visualising the PCR product at this point does not allow for the quantitation of 
mRNA expression levels, however it does allow for a rapid and cost-effective 
method for the confirmation of the presence or absence of key genes within sample 
types.  
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2.3.2.1 Reaction 
All reagents were sourced from Promega™, the following was used for each end 
point PCR sample and all reactions were prepared within a bench top PCR hood 
cleaned with 70% ethanol and UV irradiation for 15 minutes prior to use. The 
cycling conditions were performed within a BioRad CFX Connect and specific cyclic 
conditions for each primer set are described in Appendix 2. 
10 µL 5X Colourless Go®Taq Flexi Buffer 
3 µL MgCl2 [25 mM] 
1 µL dNTP mix [40 mM] 
0.5 µL Go®Taq G2 Flexi DNA Polymerase [5 U/µL] 
1 µL Forward Primer [15 pmol] 
1 µL Reverse Primer [15 pmol] 
30.5 µL Deionised, sterile H2O 
3 µL Sample cDNA or negative control (H2O) 
 
2.3.2.2 Gel electrophoresis  
PCR products were visualised on a 12% polyacrylamide gel using the following 
reagents: 
Acrylamide:Bisacrylamide (37.5:1) stock solution, containing 30% w/v 
acrylamide (Severn Biotech Ltd) 
10x Tris/Borate/EDTA Buffer (Invitrogen) 
TEMED (N1N1 N1 N1-tetramethylethylene diamine) (Sigma-Aldrich) 
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10% Ammonium persulphate (Sigma-Aldrich) 
12% polyacrylamide gels were made by diluting 16 mL Acrylamide:Bisacrylamide 
solution and 4.5 mL 10X TBE buffer in 24 mL distilled water. Polymerisation of the 
acrylamide was initiated by the addition of 220 µL of 10% APS and 45 µL of TEMED. 
The solution was then placed into four BioRad caskets and a 15-tooth comb 
inserted. The gels were set at room temperature for approximately 30 minutes then 
wrapped and stored at 4°C for future use.  
Gels were placed into vertical gel cases and filled with 1x TBE buffer. 5 µL 
PCR product was mixed with 2 µL gel loading buffer (50% v/v glycerol, 10% v/v 0.1M 
EDTA, 1% v/v bromophenol blue, 1% SDS) (Sigma-Aldrich), with 5 µL of mixture  
pipetted into the loading well. Each gel also contained a reference 100 base pair 
(bp) ladder, 5 µL of a premixed ladder was loaded into the first well of every gel. 
The premixed ladder contained; 1 µL 100 bp ladder (Promega), 2 µL gel loading 
buffer and 5 µL distilled water.  
Gels were visualised using silver staining, which required the gel being 
placed in silver nitrate solution (1g AgNO3 (Sigma-Aldrich) in 1 L H2O) under gentle 
agitation for 10 minutes. Silver nitrate solution was decanted off and residual 
solution washed off with distilled water. The gel was then placed in sodium 
hydroxide solution (13.5g NaOH (Sigma-Aldrich) in 900 mL H2O and 3.6 mL 
formaldehyde (Sigma-Aldrich)) for a further 10 minutes under gentle agitation. Gels 
were imaged using a white tray on a BioRad EZ Imager and analysed using BioRad 
Image Tool software. 
 
65 
 
2.3.3 Quantitative Real time PCR  
Gene expression profiling analysis via quantitative real time PCR (qReal Time PCR) 
allows for the reliable detection and quantification of nucleic acids during the 
exponential phase of a PCR. qReal Time PCR works on the same amplification 
principle of PCR, however the experimental design is based on the detection and 
quantification of fluorescence emitted by a reporter molecule in real time. RNA 
transcripts are reverse transcribed into cDNA first then used in the qReal Time PCR. 
The accumulation of PCR product generated with each cycle emits an increased 
fluorescence that once it has passes a certain threshold, the cycle in which this 
occurs can be quantified (Ct value). The Ct value is directly correlated to the initial 
amount of target template, allowing for the quantification of gene expression. 
Reporter molecules that are most commonly used are DNA binding agents 
(SYBRgreen dye) and hydrolysis probes (Taqman).  
 
2.3.3.1 SYBRgreen 1 
Throughout the analysis, SYBRgreen I (BioRad™) was utilised as a reporter 
molecule. SYBRgreen I is an intercalating dye that binds to the double stranded 
DNA, emitting fluorescence that correlates with DNA amplification. The advantage 
of using SYBRgreen I over complex probes is that it is an intercalating dye which 
offers a simple and cost-effective approach. However, due to its ability to bind to 
any double stranded DNA it is susceptible to error. Primer optimisation is key to 
decreasing the risk of non-specific primer dimer formation.  
66 
 
2.3.3.2 Real time PCR primer design 
Real Time PCR primers were designed using the NCBI tool Primer BLAST. All primers 
were designed using the RNA gene sequence to be approximately 20 nucleotides in 
length, with an annealing temperature of approximately 60°C. The tool returned 
several primer pairs for comparison and the primer pair selected was based on a GC 
content of around 50-60% to ensure product stability and avoiding self- 
compatibility, reducing the possibility of primer dimer. The primer sequences were 
then located within the gene sequence to ensure they crossed an exon-exon 
boundary. The primers were designed to produce an amplicon of 150-250 bp in size 
from GHRL, PPARγ, ABCG1, LXRβ and LYPLA1 as target genes, and β-actin as a 
housekeeper gene. 
 Oligonucleotides were synthesised by Eurofins MWG Operons (Germany) 
and shipped desalted and dehydrated. Upon arrival, they were re-hydrated with the 
stated volume of filter sterilised water to produce a concentration of 100 pmol/µL, 
then diluted to 15 pmol/µL, aliquoted and stored at -20°C. 
Due to the quantity of time required to design and optimise, additional 
primers for SREBF1 and mBOAT4 that proved difficult to optimise in-house, were 
designed and validated by Primerdesign™. The company was supplied with the 
target genes of interest and returned the designed and optimised primer sets. The 
product came with a guaranteed priming specificity and efficiency of >90%. The 
lyophilised primer mix was resuspended in 660 µL filter sterilised water to achieve a 
300 nM working concentration, aliquoted and stored at -20°C. All primer sequences 
are listed in Appendix 2. 
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2.3.3.3 Real Time PCR reaction 
All reactions were prepared within a bench top PCR hood that was cleaned with 
70% ethanol and UV irradiated for 15 minutes prior to use. The cycling conditions 
were performed within a BioRad CFX Connect and each primer set required a 
distinct and optimised cycling condition (Appendix 2). However, each Real Time PCR 
reaction conducted was uniform, consisting of the following reagents: 
12.5 µL SYBRgreen I 
1 µL Forward Primer [15 pmol] 
1 µL Reverse Primer [15 pmol] 
5 µL cDNA 
5.5 µL Deionised, sterile H2O 
 
2.3.3.4 Analysis of Real Time PCR data; 2-ΔΔCT Method 
Relative quantitation was used to determine differences in expression levels of the 
specific target genes between different samples. This generates a fold change 
output that represents the change in expression of a particular gene either over 
time or in varying treatments. In order to obtain accurate relative quantitation of 
an mRNA target, the expression level of an endogenous control (housekeeper) β-
actin were also measured (Livak and Schmittgen, 2001). 
To ensure that the comparative Ct method or 2-ΔΔCT method could be used 
for data analysis a validation experiment was conducted. In order to determine a 
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fold change value, the raw Ct values were analysed using a 3 step process. Firstly, it 
was required make the target Ct value relative to an endogenous housekeeper: 
 
Then, determine the magnitude of the fold change in respect to a calibrator group 
i.e. treated versus an untreated sample: 
 
Finally, the ΔΔCt must be log transformed: 
 
A positive ΔΔCt will produce a fold change of <1. In order to establish the 
magnitude of fold change the value is expressed as either a fraction or 1 over. For 
example, 2-ΔΔCt = 2-(2.0) = 0.25, fold change can either be expressed as ¼ or as 1/0.25 
to produce a 4-fold down regulation. 
 
2.3.4 PCR controls and validations 
2.3.4.1 PCR controls 
The controls within PCR consisted of a no-template control (NTC) and no-reverse 
transcription control (NRTC). NTC contains all the Real Time PCR reagents without 
the cDNA template, allowing the detection of any contamination within the 
ΔCt = Ct(target) - Ct(housekeeper) 
ΔΔCt = ΔCt(test sample) - ΔCt(calibrator sample) 
2-ΔΔCt 
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mastermix. NRTC allows for the detection of any contamination within the reverse 
transcription step since it contains all reagents other than template RNA.   
 
2.3.4.2 Primer validation 
To ensure a comparative method could be used within data analysis, all primers had 
to have the same standard efficiency. If the primer efficiencies were approximately 
equal then there would be limited variation in the ΔCT value within the template 
dilution (Schmittgen and Livak, 2008). To ensure this was correct for all primers, 
cDNA was generated from 3 separate RNA samples of hVAT (Section 2.2.5) and a 
template dilution series over 3 points produced. Real Time PCR was performed for 
each sample using all generated primers and ΔCT values established. Data was 
plotted to produce a semi-regression plot, where primers were accepted on the 
basis of slope value of <0.1. Validation plots for each primer set can be found in 
Appendix 3.  
 
2.3.3.3 Real Time PCR Validation  
In order to determine the assay’s reproducibility, both inter- and intra-assay 
variation for Real Time PCR data generated were assessed from each primer set 
used. Intra-assay variation was determined by performing 5 assays (each in 
triplicate) for each primer set, on 3 different RNA samples (from hVAT) on a single 
plate within the same Real Time PCR run. Inter-assay variation examined the 
variation produced within a sample for each primer set on different Real Time PCR 
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runs. Therefore, 3 samples sourced from hVAT were run in triplicate for each 
primer set on 5 different assays over the course of 10 days. Intra- and inter-assay 
coefficient of variances are given in Table 2.5 (raw data found in Appendix 4). 
 
Primer Set Intra-variation (CV%) Inter-variation (CV%) 
β-actin 0.66 - 0.84 1.06 - 1.47 
PPARγ 1.10 - 1.85 1.60 - 2.02 
ABCG1 0.74 - 1.10 1.05 - 1.24 
LXRβ 0.83 - 1.38 1.76 - 2.34 
GHRL 0.88 - 1.39 1.22 - 1.63 
LYPLA1 0.42 - 0.84 0.74 - 1.01 
mBOAT4 0.93 - 1.10 1.34 - 2.01 
SREBF1 1.02 - 1.26 0.83 - 1.42 
Table 2.5. Intra- and inter-variations for Real Time PCR for all primer sets. 
 
 
 
 
 
71 
 
2.4 Adipokine ELISAs 
Tumor necrosis factor alpha (TNFα), interlukin-6 and interleukin-10 (IL-6 and IL-10) 
were measured using sandwich ELISA assays purchased from R&D systems™, as 
described in Section 2.2.7.1. The ELISA for each adipokine used reagents within the 
kit and in accordance with the manufacturer’s guidance. Within this project, both 
SGBS cell culture supernatants and human plasma collected at time of procedure 
were needed. Each kit was brought to room temperature before use and standards 
made from a supplied lyophilised stock. All samples were thawed and centrifuged 
at 4000 rpm (1,431 x g) for 5 minutes before assaying and plated onto a standard 
plate layout (Figure 2.6).  
 
Figure 2.6. Plate layout for adipokine ELISAs. The 8 standards in duplicate were placed in ascending 
concentration (1-8, blue gradient). Standard curve is followed by unknown samples in duplicate (1 & 
2, purple and orange). 
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2.4.1 TNFα 
The protocol required the addition of 50 µL of assay diluent to each well, followed 
by 200 µL of known standards, quality controls and unknown samples in duplicate. 
After a 2 hour incubation at room temperature, the plate was washed and 
aspirated. Subsequently 200 µL of TNFα conjugate was added and incubated at 
room temperature for either 1 hour for cell culture supernatant or 2 hours for 
human plasma samples. The plates underwent a final wash cycle before the 
initiation of the colourimetric reaction as described in Section 2.4.4.  
 
2.4.2 IL-6 
The IL-6 assay protocol required the addition of 100 µL assay diluent, then 100 µL of 
standards and unknown samples to each well in accordance with standard plate 
layout (Figure 2.6). After a 2 hour incubation at room temperature, the plate was 
washed and aspirated and 200 µL of human IL-6 conjugate added to each well for a 
further 2 hour room temperature incubation. The microplate then underwent a 
final wash cycle before initiating the colourimetric reaction as described in Section 
2.4.4. 
 
2.4.3 IL-10 
The IL-10 procedure required a 10-fold dilution of cell supernatant samples in 
specific calibrator diluent before running, however plasma samples were run neat. 
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For plasma samples the microplate required the addition of 50 µL of assay diluent 
before loading 200 µL of standards or samples per well, whilst 200 µL diluted cell 
supernatant samples were added directly to the plate. Both sample types required 
a 2 hour room temperature incubation. The plate was then washed and aspirated 
and 200 µL of human IL-10 conjugate added. Sample types required different 
incubation times at room temperature, with cell supernatants requiring a 1 hour 
incubation and plasma samples requiring a 2 hour incubation. The plate underwent 
a final wash cycle before initiating the colourimetric reaction as described in Section 
2.4.4. 
 
2.4.4 Colourimetric reaction 
All assays underwent the same protocol to produce a colourimetric reaction. The 
colourimetric reaction was initiated with the addition of 200 µL of substrate 
solution and incubated for 20 minutes dependent on the rate of colour change. 50 
μL of stop solution was added causing the blue colouration to turn yellow after 
acidification. Absorbance was read at 450 nm and corrected at 590 nm in a plate 
reader within 5 minutes of addition of stop solution. Adipokine concentration was 
determined via comparison of the absorbance of unknown samples against the 
known concentration of the standards.   
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2.5 Statistical analysis  
All statistical analysis of raw data was conducted using SPSS version 22 and figures 
were constructed using Microsoft Excel. A p-value of <0.05 was deemed statistically 
significant for all tests.  
 
2.5.1 Categorical data 
Categorical data that was represented by numbers (n) and percentage (%) were 
analysed using pearson chi squared test.  
 
2.5.2 Continuous data 
The continuous data throughout this thesis is summarized by mean (±standard 
deviation (SD)), when the data were normally distributed and by median and 
interquartile range (IQR) if not normally distributed. Normality was checked using 
Kolmogorov-Smirnov test and visualised on q-q plots. The student t-test was used 
to compare the mean of two groups and analysis of variance (ANOVA) to compare 
the mean of more than two groups for normally distributed data. Alternatively, 
non-normally distributed data was analysed using Whitney U and Kruskal Wallis 
tests. For the analysis of association between two continuous variables within 
normally distributed data, a Pearson correlation coefficient test was conducted, 
where a positive or negative correlation spanned from -1 to 1, with 0 indicating no 
correlation. Within non-normally distributed data, a Spearman's Rho test was 
conducted. 
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Chapter 3 
Effect of acyl-ghrelin in vitro on mature 
adipocytes in hyper- and normoglycaemic 
environments 
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3.1 Introduction  
Adipose tissue provides a vast store of energy which contributes to whole body 
homeostasis. In mammals, long term energy is stored within the lipid droplets of 
adipocytes, with over 90% stored in the form of triglycerides (Shen et al., 2003). 
Obesity results in the enlargement of adipose tissue to store the excess energy 
intake. The way in which adipose tissue facilitates this enlargement is dependent 
upon both diet and genetics; and their interaction together (Jo et al., 2009).  
 
3.1.1 Lipid droplet storage in mature adipocytes 
Mature adipocytes contain multiple lipid droplets, ranging between 25 and 150 μm 
in diameter. In a fed state, the human body will store excess energy via active 
insulin-dependent GLUT4, allowing for the uptake of glucose from the bloodstream 
into adipocytes. Intracellular adipocyte esterification of FFA (lipogenesis) occurs 
when the chylomicrons from the intestine esterify glycerol-3-phosphate, the 
product of glycolysis, to form lipid droplets of triglycerides. Adipocyte hydrolysis of 
triglycerides (lipolysis) produces adipose tissue’s major secretory product, FFA 
(Wood and Trayhurn, 2006). If the rate of lipogenesis exceeds that of lipolysis then 
adipocyte cells either adapt via expansion in lipid droplet size or cellular lipid area 
(hypertrophy), or recruit an increased number of adipocytes (hyperplasia). 
Hypertrophy occurs prior to hyperplasia and this is the initial cellular response to 
allow for storage of additional triglycerides in the progression of obesity.   
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3.1.2  Hypertrophy-induced inflammation and Type 2 diabetes 
An increase in adipocyte size due to an inability to proliferate is deemed to have 
pathological consequences for both metabolic and immune functions (Bays et al., 
2008). Human studies indicate that in individuals with obesity and T2D there is a 
decline in the expression of adipogenic genes, resulting in the storage of energy 
predominantly through lipogenesis and adipocyte hypertrophy, rather than the 
promotion of hyperplasia (Bays et al., 2008, Dubois et al., 1979, Dubois et al., 2006). 
Adipose tissue that contains hypertrophic adipocytes secrete pro-inflammatory 
proteins that result in low-grade inflammation and insulin resistance in obese 
individuals, which are implicated in the onset of T2D (Figure 3.1) (Kennedy et al., 
2009).  
Pro-inflammatory adipokines promote insulin resistance via the suppression 
of insulin signalling and alterations in glucose homeostasis. Saturated FFA, gut-
derived bacteria, LPS and pro-inflammatory adipokines have been shown to 
activate key inhibitory molecules within insulin signalling such as NFΚB, suppressor 
of cytokine signalling (SOCS) and JNK (Shi et al., 2006, Ghoshal et al., 2009, Kwon 
and Pessin, 2013).  
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Figure 3.1. Overview of the downstream effects of hypertrophic adipocytes in obesity. The Red outer 
circles within adipocytes indicate hypertrophic stress, purple segments represents the nucleus and 
triglycerides are indicated by TG. Dysregulated adipokine release produces systemic inflammation 
and alters lipid and glucose metabolism in the liver and skeletal muscle. 
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3.1.3 Markers of inflammation 
Controversy exists as to which are the most appropriate adipokines to measure in 
relation to adipose tissue and its relationship to the metabolic state. Most notably 
described in association with the metabolic state and adipocyte size are the pro-
inflammatory factors TNFα and IL-6 (Ronti et al., 2006), and the anti-inflammatory 
factor IL-10 (Esposito et al., 2003). 
3.1.3.1 TNFa 
TNFα was the first recorded adipokine to demonstrated an association between 
obesity, inflammation and T2D. This finding was underpinned by studies 
demonstrating that TNFα is highly expressed in obesity and is implicated in the 
pathogenesis of insulin resistance in adipose tissue (Stanley et al., 2011, 
Hotamisligil et al., 1995, Hotamisligil et al., 1993). TNFα impairs insulin action 
through inhibition of IRS signalling via the activation of serine kinases (Kwon and 
Pessin, 2013). Furthermore, TNFα promotes the expression of inflammatory 
cytokines and chemokines within adipocytes (Rotter et al., 2003). 
3.1.3.2 IL-6 
IL-6 is a pro-inflammatory adipokine that is involved in obesity-related insulin 
resistance (Ouchi et al., 2011). IL-6 is secreted from WAT, with approximately equal 
gene expression produced by adipocytes and infiltrated macrophages (Wisse, 
2004). IL-6 function in insulin resistance and glucose homeostasis is influenced by 
tissue type and metabolic state. Systemic increase in IL-6 is has a detrimental effect 
by increasing insulin resistance (Makki et al., 2013). Within adipose tissue and the 
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liver, IL-6 results in increased insulin resistance through impairing insulin-induced 
insulin receptor and IRS action via the up regulation of SOCS3 (Rotter et al., 2003, 
Senn et al., 2003)  
3.1.3.3 IL-10 
The anti-inflammatory adipokine IL-10 has a role in the attenuation of the immune 
response triggered by the action of pro-inflammatory markers such as IL-6 and 
TNFα (Stenvinkel et al., 2005). IL-10 secretion has been described from both non-
adipocyte and adipocytes fractions, with adipocyte size being negatively associated 
with IL-10 release (Skurk et al., 2007). Clinical studies have shown an association 
between reduced levels of IL-10 in obesity and the metabolic syndrome (Esposito et 
al., 2003, Skurk et al., 2007).  
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3.2 Aims 
Within this chapter I predict that findings will provide evidence for a detrimental 
role for acyl-ghrelin in the regulation of key genes within the lipid retention 
pathway, resulting in an increase in lipid retention area and in turn the promotion 
of inflammatory marker levels. To provide insight into my hypothesis, this chapter 
aimed to:- 
1. Determine the effect of acyl-ghrelin exposure on human mature 
adipocytes in different glycaemic environments 
2. Establish the effect of chronic hyperglycaemia and acyl-ghrelin exposure 
on lipid retention 
3. Establish the effect of chronic hyperglycaemia and acyl-ghrelin exposure 
on inflammation  
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3.3 Methods 
3.3.1 SGBS cell treatment 
SGBS cells were cultured and differentiated as described in Sections 2.1.1 to 2.1.4. 
Cell dosage concentrations with acyl-ghrelin were based on previous published 
literature. Due to the novel aspect of the experiment, whereby acyl-ghrelin 
treatment of human mature adipocytes has not been previously recorded, 
therefore, dosage was based on acyl-ghrelin treated human macrophage and 
endothelial cell lines (Asakawa et al., 2003, Zhu et al., 2014). Chronic 
hyperglycaemic environments were introduced 48 hours prior to cell dosage with 
acyl-ghrelin or PBS vehicle. As previously mentioned in Section 2.1.5, glucose levels 
were determined by the physiological ranges present within individuals with T2D 
(25 mM) and healthy controls (5.5 mM). To examine acyl-ghrelin mediated effects 
on the inflammatory state, cells underwent an immune challenge with the 
administration of 1 µg/mL LPS, with dosage determined via previously published 
data within similar experiments (Beynon et al., 2013, Waseem et al., 2008). LPS is 
an integral component of the outer membrane of gram negative bacteria that 
stimulates innate immunity, and is a potent tool in the examination and evaluation 
of anti-inflammatory agents. Cell supernatant measure of key inflammatory 
markers (TNFα, IL-6 and IL-10) post exposure to LPS, acyl-ghrelin or a combination 
of LPS and acyl-ghrelin allows for the exploration of acyl-ghrelin as an inflammatory 
mediator. Oil red O staining and RNA extraction occurred at two time points; 17 and 
34 hours. The time points depict a point of collection before a half and a full cell 
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cycle respectively, which would normally consist of 38 hours. Treatment wells were 
run in duplicate on each 6-well plate, and each plate was run in triplicate.   
 
3.3.2 Validation of GHS-R1α 
To validate whether acyl-ghrelin presence could alter adipocyte function via the 
GHS-R1α, end point PCR was used to determine the presence of the acyl-ghrelin 
receptor (Section 2.3.2). All samples provided a positive result for the presence of 
GHSR-1α, with a product band at 118 bp, as shown below (Figure 3.2). 
 
Figure 3.2. 12% polyacrylamide gel showing PCR products for GHSR1α (118 bp) for RNA extracted at 
17 hours from cells grown in a high glucose environment with acyl-ghrelin (G) or vehicle/PBS (V). 
 
3.3.3 Lipid accumulation measurements  
Lipid area was determined using Oil red O staining as described in Section 2.1.6. 
Image analyses were conducted using ImageJ software (Version 2) and a published 
protocol for the quantification of lipid area (Mehlem et al., 2013). Each 
experimental well produced 3 magnifications of images in 5 fields, each field was 
predefined and set prior to cell seeding to remove experimental bias, with 20 cells 
at x50 magnification analysed to determine cell diameter and intracellular lipid 
V -ve G 
100bp 
200bp 
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area. This equates to 100 cells analysed per treatment, in duplicate. Cellular size 
measurements were recorded as followed; 
 Cellular diameter- the average span of the cell across its longitudinal axis 
(µm) within a treatment well 
 Cellular area- the average intracellular lipid area for cells (µm2) within a 
treatment well  
 Global cellular diameter- the average span of the cell across its longitudinal 
axis (µm) across all experiment wells 
 Global cellular area- the average intracellular lipid area for cells (µm2) across 
all experiment wells 
 
3.3.4 Gene expression measurements 
Gene expression levels were determined using Real Time PCR (Section 2.3) from 
RNA extracted from cells (Section 2.1.8). Each gene had a specific primer set and 
was subject to an optimised Real Time PCR cycling condition (Appendix 2). Results 
were analysed using the 2-ΔΔCT method as previously described (Section 2.3.4), thus 
allowing for the calculation of gene expression in a relative manner. The mean Ct 
for each gene within the treatment well was normalised against the threshold cycle 
data of the housekeeping gene (β-actin). The normalised ΔCt data was used in 
further analysis to measure gene expression fold change across the treatment sets 
for each gene of interest. Fold change differences less than 0.5 were classified as 
down regulation of gene expression and 1/x representing a true fold change. A fold 
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change difference of greater than 1.5 illustrated an up-regulation in gene 
expression (raw data shown in appendix 5).  
 
3.3.5  Inflammatory marker measurements 
 
Inflammatory markers (TNFα, IL-6 and IL-10) were measured in LPS and acyl-ghrelin, 
separately and combined, treated cells, in both normo- and hyperglycaemic 
environments using specific ELISAs (Quantikine®, R&D systems), as principal 
discussed in Section 2.4. Two aliquots of 1 mL cell supernatant were collected at 
each time point for each treatment duplicate and stored at -80°C until analysed. 
Each ELISA consisted of an 8-point standard curve from which protein 
concentration was determined via sample absorbance plotting and a positive 
quality control sample (see plate layout (Figure 3.3)). Sample values with a 
coefficient of variance of less than 15% between duplicates were accepted.  
 
3.3.6  Data analysis 
Raw data retrieved from this chapter was treated as described in Section 2.5 using 
SPSS™ Version 22. Only continuous data was analysed within this chapter which 
was tested in accordance to normality (Section 2.5.2). 
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Figure 3.3. Plate layout for adipokine ELISA for each experimental repeat.  
STD= standard, QC= quality control, green boxes indicate hyperglycaemic environment, blue boxes 
indicate normoglycaemic environment and treatments are denoted by G= acyl- ghrelin, V=vehicle, 
L=LPS and LG=acyl-ghrelin and LPS. 17 and 34 indicate the relevant time point samples where 
extracted i.e. 17 hours and 34 hours post treatment.  
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3.4 Results 
3.4.1 Acyl-ghrelin treated human mature adipocytes in a normoglycaemic 
environment 
Lipid area 
There was a significant increase in lipid area (µm2) in acyl-ghrelin treated cells when 
compared to vehicle at both time points (Table 3.1 & Figure 3.4). Between 17 and 
34 hours, acyl-ghrelin mediated lipid retention increased cell lipid area significantly 
from 4348.0 µm2 to 5595.6 µm2 respectively (p<0.01) (Figure 3.4A & 3.4C). 
However, over the time course, the lipid area of the vehicle treated cells remained 
unchanged with an area of 3461.4 µm2 at 17 hours and 3516.5 µm2 at 34 hours (p= 
0.98) (Figure 3.4B).  
Cell diameter (µm) and lipid area (µm2) were compared during data analysis 
to ensure an increase in lipid area was not due to an increase in cellular size. Results 
confirm no significant correlation between global cell diameter and global lipid area 
within the normoglycaemic environment of both acyl-ghrelin and vehicle treated 
cells (r=-0.003, p= 0.95) (Table 3.1, Figure 3.5). 
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  Lipid area (µm
2
)  Cell diameter (µm)   
Time 
point 
Vehicle 
treated  
(n=600) 
Acyl-ghrelin 
treated 
(n=600)  
P-value Vehicle 
treated  
(n=600) 
Acyl-ghrelin 
treated 
(n=600)  
P-value 
17 
hours 
3461.4 
[3335 – 3914] 
4348.0 
[4371 – 4896] 
<0.001 
176.7 
[152 – 203] 
171.1 
[150 – 194] 
0.44 
34 
hours 
3516.5 
[3457 – 3734] 
5595.6 
[5254 – 5742] 
<0.001 
164.2 
[147 – 188] 
167.3 
[152 – 194] 
0.64 
P-value 0.98 <0.01  0.10 0.38  
Table 3.1. Lipid area and cell diameter for acyl-ghrelin treated cells in normoglycaemic environment. 
Median and IQR shown as not normally distributed and Kruskal-Wallis used for data analysis. P-
values <0.05 are statistically significant and in bold. 
 
Figure 3.4.A-D. Representative Oil red O imaging of mature SGBS cells in 5.5 mM (normoglycaemia) 
glucose at x50 magnification. Red stain- lipid droplets; purple stain- nuclei. (A)- Cells grown in 
presence of acyl-ghrelin for 17 hours. (B)-Cells grown in presence of PBS vehicle for 17 hours. (C)- 
Cells grown in presence of acyl-ghrelin for 34 hours. (D)-Cells grown in presence of PBS vehicle for 34 
hours.  
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Figure 3.5. Scatter graph between cell diameter (µm) and lipid area (µm
2
) of all cell treatments in 
normoglycaemic environment. Pearson’s correlation, r=-0.003, p=0.95. y=-0.0003x + 166.55. 
R²=0.0002 
Gene expression  
ABCG1 
Gene expression data indicated a significant 8.1 (±2.1)-fold down-regulation of 
ABCG1 in acyl-ghrelin treated cells after 17 hours exposure in comparison to vehicle 
treated cells (p<0.001). However, at 34 hours, this down-regulation had curtailed, 
exhibiting no overall change in ABCG1 expression between acyl-ghrelin treated cells 
and vehicle control (0.9 ±0.4-fold change; p=0.15) (Figure 3.6A).  
LXRβ 
LXRβ expression showed no significant change in gene expression at 17 hours in 
cells exposed to acyl-ghrelin compared to those of vehicle treatment (0.9 ±0.3-fold 
0
50
100
150
200
250
300
0 2000 4000 6000 8000 10000 12000
C
el
lu
la
r 
d
ia
m
et
er
 (
µ
m
) 
Cellular lipid area (µm2) 
90 
 
change; p=0.45). However, at 34 hours post acyl-ghrelin exposure, it exhibited a 
significant 3.6 ±0.3-fold up regulation (p<0.001) (Figure 3.6B). 
SREBF1 
SREBF1 expression in acyl-ghrelin treated cells had a non-significant up-regulation 
at 17 hours of 1.8 ±0.2-fold change (p=0.06) compared to vehicle treated cells. This 
increased over the course of the experiment, producing a significant up-regulation 
in the presence of acyl-ghrelin at 34 hours (5.9 ±1.8-fold, p<0.001) (Figure 3.6C). 
 
Figure 3.6A-C. Relative fold change values for gene expression data in acyl-ghrelin treated cells in 
normoglycaemic environment in comparison to vehicle at both time points (17 and 34 hours). Fold 
change between -1.5 and 1.5 is classed as no relative gene expression change (grey region). (A)- 
ABCG1-fold change, (B)- LXRβ-fold change and (C)- SREBF1-fold change. Error bars indicate standard 
deviation between ΔΔCt of experimental repeats (n=6). * indicates a significant (p<0.05) difference 
of ΔCt in acyl-ghrelin treated cells versus vehicle treated cells, determined using an independent t-
test.  
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Inflammatory markers 
IL-6 
IL-6 release was measured in cell supernatants after exposure to acyl-ghrelin, LPS or 
a combination of the two (acyl-ghrelin and LPS) (Table 3.2). Exposure to acyl-ghrelin 
showed no significant change in IL-6 release in comparison to vehicle treated cell 
supernatant at 17 hours (46.9 v 53.0 pg/mL; p= 0.149), however at 34 hours there 
was a significant decline in IL-6 levels in comparison to vehicle treated cell 
supernatant (74.8 v 94.1 pg/mL; p<0.05). Immune challenging vehicle cells with LPS 
resulted in a significant increase in IL-6 at both 17 and 34 hours (425.1 pg/mL and 
480.3 pg/mL; both p<0.05, respectively). There was no change in IL-6 levels when 
acyl-ghrelin and LPS exposure was compared to LPS only treatments at both 17 and 
34 hours (412.8 v 425.1 pg/ml; p=0.248 and 451.6 v 480.3 pg/mL; p=0.08; 
respectively).  
 IL-6 [pg/mL] 
Treatment 17 hours 
(n=6) 
34 hours 
(n=6) 
Vehicle 53.0 [43.7-54.8] 94.1 [89.9-99.7] 
Acyl-ghrelin 46.9 [32.4-48.5] 74.8 [67.9-84.3] 
LPS 425.1 [391.2-450.8] 480.3 [462.5-519.4] 
LPS & Acyl-ghrelin 412.8 [401.1-417.2] 451.6 [444.1-464.5] 
Table 3.2. IL-6 levels for acyl-ghrelin and vehicle treated cells in normoglycaemic environments. 
Median and IQR shown as not normally distributed. 
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TNFα  
TNFα release were measured in cell supernatants after exposure to acyl-ghrelin, LPS 
or a combination of the two (acyl-ghrelin and LPS) (Table 3.3). Acyl-ghrelin 
treatment showed no significant alterations of TNFα levels in cell supernatants at 
both 17 and 34 hour (7.3 pg/mL and 6.2 pg/mL: p=0.245 and p=0.08, respectively). 
LPS exposure caused a significant increase in TNFα levels at both 17 and 34 hours 
(79.0 pg/mL and 78.0 pg/mL: both p<0.05, respectively). This increase was also 
present in cell supernatant of cells pre-treated with acyl-ghrelin prior to LPS 
exposure (72.3 pg/mL and 76.2 pg/mL: both p<0.05, respectively). However, there 
was no significant change when comparing LPS and combined LPS and acyl-ghrelin 
treatment on TNFα levels at 17 and 34 hours (LPS v LPS& acyl-ghrelin: 79.0 pg/mL v 
72.3 pg/mL and 78.0 pg/mL v 76.2 pg/mL: p=0.08 and p=0.248, respectively).  
 
 TNFα [pg/mL] 
Treatment 17 hours 
(n=6) 
34 hours 
(n=6) 
Vehicle 4.0 [2.2-7.3] 1.5 [1.4-3.1] 
Acyl-ghrelin 7.3 [6.1-7.7] 6.2 [4.6-6.3] 
LPS 79.0 [74.6-84.7] 78.0 [77.7-79.1] 
LPS & Acyl-ghrelin 72.3 [67.0-77.2] 76.2 [70.5-82.2] 
Table 3.3. TNFα levels for acyl-ghrelin and vehicle treated cells in normoglycaemic environments. 
Median and IQR shown as not normally distributed.  
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IL-10 
IL-10 levels was measured after exposure to acyl-ghrelin, LPS or a combination of 
the two (acyl-ghrelin and LPS) (Table 3.4). Mature adipocytes treated with acyl-
ghrelin showed a significant increase in the level of IL-10 present in cell 
supernatants in comparison to the vehicle control at 17 and 34 hours (314.1 pg/mL 
and 341.0 pg/mL: both p<0.001, respectively). Immune challenged cells 
demonstrated no overall change in IL-10 levels at both 17 and 34-hour time points 
(264.3 pg/mL and 196.4 pg/mL: p=0.137 and p=0.934, respectively). Pre-treatment 
of cells with acyl-ghrelin before LPS exposure resulted in no change in IL-10 levels 
compared to cell supernatant of LPS only exposure at 17 hours (292.3 pg/mL v 
264.4 pg/mL; p=0.30, respectively), and a significant increase at 34 hours (303.9 
pg/mL v 196.4 pg/mL; p<0.001, respectively). 
  
 IL-10 [pg/mL] 
Treatment 17 hours 
(n=6) 
34 hours 
(n=6) 
Vehicle 226.8 (13.7) 188.2 (20.8) 
Acyl-ghrelin 314.1 (27.3) 341.0 (14.0) 
LPS 264.3 (26.6) 196.4 (17.5) 
LPS & Acyl-ghrelin 292.3 (19.5) 303.9 (25.2) 
Table 3.4. IL-10 levels for acyl-ghrelin and vehicle treated cells in normoglycaemic environments.  
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3.4.2 Acyl-ghrelin treated human mature adipocytes in a hyperglycaemic 
environment 
Lipid area 
Within a hyperglycaemic environment, cells treated with acyl-ghrelin exhibited a 
significant increase in lipid area (µm2) when compared to vehicle substitute (Figure 
3.7A-D). This marked increase in lipid area was present at both 17 hour (4788.7 µm2 
v 3592.5 µm2; p<0.001) and 34 hour time points (4435.8 µm2 v 3484.0 µm2; 
p<0.001) (Table 3.5). Over the time course, there was no significant increase in 
cellular lipid area within cells treated with acyl-ghrelin (4788.7 µm2 v 4435.8 µm2, 
p=0.086). Furthermore, cells exposed to the vehicle substitute also showed no 
significant intracellular lipid area change, (17 hour v 34 hour; 3592.5 µm2 v 3484.0 
µm2; p=0.174) (Table 3.5).  
When global cell diameter and lipid area were analysed within a hyperglycaemic 
environment there was no significant correlation between the two, indicating that 
lipid area was independent of cellular diameter (r=-0.065, p= 0.13) (Table 1, Figure 
3.8). 
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  Lipid area (µm
2
)  Cell diameter (µm)   
Time 
point 
Vehicle 
treated  
(n=600) 
Acyl-ghrelin 
treated 
(n=600)  
P-value Vehicle 
treated  
(n=600) 
Acyl-ghrelin 
treated 
(n=600)  
P-value 
17 
hours  
3592.5 
[2491 – 4696] 
4788.7 
[4040 – 5976] 
<0.001 
175.9 
[154 – 204] 
170.0  
[131 – 210] 
0.28 
34 
hours 
3484.0 
[2892 - 4005] 
4435.8 
[3828 – 5416] 
<0.001 
178.9 
[156 – 208] 
166.4 
[138 – 191] 
0.10 
P-value 0.17 0.09  0.54 0.55  
Table 3.5. Lipid area and cell diameter for acyl-ghrelin and vehicle treated cells in hyperglycaemic 
environment. Median and IQR shown as not normally distributed and Kruskal-Wallis used for data 
analysis. P-values <0.05 are statistically significant are in bold. 
 
Figure 3.7 A-D. Representative Oil red O imaging of mature SGBS cells in 25 mM (hyperglycaemia) 
glucose at x50 magnification. Red stain- lipid droplets; purple stain- nuclei. (A)- Cells grown in 
presence of acyl-ghrelin for 17 hours. (B)- Cells grown in presence of PBS vehicle for 17 hours. (C)- 
Cells grown in presence of acyl-ghrelin for 34 hours. (D)- Cells grown in presence of PBS vehicle for 
34 hours.  
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Figure 3.8. Scatter graph between cell diameter (µm) and lipid area (µm
2
) of all cell treatments in a 
hyperglycaemic environment. Pearson’s correlation, r=-0.065, p= 0.13. y = -0.0021x + 175.83. R
2
= 
0.0043.  
 
Gene expression 
ABCG1 
ABCG1 showed an initial non-significant down regulation of 3.0 (±1.3)-fold change 
at 17 hour (p=0.05), however acyl-ghrelin exposure over time produced a significant 
down regulatory effect on ABCG1 producing a 6.2 (±2.2)-fold change at 34 hours 
(p<0.05) (Figure 3.9A).  
LXRβ 
LXRβ showed a significant initial down regulation of 2.9 (±0.7)-fold change (p<0.01) 
at 17 hours within cells exposed to acyl-ghrelin, this effect was enhanced over the 
time course of the experiment, demonstrating acyl-ghrelin exposure for 34 hours 
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caused a further decrease in the down regulation of LXRβ (10.8 (±3.4)-fold change; 
p<0.001) (Figure 3.9B).  
SREBF1 
SREBF1 expression was not significantly altered within cells treated with acyl-
ghrelin in comparison to those treated with a vehicle exhibiting a fold change of 1.4 
(±0.1) at 17 hours (p=0.24) and 1.2 (±0.1) at 34 hours (p=0.43) (Figure 3.9C).   
 
Figure 3.9.A-C. Relative fold change values for gene expression data in acyl-ghrelin treated cells in 
hyperglycaemic environment in comparison to vehicle at both time points (17 and 34 hours). Fold 
change between -1.5 and 1.5 is classed as no relative gene expression change (grey region). (A)- 
ABCG1-fold change, (B)- LXRβ-fold change and (C)- SREBF1-fold change. Error bars indicate standard 
deviation between ΔΔCt of experimental repeats (n=6). * indicates a significant (p<0.05) difference 
of ΔCt in acyl-ghrelin treated cells versus vehicle treated cells, determined using an independent t-
test.  
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Inflammatory markers 
IL-6 
IL-6 levels within a hyperglycaemic environment were compared across all 
treatments (Table 3.6). Cells treated with acyl-ghrelin only showed no significant 
change in IL-6 levels at 17 hours (75.5 v 89.5 pg/mL; p= 0.149), however at 34 hours 
there was a significant decline in IL-6 levels in comparison to vehicle treated cell 
supernatant (107.2 v 147.0 pg/mL; p<0.05). LPS exposure resulted in a significant 
increase in IL-6 at both 17 and 34 hours (561.5 pg/mL and 650.0 pg/mL; both 
p<0.05, respectively). Pre-treatment of the cells to acyl-ghrelin before 
administering LPS also indicated a significant increase in IL-6 at both 17 and 34 
hours (528.0 pg/mL and 521.4 pg/mL; both p<0.05). Cells treated with acyl-ghrelin 
prior to LPS exposure showed a significant decline in IL-6 levels in comparison to 
cell supernatant of LPS only treated cells across both timepoints (17 hour: 528.0 
pg/mL v 561.5 pg/mL and 34 hours: 521.4 pg/mL v 650.0 pg/mL; both p<0.05; 
respectively).  
 IL-6 [pg/mL] 
Treatment 17 hours 
(n=6) 
34 hours 
(n=6) 
Vehicle 89.5 [87.7-95.5] 147.0 [138.7-151.7] 
Acyl-ghrelin 75.5 [69.0-89.5] 107.2 [94.0-121.4] 
LPS 561.5 [547.4-574.1] 650.0 [638.3-653.9] 
LPS & Acyl-ghrelin 528.0 [515.8-540.3] 521.4 [511.1-533.8] 
Table 3.6. IL-6 levels for acyl-ghrelin and vehicle treated cells in hyperglycaemic environment. 
Median and IQR shown as not normally distributed.  
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TNFα 
TNFα levels within cell supernatants was measured after exposure to acyl-ghrelin, 
LPS or both LPS and acyl-ghrelin (Table 3.7). Exposure to acyl-ghrelin deemed no 
significant alterations in TNFα levels at both time points (17 hours: 9.5 pg/mL and 
34 hours: 8.9 pg/mL: p=0.248 and p=0.245, respectively). Cell exposure to LPS 
produced a significant increase in cell supernatant TNFα levels at 17 and 34 hours 
(80.7 pg/mL and 78.9, respectively: both p<0.05,). Furthermore, in comparison to 
vehicle treated cells, a significant increase was present when cells were pre-treated 
with acyl-ghrelin before LPS exposure (17 hours: 77.0 pg/mL and 34 hours: 75.3 
pg/mL: both p<0.05, respectively). Pre-treatment with acyl-ghrelin within LPS 
exposure did not alter the cellular release of TNFα across 17 and 34-hour time 
points (LPS v LPS&Ghrelin: 77.0 pg/mL v 80.7 pg/mL and 78.9 pg/mL v 75.3 pg/mL: 
p=0.343 and p=0.248, respectively). The data indicate that acyl-ghrelin had no 
significant effect on TNFα levels within cell supernatants across either time point 
within a hyperglycaemic environment, with or without immune challenge. 
 TNFα [pg/mL] 
Treatment 
17 hours 
(n=6) 
34 hours 
(n=6) 
Vehicle 5.7 [1.8-9.3] 6.4 [5.3-7.0] 
Acyl-ghrelin 9.5 [8.4-10.8] 8.9 [6.4-10.8] 
LPS 80.7 [79.5-83.4] 78.9 [72.7-86.2] 
LPS & Acyl-ghrelin 77.0 [72.5-81.4] 75.3 [74.2-76.8] 
Table 3.7. TNFα levels for acyl-ghrelin and vehicle treated cells in hyperglycaemic environment. 
Median and IQR shown as not normally distributed.  
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IL-10 
Data for IL-10 levels were analysed post acyl-ghrelin, LPS or both LPS and acyl-
ghrelin exposure (Table 3.8).  Cells exposed to acyl-ghrelin demonstrated no change 
in cell supernatant IL-10 levels at both 17 hours (275.2 pg/mL; p=0.946) and 34 
hours (378.2 pg/mL; p=0.560). At 17 hours, immune challenge with LPS exposure 
demonstrated no overall change in IL-10 levels within cell supernatants (234.6 
pg/mL; p=0.682), however at 34 hours there was a marked decrease in IL-10 levels 
in comparison to vehicle treated cells (178.4 pg/mL; p<0.001). Mature adipocytes 
pre-treated with acyl-ghrelin prior to immune challenge resulted in a significant 
decline in IL-10 levels at 17 hours in comparison to LPS only, and no significant 
difference at 34 hours (140.0 ± 23.4 pg/mL v 234.6 ±34.3 pg/mL and 173.1 ± 14.9 
pg/mL v 178.4 ±17.5 pg/mL; p<0.05 and p=0.91, respectively). 
 IL-10 [pg/mL] 
Treatment 17 Hours 
(n=6) 
34 Hours 
(n=6) 
Vehicle 261.9 (20.3) 361.6 (14.9) 
Acyl-ghrelin 275.2 (50.9) 378.2 (22.1) 
LPS 234.6 (34.3) 178.4 (17.5) 
LPS & Acyl-ghrelin 140.0 (23.4) 173.1 (14.9) 
Table 3.8. IL-10 levels for acyl-ghrelin and vehicle treated cells in hyperglycaemic environment. 
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3.4.3 Comparison of glycaemic environment on acyl-ghrelin treated human 
mature adipocytes  
This section compares lipid retention and inflammatory markers present within 
cells grown in either a high glucose [25mM] or normal glucose [5.5mM] 
environments to mimic that of circulating blood glucose levels within a hyper- and  
normoglycaemic state, respectively.  
Lipid area 
Data analysis for determining the effect of differences relating to glycaemic 
environment on cellular lipid area were undertaken. At 17 hours, within the vehicle 
treated mature adipocytes, the cellular lipid area was independent of glycaemic 
environment, showing no significant change between hyper- and normoglycaemic 
treatments (3592.5 [2491 - 4696]. vs. 3461.4 [2502 - 4511], respectively; p=0.62). 
However, acyl-ghrelin treated cells within hyperglycaemic condition showed a 
significantly increased lipid area when compared to those grown in a 
normoglycaemic condition (4788.7 [4040 - 5975]. vs. 4348.0 [3693 - 5727], 
respectively; p<0.05) (Figure 3.10). 
At 34 hours, vehicle treated cells demonstrated a no change in lipid area in 
the hyperglycaemic environment compared to normoglycaemia (3483.9 [2892 - 
4005]. vs. 3516.5 [3156 - 4114], respectively; p=0.28). In acyl-ghrelin treated 
mature adipocytes, there was a significant decrease in the accumulated lipid area in 
the hyperglycaemic environment in comparison to the normoglycaemic 
environment (4435.8 [3828 - 5416]. vs. 5595.6 [5254 - 5742], respectively; p<0.001) 
(Figure 3.11).  
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Figure 3.10. Cellular lipid area for acyl-ghrelin and vehicle treated cells within both 5.5 mM 
(normoglycaemia) and 25 mM (hyperglycaemia) glucose for 17 hours. * indicate statistical 
significance (p<0.05) determined via Kruskal-Wallis. . n=600 per variable. AG- acyl-ghrelin. 
                
Figure 3.11. Cellular lipid area for acyl-ghrelin and vehicle treated cells within both 5.5 mM 
(normoglycaemia) and 25 mM (hyperglycaemia) glucose for 34 hours. * indicate statistical 
significance (p<0.05) determined via Kruskal-Wallis. n=600 per variable. AG- acyl-ghrelin. 
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Gene expression 
Gene expression analysis used the 2-ΔΔCt method, where normalised Ct values from 
each treatment (acyl-ghrelin or vehicle exposure) group were individually 
compared, in relation to normoglyceamic against hyperglycaemic environments. 
 
 
 
ABCG1 
Comparison of the hyperglycaemic to normoglycaemic environment in vehicle 
treated cells, indicates an initial significant down regulation of ABCG1 after 17 
hours (14.0 (±0.3)-fold; p<0.001). At 34 hours, vehicle treated cells demonstrated a 
significant down regulation of 5.6 (±0.9)-fold change (p<0.01) however, it is clear to 
see a curtailment in the magnitude of the effect of a hyperglycaemic environment 
on ABCG1 expression over time (Figure 3.12A). Exposure to acyl-ghrelin showed a 
converse effect of hyperglycaemic environment on lipid retention genes to that 
seen within a vehicle control. ABCG1 expression exhibits a significant down 
regulation of 4.3 (±0.2)-fold change (p<0.001) at 17 hours and a significant 29.3-fold 
change (±0.8) (p<0.001) down regulation at 34 hours’ post acyl-ghrelin 
administration in a hyperglycaemic environment in comparison to a 
normoglycaemic environment (Figure 3.13A).  
 
 
ΔCt= Treatment Raw Ct – Housekeeping Raw Ct 
Fold Change = 2-(hyperglycaemic ΔCt – normoglycaemic ΔCt) 
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LXRβ 
LXRβ expression mirrored the gene expression pattern exhibited by ABCG1 when 
the effect of a hyperglycaemic environment was compared to normoglycaemia. 
Vehicle treated cells showed a marked decrease in the expression of LXRβ at both 
17 and 34 hours (14.6 (±0.4) & 8.3 (±1.0)-fold change; p<0.001 and p<0.001, 
respectively) (Figure 3.12B). However, within cells exposed to acyl-ghrelin in a 
hyperglycaemic environment there was a significant down regulation of LXRβ in 
comparison to those exposed to acyl-ghrelin within a normoglycaemic environment 
across both time points, with the magnitude of the effect increasing over time (17 
hours & 34 hours; 4.8 (±0.6) & 34.9 (±0.7)-fold change, respectively; both (p<0.001)) 
(Figure 3.13B). 
 
SREBF1 
Vehicle treated cells demonstrated that a hyperglycaemic environment was 
producing a significant reduction in SREBF1 expression at 17 hours (13.3 (±0.7)-fold 
change; p<0.001). Furthermore, this reduction in expression was also present at a 
diminished but significant level at 34 hours (4.2 (±0.3)-fold change; p<0.001) (Figure 
3.12C). SREBF1 also showed a further down regulation from 17 hours to 34 hours’ 
post treatment when acyl-ghrelin exposure was combined with a hyperglycaemic 
environment (17 hours & 34 hours; 5.2 (±0.7) & 30.1 (±0.7)-fold change, 
respectively; both p<0.001) (Figure 3.13C). 
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Figure 3.12A-C. Relative fold change values for gene expression data in vehicle treated cells in 
hyperglycaemic environment in comparison to normoglycaemic environment at both time points (17 
and 34 hours). Fold change between -1.5 and 1.5 is classed as no relative gene expression change 
(grey region). (A)- ABCG1-fold change, (B)- LXRβ-fold change and (C)- SREBF1-fold change. Error bars 
indicate standard deviation between ΔΔCt of experimental repeats (n=6). * indicates a significant 
(p<0.05) difference of ΔCt in acyl-ghrelin treated cells versus vehicle treated cells, determined using 
an independent t-test. 
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Figure 3.13A-C Relative fold change values for gene expression data in acyl-ghrelin treated in chronic 
hyperglycaemic environment in comparison to normoglycaemic environment at both time points (17 
and 34 hours). Fold change between -1.5 and 1.5 is classed as no relative gene expression change 
(grey region). (A)- ABCG1-fold change, (B)- LXRβ-fold change and (C)- SREBF1-fold change. Error bars 
indicate standard deviation between ΔΔCt of experimental repeats (n=6). * indicates a significant 
(p<0.05) difference of ΔCt in acyl-ghrelin treated cells versus vehicle treated cells, determined using 
an independent t-test. 
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Inflammatory markers 
IL-6 
IL-6 levels for each treatment at both time points was analysed in comparison to 
glycaemic environment to establish whether there was a glycaemic effect. A 
hyperglycaemic environment produced a significant increase in the cell supernatant 
level of IL-6 across all treatments at 17 hours (Table 3.9) and 34 hours (Table 3.10). 
 IL-6 [pg/mL]  
Treatment 
Normoglycaemic 
(n=6) 
Hyperglycaemic 
(n=6) 
P-Value 
Vehicle 52.9 [43.7-54.8] 89.5 [87.7-95.5] 0.02 
Acyl-ghrelin 46.9 [32.4-48.5] 75.5 [69.0-89.5] 0.02 
LPS 427.1 [391.2-450.8] 561.5 [547.4-574.1] 0.02 
LPS & acyl-ghrelin 412.8 [401.1-417.2] 528.0 [515.8-540.4] 0.02 
Table 3.9. Comparison of IL-6 levels in different environments at 17 hours. Statistical analysis 
conducted using Kruskal-Wallis test. P-value less than 0.05 deemed significant and are in bold. 
 IL-6 [pg/mL]  
Treatment 
Normoglycaemic 
(n=6) 
Hyperglycaemic 
(n=6) 
P-Value 
Vehicle 94.1 [89.9-99.7] 147.0 [138.7-151.7] 0.02 
Acyl-ghrelin 74.8 [68.0-84.3] 107.2 [94.0-121.4] 0.02 
LPS 480.3 [462.5-519.4] 650.0 [638.3-653.9] 0.02 
LPS & acyl-ghrelin 451.6 [444.1-464.5] 521.4 [511.1-533.8] 0.02 
Table 3.10. Comparison of IL-6 levels in different environments at 34 hours. Statistical analysis 
conducted using Kruskal-Wallis test. P-value less than 0.05 deemed significant and are in bold. 
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TNFα  
TNFα levels were analysed in comparison of glycaemic environments across all 
treatments and time points. Mostly, TNFα levels were not significantly altered 
within cell supernatants for treatments when comparing hyper- to normoglycaemic 
environment at 17 hours (Table 3.11) or 34 hours (Table 3.12). However, within 
acyl-ghrelin treated mature adipocytes there was a significant increase in TNFα 
levels at 17 hours when grown in a hyperglycaemic environment (p<0.05). 
 
 TNFα [pg/mL]  
Treatment 
Normoglycaemic 
(n=6) 
Hyperglycaemic 
(n=6) 
P-Value 
Vehicle 4.0 [2.2-7.3] 2.0 [1.8-2.7] 0.25 
Acyl-ghrelin 7.3 [6.1-7.7] 9.5 [8.4-10.8] 0.02 
LPS 78.9 [74.6-84.7] 80.7 [79.5-83.4] 0.77 
LPS & acyl-ghrelin 72.3 [67.0-77.2] 77.0 [72.5-81.4] 0.25 
Table 3.11. Comparison of TNFα levels in different environments at 17 hours. Statistical analysis 
conducted using Kruskal-Wallis test. P-value less than 0.05 deemed significant and are in bold. 
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 TNFα [pg/mL]  
Treatment Normoglycaemic 
(n=6) 
Hyperglycaemic 
(n=6) 
P-Value 
Vehicle 1.5 [1.5-2.1] 2.4 [2.3-3.0] 0.08 
Acyl-ghrelin 6.2 [4.6-6.3] 8.9 [6.4-10.8] 0.15 
LPS 78.0 [77.7-79.1] 78.9 [72.7-86.5] 1.00 
LPS & acyl-ghrelin 76.2 [70.5-82.2] 75.3 [74.2-76.8] 0.77 
Table 3.12. Comparison of TNFα levels in different environments at 34 hours. Statistical analysis 
conducted using Kruskal-Wallis test. P-value less than 0.05 deemed significant and are in bold. 
 
IL-10 
A hyperglycaemic environment was associated with a significant increase in IL-10 
levels at both 17 and 34 hours within cell supernatants of vehicle treated mature 
adipocytes (Table 3.13) and only for acyl-ghrelin treated cells at 34 hours (Table 
3.14). A hyperglycaemic environment demonstrated no significant effect on IL-10 
levels at either time point when mature adipocytes were immuno-challenged with 
LPS. However, when LPS treatment was combined with acyl-ghrelin exposure there 
was a significant decline in IL-10 in a hyperglycaemic state at both 17 and 34 hours. 
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 IL-10 [pg/mL]  
Treatment Normoglycaemic 
(n=6) 
Hyperglycaemic 
(n=6) 
P-Value 
Vehicle 226.8 (±13.7) 261.9 (±20.3) 0.03 
Acyl-ghrelin 314.1 (±27.3) 275.2 (±50.9) 0.23 
LPS 264.3 (±26.6) 234.6 (±34.3) 0.22 
LPS & acyl-ghrelin 292.3 (±19.5) 140.0 (±23.4) <0.001 
Table 3.13. Comparison of IL-10 levels in different environments at 17 hours. Statistical analysis 
conducted using an independent t-test. P value less than 0.05 deemed significant and are in bold. 
 
 
 IL-10 [pg/mL]  
Treatment Normoglycaemic 
(n=6) 
Hyperglycaemic 
(n=6) 
P-Value 
Vehicle 188.2 (±20.8) 361.6 (±14.9) <0.001 
Acyl-ghrelin 341.0 (±14.0) 378.2 (±22.1) 0.03 
LPS 196.4 (±17.5) 178.4 (±17.5) 0.19 
LPS & acyl-ghrelin 303.9 (±25.2) 173.1 (±14.9) <0.001 
Table 3.14. Comparison of IL-10 levels in different environments at 34 hours. Statistical analysis 
conducted using an independent t-test. P-value less than 0.05 deemed significant and are in bold. 
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3.5       Discussion 
As this chapter focuses on the effect of acyl-ghrelin on lipid retention and 
inflammatory response, this discussion will be split into two sections; (i) acyl-ghrelin 
mediated lipid retention and (ii) acyl-ghrelin mediated inflammatory response.  
 
3.5.1 Acyl-ghrelin mediated lipid retention 
Exposure to acyl-ghrelin showed an increase in lipid retention within human mature 
adipocytes, this was seen in both a normo- and hyperglycaemic environment. These 
data correspond with previously published literature that has demonstrated acyl-
ghrelin promotes lipid accumulation in stromovascular fraction cells from omental 
tissue of obese normoglycaemic subjects (Rodriguez et al., 2009), murine mature 
adipocytes (3T3-L1) (Miegueu et al., 2011), male rat adipocytes (Muccioli et al., 
2004) and in rat depot specific abdominal WAT (Davies et al., 2009). However, 
published data thus far only encompass a normoglycaemic environment, allowing 
this study to provide novel findings into the effect of acyl-ghrelin in hyperglycaemia 
on hypertrophy. When comparing glycaemic environments, it is evident that in 
normoglycaemia there is a gradual increase in lipid area upon exposure to acyl-
ghrelin, however in a hyperglycaemic environment there is a significant rise in lipid 
area as an immediate response to acyl-ghrelin treatment that remains unaltered 
over time. Thus, indicating that a hyperglycaemic environment is associated with a 
rapid acyl-ghrelin mediated response of lipid accumulation.  
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In addition to an increased lipid area, acyl-ghrelin treatment demonstrated a 
role in the dysregulation of key lipid retention genes. Normoglycaemia showed an 
initial decrease in ABCG1 expression, which was previously highlighted by Davies 
and colleagues, in rat abdominal WAT (Davies et al., 2009). This may be due to a 
delayed increase in LXRβ expression that has been shown to induce the expression 
of ABCG1, counteracting acyl-ghrelin’s effect (Maqdasy et al., 2016). However, 
these data do not correspond with previously published work that indicates both 
ABCG1 and LXRβ expression are decreased in the presence of acyl-ghrelin (Davies et 
al., 2009). In contrast, a hyperglycaemic environment agreed with published 
literature indicating a marked decrease in ABCG1 and LXRβ expression. This could 
account for the immediate increase in cell lipid mass due to a resultant deficiency in 
the cellular export system. During both normoglycaemic and hyperglycaemic states, 
LXRβ and ABCG1 were dysregulated in the presence of acyl-ghrelin, which could 
impede the removal of cellular lipids. ABCG1 knockout mice have previously 
demonstrated the accumulation of cholesterol and phospholipids in macrophages 
(Kennedy et al., 2005). Evidence reported within this chapter demonstrates that 
acyl-ghrelin not only affects infiltrated macrophages in WAT but mature adipocytes 
themselves. 
In agreement with other human mature adipocyte data (Rodriguez et al., 
2009), SREBF1 expression was increased in the presence of acyl-ghrelin within a 
normoglycaemic state and continued to increase over time. This could either 
indicate the de novo synthesis of lipid droplets, or it suggests that SREBF1 is 
involved in regulating genes involved in cholesterol metabolism and counteracting 
acyl-ghrelin mediated lipid retention (Kersten, 2001, Wells, 2009). Further evidence 
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regarding SREBF1 action shows that within a hyperglycaemic environment, 
expression remained unaltered in the presence of acyl-ghrelin, supporting data that 
show that a hyperglycaemic environment has diminished SREBF1 regulatory 
function allowing for a larger lipid area accumulation (Kersten, 2001, Wells, 2009). 
When investigating the effect of the glycaemic environment, it was evident 
that hyperglycaemia caused a down regulation of lipid retention genes in both 
vehicle and acyl-ghrelin treatments. In humans, a study of lipid retention genes 
within obesity and patients with gestational diabetes showed a down regulation in 
LXR and SREBF1 expression, thus demonstrating that transcriptional levels of the 
LXR-ABC pathway are dysregulated in the presence of hyperglycaemia (Lappas, 
2014). Secondary to a hyperglycaemic effect on lipid genes, the LXR pathway may 
play a role in the progression of T2D via an effect on regulation of glucose 
homeostasis and insulin secretion (Maqdasy et al., 2016). GLUT4 is a key mediator 
in insulin induced glucose uptake (Tozzo et al., 1997) and is targeted by LXR, also its 
expression can be correlated with ABCG1 expression in cultured human adipocytes 
(Dalen et al., 2003, Le Lay et al., 2001). 
 
3.5.2 Acyl-ghrelin mediated inflammatory response 
Pro-inflammatory response 
Within normo- and hyperglycaemia environments, treatment with acyl-ghrelin on 
mature adipocytes exhibited a significant decline in IL-6 levels over time. Previous 
studies have confirmed a role for acyl-ghrelin in the attenuation of IL-6 release but 
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only in the mucosa of colitic mice (Baatar et al., 2011), rat peritoneal macrophages 
(Chorny et al., 2008) and in plasma in acyl-ghrelin treated rats (Wu et al., 2008). 
LPS-stimulated release of IL-6 was not inhibited by acyl-ghrelin in normoglycaemia, 
however in a hyperglycaemic environment there was acyl-ghrelin-related inhibition 
of IL-6 levels. Wu and colleagues, reported similar findings within normoglycaemic 
male rats, where acyl-ghrelin did not directly inhibit cytokine release, such as IL-6, 
from LPS-stimulated cells (Wu et al., 2007). In contrast, within a normoglycaemic 
environment, LPS-treated human monocytes (Dixit et al., 2004) and mouse 
dopaminergic neurones (Beynon et al., 2013) were shown to exhibit an acyl-ghrelin 
inhibition of an LPS-induced increase of IL-6 levels, as only seen within human 
mature adipocytes in a hyperglycaemic state within this investigation.  
TNFα data revealed no significant findings throughout this chapter, however 
further analysis of results indicate that all values were located at the lower end of 
the standard curve and obtained greater standard deviations to other experimental 
measures, therefore any statistical significance within this group would have been 
hard to elucidate. Previous studies have also reported that acyl-ghrelin effects on 
TNFα levels were not identified due to a lack of detection (Beynon et al., 2013). 
However, alternative sample sources have indicated that acyl-ghrelin does in fact 
supress TNFα levels with or without LPS induction (Baatar et al., 2011, Wu et al., 
2007, Wu et al., 2008, Chorny et al., 2008, Dixit et al., 2004). 
These findings highlight the relevant importance to the site-specific role 
acyl-ghrelin may play within an immune-compromised state in a pro-inflammatory 
response. Furthermore, the results enhance published evidence that acyl-ghrelin 
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administration is shown to mediate protective effects in an LPS-mediated 
inflammatory state, especially in the presence of hyperglycaemia.  
 
Anti-inflammatory response 
The effects of acyl-ghrelin on IL-10 are contradictory. Acyl-ghrelin is predominantly 
reported to supress the response of IL-10 in T lymphocytes in mice (Xia et al., 2004, 
Hattori, 2009), however acyl-ghrelin has also been reported to increase IL-10 levels 
in mouse models (Gonzalez–Rey et al., 2006). Data presented in this chapter are 
also contradictory, finding that acyl-ghrelin significantly increased the level of IL-10 
in a normoglycaemic environment, but exhibited no effect on IL-10 levels in a 
hyperglycaemic environment when compared to a vehicle. This could indicate that 
IL-10 levels within normoglycaemia are due to acyl-ghrelin promoting an anti-
inflammatory response in parallel to diminishing a pro-inflammatory response. 
Furthermore, I conclude that exposure to hyperglycaemia inhibits acyl-ghrelin’s 
promotion of an anti-inflammatory response.  
 
3.6       Conclusion 
 This chapter has presented relevant data to establish a role for acyl-ghrelin in the 
promotion of hypertrophy accompanied by the dysregulation of key lipid retention 
genes; ABCG1, LXRβ and SREBF1. Furthermore, acyl-ghrelin has demonstrated a 
role in altering the immune response within human mature adipocytes in both 
normo- and hyperglycaemic environments. The prolonged effect of lipid export 
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dysregulation is unknown and further in vivo work into acyl-ghrelin’s effect in 
humans is required to establish whether an acyl-ghrelin mediated effect could have 
a downstream effect within T2D.  
 
3.7       Limitations 
Findings presented within this chapter were based on the culture of a human 
adipocyte cell line. As previously mentioned in section 2.1.1, primary adipocytes 
could also be utilized. The use of primary cells could have produced a more 
biologically relevant sample source, due to them being isolated directly from 
human tissue using either an enzymatic or mechanical method, however are 
notoriously difficult to culture and prone to contamination. Experimental design 
was developed to limit the phenotypical or morphological changes that can present 
within an infinite cell line and the protocol was successful in achieving this, however 
when comparing in vitro to ex vivo analysis this must be taken into consideration.   
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Chapter 4 
Exploration of acyl-ghrelin associated lipid 
retention within ex vivo human visceral 
adipose tissue  
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4.1 Introduction 
Visceral adipose tissue (VAT) is a blanket term used for adipose tissue 
located within the peritoneal cavity. In comparison to subcutaneous adipose tissue, 
VAT is often investigated in relation to metabolic disease due to visceral adipocytes 
having higher basal lipolysis, leaving it vulnerable to insulin resistance (Mårin et al., 
1992). VAT is often split into five distinct types dependent upon the depot’s 
anatomical location (Figure 4.1) (Mårin et al., 1992). Perirenal, gonadal (or 
surrounding the ovaries in females), pericardial, mesenteric and omental fat are all 
classed as visceral fat but they differ in metabolic function due to varying 
environmental stimuli in the distinct location in which they are found. Omental fat 
extends from the lower region of the stomach and encapsulates the abdomen (Lam 
et al., 2011). The accumulation of omental fat is associated with detrimental effects 
on an individual’s health, thus, making it the primary source of visceral fat utilised 
for the study of obesity and related comorbidities (Lam et al., 2011, Matsuzawa, 
2006, Maury et al., 2007). In vitro research on mature human adipocytes allows 
insight into adipose tissue function, however it does not consider that adipose 
tissue as an organ is comprised of a spectrum of cell types. Previous work involving 
ghrelin mediated lipid retention has predominantly focused on rodent epididymal 
fat (Davies et al., 2009). Findings indicated a relevant role for acyl-ghrelin and the 
model allowed for the ease of experimental design, however, it is likely to be 
limited in the translation to human pathophysiology due to the ever-evolving 
functionality of species-specific fat depots. 
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Figure 4.1. Visceral fat depots in the human body. Red colour indicates increased risk factor in 
metabolic disease. Orange colour indicates a lower risk level and red indicates higher risk associated 
with metabolic disease.  
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4.1.1 Adipose tissue, inflammation and oxidative stress 
The vast proportion of human adipose tissue is comprised of mature adipocytes, 
however it also contains pre-adipocytes (undifferentiated adipocytes), 
macrophages, monocytes, fibroblasts and a rich supply of blood vessels (Trujillo and 
Scherer, 2006). Adipose tissue within obesity results in a state of low grade 
inflammation, which is mediated and activated due to the infiltration of both pro- 
and anti-inflammatory macrophages (M1 and M2) (Shoelson et al., 2007). With 
obesity, adipose tissue macrophages (ATM) equate to 50% of all adipose tissue 
cells, in contrast to only 5% within lean individuals (Trujillo and Scherer, 2006). As 
previously discussed in Chapter 3, acyl-ghrelin can be associated with an increase of 
cellular lipid retention and altered immune response. Emerging evidence has linked 
the presence of GHSR-1 to M1 and M2 macrophages, which could alter adipose 
tissues inflammation via macrophage polarization (Lin et al., 2016). Adipose tissue 
contains numerous other immune cell types that can contribute towards 
inflammation and insulin resistance, for instance; dendritic cells, neutrophils, B cells 
and T cells.  
Adipose tissue in obesity often has a dysregulated secretion of adipokines 
which has demonstrated a role in the pathogenesis of obesity-associated diseases 
such as T2D (Matsuzawa et al., 1999, Matsuda and Shimomura, 2013, Spiegelman 
and Flier, 2001). Obesity is also associated with increased formation of ROS (Fujita 
et al., 2006, Furukawa et al., 2017) and its subsequent harmful effects in promoting 
vascular (Stephens et al., 2009) and β-cell (Evans et al., 2003, Tiedge et al., 1997, 
Robertson et al., 2003) dysfunction, and ultimately diabetes (Stocker et al., 2007, 
Grattagliano et al., 2008). In vitro studies suggest that ROS generation is selectively 
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increased in the fat tissues of obese mice which may facilitate insulin resistance and 
alter adipokine gene expression (Furukawa et al., 2017). A relationship for acyl-
ghrelin within the inflammatory state may be elucidated from the exploration of 
the effect of acyl-ghrelin on oxidative stress. Current literature demonstrated that 
increased plasma levels of acyl-ghrelin can be associated with a decrease in 
oxidative burden within obese subjects (Suematsu et al., 2005). Furthermore, 
evidence linking acyl-ghrelin to an increased adipose tissue mass may indicate a 
plausible role for acyl-ghrelin interaction within systemic oxidative stress, due to 
biomarkers of oxidative stress being correlated with fat accumulation (Matsuda and 
Shimomura, 2013, Keaney et al., 2003). 
 
4.1.2 Genes of interest  
Key lipid retention genes have been mentioned in detail (see Chapter 3) in relation 
to lipid profile; LXRβ, ABCG1 and SREBF1. Furthermore, within this chapter ghrelin 
axis gene expression will be examined to elucidate whether expression levels are 
altered as a result of transcriptional or translational effects of a hyperglycaemic 
environment. Desacyl-ghrelin is expressed in a prepro-ghrelin molecule and 
requires post translational octanoylation to produce the acyl-ghrelin complex. 
Investigation into transcriptional and translational causative agents are key for a 
further understanding of acyl-ghrelin effect, as to whether the variation in plasma 
levels of acyl-ghrelin is due to changes in ghrelin (GHRL) gene expression or the 
presence of key octanoylation genes i.e. LYPLA1 and mBOAT4 (Satou et al., 2010, 
Kirchner et al., 2012).  
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4.2 Aim 
To expand on the outcomes gained in Chapter 3, the goal was to translate the in 
vitro results into an ex vivo system, allowing for the comparison of a local versus 
global effect. I hypothesis this would result in evidence providing an association 
between circulatory acyl-ghrelin levels with lipid retention gene and circulatory lipid 
profiles. Furthermore, in line with Chaper 3 I envisaged that acyl-ghrelin levels 
would demonstrate a positive association with anti-inflammatory markers and a 
negative association with pro-inflammatory markers. Therefore, this chapter aims 
to:- 
1. Evaluate plasma acyl-ghrelin levels in relation to the ghrelin gene axis within 
hVAT 
2. Investigate the expression levels of lipid retention genes within hVAT 
3. Investigate levels of circulating inflammatory marker within cohorts 
4. Explore the association of lipid retention genes and inflammatory markers 
with acyl-ghrelin levels 
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4.3 Methods 
4.3.1  Sample collection 
Human visceral adipose tissue biopsies, were collected as described in detail in 
Section 2.2.1. Briefly, 30 participants, 10 per group for non-obese (NO), obese (O) 
and obese with T2D (OT2D). 
 
4.3.2 Baseline characteristics 
To establish participant’s metabolic state, key analytical chemistry including lipid 
and glucose profiles, were analysed from fasted plasma samples from each 
participant. Analysis of glucose, cholesterol, HDL, albumin, creatinine and 
triglycerides was undertaken using a Randox Daytona plus, with LDL concentration 
calculated using the Friedewald equation as discussed in Section 2.2.6.1. 
Determination of HbA1c was done using the BioRad D-10 haemoglobin analyser, as 
discussed in Section 2.2.6.1. All other data was acquired from patient hospital notes 
and was correct at the time of operation.  
 
4.3.3  Quantitative Real Time PCR 
Real Time-PCR was performed on 30 hVAT, which included samples from 
participants classed as non-obese (NO, n=10), obese (O, n=10) and obese with T2D 
(OT2D, n=10). RNA was extracted from the hVAT as previously described (Section 
2.2.5) and reverse transcribed to cDNA (Section 2.3.1.2). Specific primers were 
designed and synthesised either by Eurofins MWG Operon or were purchased from 
PrimerDesign as previously mentioned (Section 2.3.3.2). The primer sequences 
were run on a primer specific amplification programme dependent upon annealing 
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temperatures (Appendix 2). Optimum primer conditions required a primer 
efficiency of 90-110% and a standard curve R2 value greater than 0.99, primer 
validation confirmed for all primer sets (Appendix 3). 
 
4.3.4 Gene expression analysis 
Threshold cycles (Ct) were accepted under the following criteria; single melt peak, 
triplicates within 1 Ct of each other and valid control values. The average Ct was 
taken per sample and normalised against the amplification of β-actin. Gene 
expression data are presented as fold change and deduced using the 2-ΔΔCt method 
as discussed in Section 2.3.3.4, raw data are available in Appendix 6.  
 
4.3.5 ELISA  
A human ghrelin (active) ELISA (Merck Millipore™) was used to specifically 
determine fasting plasma acyl-ghrelin levels in plasma samples collected at the time 
of surgery and treated the with protease inhibitor AESBF (2mg/mL). Plasma 
cytokine levels were determined using ELISA for IL-6, IL-10 and TNFα. All reagents 
were included in the ELISA kits and the protocols run following the manufacturers 
guidelines as described in Section 2.4.  
 
4.3.6  Oxidative stress measurement 
Oxidative stress was measured via the analysis of patient’s fasting plasma using 
total antioxidant status (TAOS) assay as previously described in detail in Section 
2.2.8. 
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4.3.7 Data analysis 
Statistical analysis was conducted on raw data using SPSS version 22 and test 
procedures were dependent on normality testing, as described in Section 2.5. 
Continuous variables included all variables except for medication which was treated 
as a categorical variable and treated as described in Section 2.5.1. 
 
4.4  Results 
Samples were split into three distinct arms for data analysis to enable the 
investigation of several factors: 
(i) Total sample cohort (NO v O v OT2D) 
(ii) Diabetes effect (NO+O) v OT2D) 
(iii) Obesity effect (O+OT2D) v NO) 
 
4.4.1 Total sample cohort 
4.4.1.1 Baseline characteristics 
The baseline characteristics of the total sample cohort were well matched in terms 
of age. However, as expected, there were significant differences between 
measurements for weight, BMI, glucose and HbA1c (Table 4.1).  
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Non Obese   
(NO) 
(n=10) 
Obese                  
(O) 
(n=10) 
Obese Type 2 
(OT2D) 
(n=10) 
P-value 
Age (Years) 51.8 (15.5) 51.1 (12.0) 45.5 (6.8) 0.44 
Weight (Kg)* 72.2 [64-81] 90.7 [86-122] 131.4 [114-152] <0.001 
BMI (Kg/m2)* 26.2 [24-28] 34.9 [32-42] 47.3 [42-51] <0.001 
Glucose 
(mmol/L)* 
4.8 [4.5-6.5] 5.4 [4.9-6.5] 6.7 [6.0-12.6] <0.01 
HbA1c 
(mmol/mol)* 
30.6 [26.3-
39.1] 
36.1 [30.3-
36.9] 
52.5 [35.8-68.1] <0.05 
HbA1c (%)* 5.1 [4.6-5.7] 5.2 [4.9-5.5] 7.0 [5.4-8.4] <0.05 
Statin 
prescription# 
(%) 
20 (2) 10 (1) 50 (5) 0.11 
 
Table 4.1 Baseline characteristics for total cohort. Mean and standard deviation shown for normally 
distributed data & p-value determined using one way ANOVA. * Median and interquartile range 
shown for data that is not normally distributed and Kruskal Wallis used for p val determination. 
#
Categorical data tested using Pearson Chi-square analysis, % shown with n in brackets. Significant p-
value are shown in bold.  
 
4.4.1.2 Plasma levels of acyl-ghrelin 
Acyl-ghrelin levels were measured in fasting plasma samples of all 30 participants. 
Analysis indicates a significantly decreased circulating level of acyl-ghrelin present 
within obese individuals with T2D in comparison to both obese (OT2D v O; 228.5 
[98.4-439.4] v 515.5 [308.7-701.2] pg/mL; p<0.05) and non-obese individuals (OT2D 
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v NO; 228.5 [98.4-439.4] v 467.2 [325.7-508.3] pg/mL; p<0.05). However, no 
significant difference was seen when the non-obese and obese cohorts were 
compared (p=0.71) (Figure 4.2). Fasting acyl-ghrelin was negatively correlated with 
fasting plasma glucose levels (rs=-0.37, p<0.05) and body weight (rs=-0.42, p<0.05), 
respectively across the total sample cohort (Figure 4.3A-B). 
 
Figure 4.2. Box plot of fasting acyl-ghrelin levels within the three cohorts. Median acyl-ghrelin levels 
shown for non-obese (NO), obese (O) and obese type 2 (OT2D)(n=10 per cohort). Statistical analysis 
was conducted using non-parametric measures, Kruskal Wallis determined statistical significance 
(p<0.05) between groups which are indicated by *. 
 
 
Figure 4.3A-B. Scatter graphs between acyl-ghrelin and glucose and acyl-ghrelin and body weight. A- 
Plasma glucose (rs = -0.414; p<0.05), y=-0.002x + 6.6695, R²=0.1129 (n=30). B- Body weight (rs=-
0.421; p<0.05), y=-0.059x + 128.15, R² = 0.2007 (n=30). 
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Ghrelin gene axis expression across cohorts 
Gene expression fold change data produced from the total sample cohort indicates 
that across groups there was no significant change in gene expression for mBOAT4 
or LYPLA1. Ghrelin gene expression was significantly down regulated, with a 2.6-
fold change within the OT2D group compared to the O group. However, fold change 
data signified no alteration between OT2D when compared to NO, despite a 
significant increase in GHRL ΔCt values (Table 4.2).  
 
Plasma acyl-ghrelin levels in relation to ghrelin gene axis 
Plasma acyl-ghrelin levels were analysed with respect to its relationship with key 
octanoylation genes (Table 4.3). The data indicates that within the total sample 
cohort circulating acyl-ghrelin levels were associated with the ΔCt values of GHRL 
expression (p<0.05), however there was no associations between circulating acyl-
ghrelin levels and LYPLA1 (p=0.620) or mBOAT4 (p=0.587). 
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Group Gene of interest Fold Change Direction P-value 
NO v O 
GHRL 1.50  0.19 
mBOAT4 0.88  0.42 
LYPLA1 1.45  0.17 
NO v OT2D 
GHRL 0.58  <0.05 
mBOAT4 0.66  0.22 
LYPLA1 1.13  0.42 
O v OT2D 
GHRL 2.60  <0.05 
mBOAT4 0.75  0.41 
LYPLA1 0.78  0.28 
Table 4.2. Relative fold change values for ghrelin axis gene expression data for total cohort. P-value 
deduced from ΔCt T-Test. Significant values shown in bold. N=10 per cohort. 
         = down regulation             = no overall change 
 
 
Plasma 
acyl-ghrelin 
GHRL 
Spearman’s Correlation 
P-value 
-0.408 
0.031* 
LYPLA1 
Spearman’s Correlation 
P-value 
-0.098 
0.620 
MBOAT4 
Spearman’s Correlation 
P-value 
0.107 
0.587 
 
Table 4.3 Correlation data for gene expression and plasma acyl-ghrelin for total cohort. Data analysis 
of relative ΔCt value and raw plasma marker levels (n=30). ΔCt values are inverse on gene transcript 
level. Non-parametric data analysis via Spearman’s rho correlation used to determine correlation 
between parameters. Significant values shown in bold. 
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4.4.1.3 Lipid profiles 
Lipid profiles were analysed across the total sample cohort, showing significant 
differences in total cholesterol (p<0.05), HDL (p<0.05) and LDL (p<0.01) levels. 
However, triglyceride concentrations did not differ between groups (p=0.19) (Table 
4.4). Further analysis showed that there were no significant differences within lipid 
marker levels between NO and O. Upon separate comparison of both the NO and O 
groups to the OT2D group, there was a significant decline in total cholesterol 
(p<0.05), HDL (p<0.01) and LDL (p<0.01) levels, with a significant increase in TGs 
within OT2D compared to NO (p<0.05). Lipid profiles were analysed to assess any 
associations between circulating acyl-ghrelin and lipid markers, which indicated 
positive correlations for total cholesterol (rs = 0.39, p<0.05) and LDL (rs = 0.39, 
p<0.05), respectively (Figure 4.4A-B). 
 
 
Non-Obese 
(NO) 
(n=10) 
Obese           
(O) 
(n=10) 
Obese Type 2 
(OT2D) 
(n=10) 
P-value 
Cholesterol (mmol/L) 4.4 (1.2) 4.8 (1.7) 3.1 (0.7) <0.05 
HDL (mmol/L) 1.1 (0.4) 1.3 (0.8) 0.7 (0.2) <0.05 
LDL (mmol/L) 2.7 (0.9) 2.8 (1.1) 1.5 (0.5) <0.01 
Triglycerides 
(mmol/L) 
1.2 (1.0) 1.5 (0.6) 1.9 (0.8) 0.19 
Table 4.4. Lipid profiles for total cohort. Mean and standard deviation shown for normally 
distributed data & p-value determined using one way ANOVA. Significant values are shown in bold. 
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Figure 4.4A-B. Scatter graphs between acyl-ghrelin and cholesterol and acyl-ghrelin and LDL. A- 
Plasma total cholesterol (rs = 0.380; p<0.05). y = 0.0025x + 3.0373, R² = 0.2301 (n=30). B- Plasma low 
density lipoprotein (LDL) (rs = 0.393; p<0.05) y = 0.0019x + 1.5463, R² = 0.2437 (n=30).  
 
Lipid retention gene expression across cohorts 
The total sample cohort indicated there was no significant change in the overall 
gene expression of lipid retention genes when the O group was compared to the 
NO group. However, when the OT2D group was compared to both the O and NO 
groups, there was a marked decrease in LXRβ, ABCG1 and SREBF1 (Table 4.5).  
 
Plasma acyl-ghrelin levels in relation to lipid retention genes 
When lipid retention gene expression was analysed against plasma acyl-ghrelin 
levels, there was a significant negative correlation between acyl-ghrelin and ABCG1 
ΔCt, with high acyl-ghrelin correlating to an increase in ABCG1 expression (rs=-0.39, 
p<0.05). LXRβ was shown to have a similar relationship with acyl-ghrelin levels as 
ABCG1, however this was non-significant (rs=-0.36, p=0.06). In addition to plasma 
acyl-ghrelin, GHRL expression also produced a significant association with plasma 
lipid levels which indicated a negative correlation between ghrelin gene ΔCt values 
versus total cholesterol (rs = -0.54, p<0.01) and LDL (rs = -0.49, p<0.01), respectively. 
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Group Gene of interest Fold Change Direction P-value 
NO v O 
LXRβ 0.73  0.16 
ABCG1 0.84  0.24 
SREBF1 1.12  0.39 
PPARγ 0.73  0.22 
NO v OT2D 
LXRβ 2.78  0.02 
ABCG1 2.44  <0.001 
SREBF1 2.70  <0.05 
PPARγ 0.66  0.27 
O v OT2D 
LXRβ 2.04  <0.05 
ABCG1 2.04  <0.05 
SREBF1 3.03  <0.001 
PPARγ 0.91  0.32 
Table 4.5. Relative fold change values for lipid retention gene expression data for total cohort. P-
value deduced from ΔCt T-Test. Significant values are shown bold. N=10 per cohort.      
         = down regulation             = no overall change 
 
4.4.1.4 Inflammation markers 
Plasma cytokine levels 
Inflammatory cytokines were analysed across the total sample cohort (NO, O and 
OT2D) using non-parametric parameters. The results indicated a non- significant 
alteration in levels of IL-6 and TNFα between the three groups, however there was 
a significant difference in IL-10 levels (Table 4.6). Analysis demonstrated that NO v 
O produced no difference in IL-6 and TNFα (IL-6; 12.9 v 11.0 pg/mL; p=0.71. TNFα; 
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11.4 v 36.0 pg/mL; p=0.26, respectively), however, IL-10 levels were significantly 
reduced within the O group when compared to NO (88.6 v 53.5 pg/mL, p<0.05). 
Results were mirrored when comparing NO v OT2D groups, which indicated a 
marked decrease in IL-10 (88.6 v 39.6 pg/mL, p<0.05) and unaltered levels of IL-6 
(12.9 v 7.9, p=0.60) and TNFα (11.4 v 20.1 pg/mL, p=0.47). However, results 
between O v OT2D indicated that IL-6 (p=0.31), TNFα (p=0.37) and IL-10 (p=0.14) 
levels were all similar between the groups.  
 
Cytokine  
[pg/mL] 
Non-Obese 
(NO) 
(n=10 
Obese 
(O) 
(n=10) 
Obese Type 2 
(OT2D) 
(n=10) 
P-value 
IL-6 12.9 
[7.0 – 20.4] 
11.0 
[8.7 – 27.2] 
7.9 
[7.1 – 15.1] 
0.61 
TNFα 11.4 
[5.1 – 43.4] 
36.0 
[17.7 – 54.0] 
20.1 
[14.0 – 32.6] 
0.42 
IL-10 88.6 
[66.3 – 129.5] 
53.5 
[27.5 – 67.0] 
39.6 
[44.2 – 15.1] 
<0.05 
Table 4.6. Cytokine levels for total cohort. Median and interquartile range for cytokine levels for 
each cohort. P-value determined via Kruskal-Wallis across global data. Significant values shown in 
bold. 
 
Total Antioxidant Status 
Data analysis of the total sample cohort showed a significant difference in overall 
TAOS (%) between groups (NO v O v OT2D; 53.5% v 44.2% v 31.1%; p<0.05, 
respectively). Post hoc analysis of data demonstrated that TAOS levels present in 
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the OT2D cohort were significantly lower than both the O and NO groups (p<0.01, 
p<0.001, respectively) (Figure 4.5).  
 
Figure 4.5. Bar graph of mean TAOS (%) within the three cohorts. Statistical analysis was conducted 
using a one-way ANOVA and post hoc Tukey. Statistical significance between groups are indicated by 
asterisks (* p<0.01 & ** p<0.001)(n=10 per cohort). 
 
Inflammation vs acyl-ghrelin  
Total sample cohort cytokine data did not show a significant association between 
any inflammatory markers and plasma acyl-ghrelin (IL-6, p=0.163; TNFα, p=0.957; 
IL-10, p=0.633; TAOS, p=0.190). However, when inflammatory markers were 
analysed against GHRL expression it showed that an increase in GHRL expression 
was associated with an increase in plasma IL-10 (GHRL ΔCt vs IL10; p<0.05) and 
TAOS % (GHRL ΔCt vs TAOS %; p<0.05) (Table 4.7). 
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 Plasma  
acyl-ghrelin 
GHRL 
ΔCt 
IL-6 Spearman’s Correlation 
P value 
-0.276 
0.163 
0.054 
0.785 
TNFα Spearman’s Correlation 
P value 
0.015 
0.957 
0.440 
0.060 
IL-10 Spearman’s Correlation  
P value 
0.129 
0.633 
-0.476 
0.044* 
TAOS % Spearman’s Correlation 
P value 
0.255 
0.190 
-0.396 
0.030* 
 
Table 4.7 Correlation data for gene expression, plasma acyl-ghrelin and inflammatory markers for 
total cohort. Data analysis of relative ΔCt value and raw plasma marker levels (n=30). ΔCt values are 
inverse on gene transcript level. Non-parametric data analysis via Spearman’s rho correlation used 
to determine correlation between parameters. Significant values were shown in bold. 
 
4.4.2 Diabetes effect 
The second arm of data analysis, aimed to investigate the effect of diabetes (No 
Diabetes (NO + O)) v Diabetes (OT2D)). To establish the effect of diabetes on the 
association of key variables, correlation analysis was conducted for samples in the 
OT2D group only.  
 
4.4.2.1 Baseline characteristics 
Comparison of baseline characteristics demonstrated no significant differences in 
participant’s ages. However, as expected, there was a significant increase in weight, 
BMI, fasting blood glucose and HbA1c in those with diabetes (Table 4.8). 
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 No Diabetes 
(NO + O) 
(n=20) 
Diabetes 
(OT2D) 
(n=10) 
P-value 
Age (Years) 51.5 (13.5) 45.4 (6.8) 0.20 
Weight (Kg)* 82.0 [72-10] 131.4 [116-148] <0.01 
BMI (Kg/m2)* 29.9 [26-35] 47.3 [43-50] <0.001 
Glucose (mmol/L)* 5.3 [4.6-5.9] 6.7 [6.0-11.1] <0.01 
HbA1c (%)* 5.2 [4.6-5.6] 7.0 [5.5-7.6] <0.01 
HbA1c (mmol/mol)* 33.3 [26.8-37.4] 52.5 [35.8-68.1] <0.01 
Statin prescription# 
(%) 
15 (3) 50 (5) <0.05 
 
Table 4.8. Baseline characteristics of the ‘No diabetes’, and ‘Diabetes’ cohorts. Mean and standard 
deviation shown for normally distributed data & p-value determined using independent t-test.  
* Median and interquartile ranges shown for not normally distributed data and Kruskal Wallis used 
for p value determination. 
#
Categorical data tested using Pearson Chi-square analysis, % shown with 
n in brackets.  Significant values shown in bold.  
 
4.4.2.2 Plasma levels of acyl-ghrelin 
Fasting plasma acyl-ghrelin levels were significantly lower within those with T2D 
(OT2D) when compared to those without T2D (NO + O) (228.5 [98.4 – 439.4] v 464.8 
[314.0 – 528.7] pg/mL; p<0.05) (Figure 4.6).  
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Ghrelin gene axis expression across cohorts 
Gene expression analysis for the ghrelin gene axis indicates that within the diabetes 
group (OT2D) there was no significant difference in gene expression for mBOAT4 or 
LYPLA1. However, GHRL expression itself was significantly down regulated at a 2.1- 
fold change within the OT2D group in comparison to the no diabetes group (p<0.05) 
(Table 4.9).  
 
Plasma acyl-ghrelin levels in relation to ghrelin gene axis 
Plasma acyl-ghrelin levels within the diabetes group were not significantly 
associated with the key octanoylation genes LYPLA1 (p=0.150) or mBOAT4 
(p=0.144) (Table 4.10). Data indicated that within the diabetes group circulating 
acyl-ghrelin levels were negatively associated with the ΔCt values of GHRL 
expression (p<0.05). 
 
Figure 4.6. Box plot of fasting acyl-ghrelin levels for ‘No diabetes’ and ‘Diabetes’ cohorts. Median 
acyl-ghrelin levels shown for no diabetes (NO + O)(n=20) and those with Type 2 diabetes 
(OT2D)(n=10). Statistical analysis was conducted using non-parametric measures, independent 
sample t-test determined statistical significance (p<0.05) between groups which are indicated by *. 
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Group  Gene of interest Fold Change Direction P-value 
(NO + O) v 
OT2D 
GHRL 2.10  <0.05 
mBOAT4 0.71  0.26 
LYPLA1 0.94  0.28 
Table 4.9. Relative fold change values for ghrelin axis gene expression data for diabetes effect 
cohort. P-value deduced from ΔCt T-Test. Significant values shown in bold.               
              = down regulation                 = no overall change 
 
 Plasma  
acyl-ghrelin 
GHRL Spearman’s Correlation  
P-value 
-0.791 
0.010* 
LYPLA1 Spearman’s Correlation 
P-value 
0.150 
0.680 
mBOAT4 Spearman’s Correlation 
P-value 
0.144 
0.691 
 
Table 4.10 Correlation data for gene expression and plasma acyl-ghrelin for diabetes effect cohort. 
Data analysis of relative ΔCt value and raw plasma marker levels (n=10). ΔCt values are inverse on 
gene transcript level. Non-parametric data analysis via Spearman’s rho correlation used to 
determine correlation between parameters. Significant values shown in bold. 
 
4.4.2.3 Lipid profiles 
Lipid profiles were analysed across the two groups, showing a significant difference 
in plasma lipid markers. Significant differences were demonstrated in total 
cholesterol (p<0.01), HDL (p<0.05) and LDL (<0.01) levels, however triglyceride 
profiles remained unaltered across the groups (p=0.10) (Table 4.11). Due to these 
data being opposed to the normal distribution of data expected to be seen within 
this group of individuals, lipid profiles were further assessed in relation to lipid 
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management drugs. However, this analysis deduced there was no significant 
variation within the groups lipid profiles between those prescribed statins (n=5) and 
those who were not (n=5) (cholesterol; p=0.202, HDL; p= 0.141, LDL; p=0.246 and 
triglycerides; p=0.794).  
 
 No Diabetes 
(NO + O) 
(n=20) 
Diabetes 
(OT2D) 
(n=10) 
P-value 
Cholesterol (mmol/L) 4.6 (1.4) 3.1 (0.7) <0.01 
HDL (mmol/L) 1.2 (0.6) 0.7 (0.2) <0.05 
LDL (mmol/L) 2.7 (1.0) 1.5 (0.5) <0.01 
Triglycerides (mmol/L) 1.4 (0.8) 1.9 (0.8) 0.10 
Table 4.11. Lipid profiles for diabetes effect cohort. Mean and standard deviation shown for 
normally distributed data & p-value determined using an independent T-Test. Significant values 
shown in bold.  
 
Lipid retention gene expression across cohorts 
Gene expression data for genes involved in lipid retention were analysed to 
produce fold change with respect to a diabetes effect ((O+NO) v OT2D). No diabetes 
compared to diabetes expression patterns mirrored that of the total sample cohort, 
showing a significant down regulation of key genes involved in lipid retention, LXRβ 
(p<0.05) and ABCG1 (p=0.01). Furthermore, within the diabetes effect cohort there 
was a significant down regulation in the lipid biosynthesis gene SREBF1 (p<0.001), 
however PPARγ produced no change in gene expression when analysed with 
respect to diabetes effect (p=0.26) (Table 4.12).  
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Plasma acyl-ghrelin levels in relation to lipid retention genes 
In contrast to the total sample cohort, plasma acyl-ghrelin levels and GHRL 
expression showed no association with plasma lipids within the diabetes effect 
cohort. Furthermore, neither demonstrated an association with key lipid retention 
genes (ABCG1; rs=-0.107, P=0.770, LXRβ; rs= -0.150, P=0.679). Finally, lipid 
biosynthesis gene, SREBF1 expression presented a significant association with GHRL 
expression (rs=0.803, p<0.01), this association was not seen with SREBF1 and 
plasma acyl-ghrelin levels (rs=0.011, p=0.977). 
 
Group Gene of interest Fold Change Direction P-value 
(NO + O) v 
OT2D 
 
LXRβ 2.22  <0.05 
ABCG1 2.22  0.01 
SREBF1 2.86  <0.001 
PPARγ 0.77  0.26 
Table 4.12. Relative fold change values for lipid retention gene expression data for diabetes effect 
cohort. P value deduced from ΔCt T-Test. Significant values shown in bold          
          = down regulation              = no overall change 
 
4.4.2.3 Inflammation markers 
Plasma cytokine levels 
Analysis of cytokine data with respect to diabetes effect yielded no significant 
differences in pro-inflammatory markers IL-6 (p=0.35) and TNFα (p=0.56). However, 
the anti-inflammatory marker IL-10 was significantly reduced within those with 
Type 2 diabetes in comparison with those without (p<0.01) (Table 4.13).  
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Cytokine  
[pg/mL] 
No Diabetes 
(NO + O) 
(n=20) 
Obese Type 2 
(OT2D) 
(n=10) 
P-value 
IL-6 11.4  
[7.9 – 24.7] 
7.9  
[7.1 – 15.1] 
0.35 
TNFα 26.8 
[10.9 – 42.0] 
20.1  
[14.0 – 32.6] 
0.56 
IL-10 68.6  
[41.8 – 92.7] 
39.6  
[15.1 – 44.2] 
<0.01 
Table 4.13. Cytokine levels for diabetes effect cohort. Median and interquartile range for cytokine 
levels for each group. P-value determined via independent T-Test comparing Diabetes (OT2D) vs No 
Diabetes (ND) cohorts. Significant values are shown in bold.  
 
Total Antioxidant Status 
Analysis indicates a significant differences of average TAOS (%) when the diabetes 
group  was compared those with the no diabetes group ((NO + O) v OT2D; 48.8 v 
31.1 %; p<0.001) (Figure 4.7), showing decreased levels of antioxidant indicative of 
an increased levels of oxidative stress in the diabetes group.  
 
Figure 4.7. Bar graph of mean TAOS (%) levels for diabetes effect. No diabetes (ND(NO+O))(n=20) 
and diabetes (OT2D)(n=10). Statistical analysis was conducted using an independent T-Test. 
Statistical significance between groups are indicated by asterisks (*p<0.001). 
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Inflammation vs acyl-ghrelin  
During the assessment of inflammatory markers association with acyl-ghrelin and 
GHRL gene expression, it was evident that within the diabetes cohort all 
associations were diminished. Acyl-ghrelin showed no significant association with 
inflammatory cytokines (IL-6; p=0.92, TNFα; p=0.29 and IL10; p=0.19), nor with 
oxidative stress marker (TAOS%; p=0.23). In addition, GHRL expression had no 
associations with inflammatory or oxidative stress markers (IL-6 (p=0.42), TNFα 
(p=0.22), IL-10 (p=0.09) or TAOS % (p=0.65)) (Table 4.14). 
 
 
Table 4.14 Correlation data for gene expression, plasma acyl-ghrelin levels and inflammatory 
markers for diabetes effect cohort. Data analysis of relative ΔCt value and raw plasma marker levels 
(n=10). ΔCt values are inverse on gene transcript level. Non-parametric data analysis via Spearman’s 
rho correlation used to determine correlation between parameters. 
  
 Plasma  
acyl-ghrelin 
GHRL 
ΔCt 
IL-6 Spearman’s Correlation 
P-value 
-0.042 
0.299 
-0.311 
0.415 
TNFα Spearman’s Correlation 
P-value 
-0.600 
0.285 
0.667 
0.219 
IL-10 Spearman’s Correlation  
P-value 
-0.700 
0.188 
0.821 
0.089 
TAOS % Spearman’s Correlation 
P-value 
-0.418 
0.229 
-0.165 
0.649 
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4.4.3 Obesity effect 
The third arm of data analysis aimed to investigate the obesity effect (Non-Obese 
(NO) v Obesity (O+OT2D)). In order to determine whether obesity was causing an 
effect on associations between variables, analysis of correlations was conducted 
within samples in the obesity (O+OT2D) cohort only.  
 
4.4.3.1 Baseline characteristics 
The baseline characteristics within the obesity group (O + OT2D) and the non-obese 
group (NO) demonstrated no significant difference within age (p=0.45) or HbA1c 
(p=0.74). However, as expected, there was a significant difference within the obese 
group for weight (p<0.01), BMI (p<0.001) and fasting glucose levels (p<0.05) (Table 
4.15). 
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Obesity 
(O+OT2D) 
(n=20) 
Non-Obese 
(NO) 
(n=10) 
P-value 
Age (Years) 48.3 (9.9) 51.8 (15.5) 0.45 
Weight (Kg)* 112.5 [89-148] 72.2 [64-81] <0.01 
BMI (Kg/m2)* 41.8 [34-48] 26.2 [24-28] <0.001 
Glucose (mmol/L)* 6.1 [5.4-7.5] 4.8 [4.5-5.7] <0.05 
HbA1c (%)* 5.5 [5.3-7.0] 5.0 [4.6-5.7] 0.74 
HbA1c (mmol/mol)* 36.6 [33.6-52.7] 30.6 [26.3-39.1] 0.07 
Statin prescription# 
(%) 
30 (6) 20 (2) 0.56 
Table 4.15. Baseline data for obesity effect cohort. Mean and standard deviation shown for normally 
distributed data & p val determined using one way ANOVA  
* Median and interquartile ranges shown for data that is not normally distributed data and Kruskal 
Wallis used for p-value determination. 
#
Categorical data tested using Pearson Chi-square analysis, % 
shown with n in brackets. Significant values are shown in bold. 
 
4.4.3.2 Plasma levels of acyl-ghrelin 
Comparison of obesity and non-obese groups revealed no significant differences in 
circulating acyl-ghrelin levels (323.3 [101 – 480] v 466.0 [312 – 490] pg/mL; p=0.48). 
Within the obesity group, fasting acyl-ghrelin was negatively correlated with BMI 
(rs= -0.58, p<0.01) and weight (rs= -0.55, p<0.05), respectively (Figure 4.8A-B).   
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Figure 4.8A-B. Scatter graphs between acyl-ghrelin and BMI and acyl-ghrelin and body weight. A- 
BMI (rs= -0.58, p<0.01), y=-0.0205x + 49.52, R
2
 = 0.332 (n=20). B- Body weight (rs= -0.55, p<0.05), y=-
0.0841x + 150.58, R
2
 = 0.3044 (n=20). 
 
Ghrelin gene axis expression across cohorts 
Gene expression data was analysed to signify whether obesity was influencing the 
expression of key ghrelin axis genes. Results confirm there was no significant 
differences in mBOAT4 (p=0.31) or LYPLA1 (p=0.44) expression between the two 
groups. Furthermore, in contrast to previous sections GHRL expression showed no 
fold change difference within the obese group versus the non-obese group (p=0.47) 
(Table 4.16).  
 
Group  Gene of interest Fold Change Direction P-Value 
NO v 
(O+OT2D) 
GHRL 0.97  0.47 
mBOAT4 0.76  0.31 
LYPLA1 1.28  0.44 
Table 4.16. Relative fold change values for ghrelin axis gene expression data for obesity effect 
cohort. P value deduced from ΔCt T-Test. 
           = down regulation                 = no overall change                                                    
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Plasma acyl-ghrelin levels in relation to ghrelin gene axis 
Association of ghrelin axis gene expression and plasma acyl-ghrelin levels within the 
obese group indicated no significant correlation with either LYPLA1 (p=0.571) or 
mBOAT4 (p=0.511), as with previous arms of the study. However, circulating acyl-
ghrelin levels were significantly association with GHRL (p<0.05) (Table 4.17).  
 
 Plasma  
acyl-
ghrelin 
GHRL Spearman’s Correlation  
P-value 
-0.493 
0.032* 
LYPLA1 Spearman’s Correlation 
P-value 
-0.139 
0.571 
mBOAT4 Spearman’s Correlation 
P-value 
0.161 
0.511 
Table 4.17 Correlation data for gene expression and plasma acyl-ghrelin for obesity effect cohort. 
Data analysis of relative ΔCt value and raw plasma marker levels (n=20). ΔCt values are inverse on 
gene transcript level. Non-parametric data analysis via Spearman’s rho correlation used to 
determine correlation between parameters. Significant values shown in bold. 
 
4.4.3.3 Lipid profiles 
Circulating lipid profiles in respect to the obese state, indicated no significant 
change across the two groups (cholesterol; p=0.45, HDL; p=0.43, LDL; p=0.25 and 
triglycerides; p=0.14) (Table 4.18). Upon analysis of acyl-ghrelin association with 
lipid profile markers, there was no significant association was present within the 
obese group (cholesterol; rs = 0.291, p=0.23, HDL; rs = 0.245, p=0.31, LDL; rs = 0.281, 
p=0.24 and triglycerides; rs = -0.462, p=0.14). Due to GHRL expression 
corresponding with acyl-ghrelin levels, it was also analysed with respect to lipid 
profile associations, which indicated a significant correlation between increased 
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GHRL expression with increased plasma cholesterol and LDL levels (rs = -0.462, 
p<0.05, rs = -0.448, p<0.05, respectively) (Figure 4.9A-B).  
 
Lipid retention gene expression across cohorts 
Contrary to other arms within this study, the obesity effect demonstrated no fold 
change alterations between key lipid retention genes when compared to the non-
obese cohort (NO V (O + OT2D); LXRβ p=0.10, ABCG1=0.06, SREBF1 p=0.14 and 
PPARγ p=0.18) (Table 4.19).  
 
Plasma acyl-ghrelin levels in relation to lipid retention genes  
Furthermore, no association was demonstrated between circulating acyl-ghrelin 
and key lipid retention genes (ABCG1 and LXRβ), nor lipid biosynthesis genes 
(SREBF1). In addition, GHRL expression also deemed no significant relation with 
lipid retention genes (ABCG1 and LXRβ), however had a significant positive 
correlation with the lipid biosynthesis gene SREBF1 (rs=0.624, p<0.01). 
 
Obesity 
(O + OT2D) 
(n=20) 
Non-Obese 
(NO) 
(n=10) 
P-value 
Cholesterol (mmol/L) 3.9 (1.5) 4.4 (1.2) 0.45 
HDL (mmol/L) 1.0 (0.6) 1.1 (0.4) 0.43 
LDL (mmol/L) 2.2 (1.1) 2.7 (0.9) 0.25 
Triglycerides (mmol/L) 1.7 (0.7) 1.2 (1.0) 0.14 
Table 4.18. Lipid profiles for obesity effect cohort. Mean and standard deviation shown for normally 
distributed data & p-value determined using one way ANOVA. 
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Figure 4.9A-B. Scatter graphs between GHRL expression and cholesterol, and GHRL expression and 
LDL. A- Plasma total cholesterol (rs = -0.462, p<0.05)(n=20). y = -0.591x + 10.688, R² = 0.3589. B- 
Plasma low density lipoprotein (LDL) (rs = -0.448, p<0.05) y = -0.4337x + 7.1351, R² = 0.3863 (n=20).  
 
 
Group  Gene of interest Fold Change Direction P-value 
NO v 
(O+OT2D) 
 
LXRβ 0.50  0.10 
ABCG1 0.63  0.06 
SREBF1 0.64  0.14 
PPARγ 0.69  0.18 
Table 4.19. Relative fold change values for lipid retention gene expression data for obesity effect 
cohort. P-value deduced from ΔCt T-Test. 
       = down regulation             = no overall change 
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4.4.3.3 Inflammation Markers 
Plasma cytokine levels 
The obesity effect showed no significant differences in the level of pro-
inflammatory markers IL-6 or TNFα, however the anti-inflammatory marker IL-10 
was significantly reduced within the obese group (NO v (O + OT2D); 55.6 v 40.8, 
p<0.01) (Table 4.20). 
 
Total Antioxidant Status 
Data analysis for obesity effect showed a significant difference in overall TAOS (%) 
(NO v (O + OT2D); 53.5% v 37.6%; p<0.001) (Figure 4.10). 
 
Cytokine  
[pg/mL] 
Obesity 
(O + OT2D) 
(n=20) 
Non-obese 
(NO) 
(n=10) 
P-value 
IL-6  10.7 
[7.7 – 18.6] 
12.6 
[7.0 – 20.4] 
0.73 
TNFα 22.8 
[16.0 – 39.5] 
11.4 
 [5.1 – 43.4]  
0.31 
IL-10 40.8 
[26.9 – 59.6] 
55.6 
[66.3 – 129.5] 
<0.01 
Table 4.20. Cytokine levels for obesity effect cohort. Median and interquartile range for cytokine 
levels for each group. P-value determined via independent T-Test comparing obesity effect. 
Significant values shown in bold. 
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Figure 4.10. Bar graph of mean TAOS (%) shown for obesity effect. Non-obese (NO)(n=10) and 
obesity effect (Ob (O + OT2D))(n=20). Statistical analysis was conducted using an independent T-
Test. Statistical significance between groups are indicated by asterisk (*p<0.001). 
 
 
Inflammation vs acyl-ghrelin  
Plasma acyl-ghrelin showed no significant association with inflammatory cytokines 
within the obese group (IL-6, p=0.59; TNFα, p=0.47; IL-10, p=0.63). Inflammatory 
cytokines also indicated no association with GHRL expression with respect to IL-6 
and TNFα. However, pro-inflammatory marker IL-10 demonstrated a significant 
association with ΔCt values of GHRL expression. TAOS (%) indicated oxidative stress 
was also independent of plasma acyl-ghrelin levels (p=0.32), however when TAOS 
(%) is analysed versus ghrelin gene expression it was indicative that an increase in 
GHRL expression was associated with an increase in TAOS (%) (GHRL ΔCt vs TAOS %; 
p<0.05) (Table 4.21). 
 
 
151 
 
 
Table 4.21 Correlation data for gene expression, plasma acyl-ghrelin and inflammatory markers for 
obesity effect cohort. Data analysis of relative ΔCt value and raw plasma marker levels (n=20). ΔCt 
values are inverse on gene transcript level. Non-parametric data analysis via Spearman’s rho 
correlation used to determine correlation between parameters. Significant values shown in bold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Plasma  
acyl-ghrelin 
GHRL 
ΔCt 
IL-6 Spearman’s Correlation 
P-value 
-0.136 
0.590 
-0.025 
0.918 
TNFα Spearman’s Correlation 
P-value 
-0.261 
0.467 
0.419 
0.199 
IL-10 Spearman’s Correlation  
P-value 
0.176 
0.627 
-0.573 
0.046* 
TAOS % Spearman’s Correlation 
P-value 
0.242 
0.318 
-0.536 
0.015* 
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4.5  Discussion 
4.5.1 Circulating acyl-ghrelin levels  
Gene expression data of the ghrelin axis provided an insight into the regulation of 
circulating ghrelin within obese individuals with and without T2D. Data suggested 
that a down regulation of GHRL was present within individuals with T2D, however 
this effect was not mirrored in obese individuals. Previously published literature 
confirms this study’s findings by indicating that low total ghrelin levels are 
significantly associated with insulin resistance (Pöykkö et al., 2003, Shiiya et al., 
2002). However, this was initially deemed to be due do a decline in desacyl-ghrelin, 
with acyl-ghrelin being increased within obese individuals with T2D (Rodríguez et 
al., 2012). However, it is evident across the literature that acyl-ghrelin levels are 
disputed, with other reports indicating a significant decline in acyl-ghrelin levels 
within obese individuals with T2D (Dardzińska et al., 2014) and those with 
gestational diabetes (Supák et al., 2016). Within this study, there is also paradoxical 
evidence with data suggesting no change in acyl-ghrelin concentrations in an obese 
state when compared to non-obese, yet a marked decline in acyl-ghrelin levels 
within obese individuals with T2D. Investigation of the ghrelin axis through gene 
expression has indicated that the expression of key regulatory enzymes in pre-pro-
ghrelin modification are unaltered throughout the total and disease effect cohorts, 
suggesting that acyl-ghrelin plasma concentrations may be correlated specifically 
with GHRL expression. Acyl-ghrelin levels within T2D are therefore hypothesised to 
be under the regulation of GHRL transcription itself, rather than an alteration in the 
mechanism involved in regulation of the octanoylation of ghrelin. Furthermore, this 
corresponds with a decline in GHRL expression, producing a lower plasma desacyl-
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ghrelin level as often reported within the metabolic state (Rodríguez et al., 2012). 
Analysis of desacyl-ghrelin within participants would also have been advantageous 
within the sample cohorts to establish whether acyl-ghrelin and desacyl-ghrelin 
share a similar or opposing relationship within the study, however due to timing 
constraints this was not possible.   
 A decline in acyl-ghrelin levels and GHRL gene expression were associated 
with a rise in fasting plasma glucose levels across the total sample cohort indicating 
that the down regulation of ghrelin could be dependent on glucose homeostasis. 
This corresponds with previously published data, which suggests an inverse 
correlation with acyl-ghrelin levels and homeostatic model assessment of insulin 
resistance (HOMA-IR) (Qarni et al., 2017). Therefore, a reduction of acyl-ghrelin 
levels in long term hyperglycaemia may not be due to post-translational 
modifications, but rather a disruption in the transcription of the GHRL gene itself. 
These findings correlate with a study undertaken in human individuals with T1D, 
T2D and normoglycaemia which indicated ghrelin secretion was suppressed by long 
term poor glycaemic control (Hiroaki et al., 2007). However, acyl-ghrelin’s 
association with plasma glucose was lost when data were analysed with respect to 
diseases effect cohorts. This could be due to data within the disease effect cohorts 
consisting of half the participants, which resulted in a loss in statistical power and 
an increase in variation (Browner et al., 2007). Additional exploratory analysis into 
disease state does however allow for the development of associations within the 
data that could be further explored in additional studies to provide greater 
statistical power and to eradicate type 1 statistical errors.     
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4.5.2 Acyl-ghrelin mediated lipid retention 
Within this chapter, the relationship of acyl-ghrelin and lipid retention was further 
examined in relation to adipose tissue as a complex source of various tissue types, 
rather than acyl-ghrelin’s effect directly on mature adipocytes as discussed in 
Chapter 3. Analysis of the findings indicate contrasting data that shows that within 
non-obese individuals, higher levels of circulating acyl-ghrelin coincides with an 
increase in key lipid transport gene expression.  This could be due to acyl-ghrelin’s 
effect on adipose tissue as a whole, including macrophages, which have shown to 
induce an increase in lipid retention gene mRNA levels in the presence of acyl-
ghrelin treatments (Demers et al., 2009). Even though acyl-ghrelin may be involved 
in mediating lipid retention, this effect however is diminished on a global scale and 
is only apparent within a local system. Previously published work demonstrates that 
within mice, the effect of acyl-ghrelin is the same, both locally in adipocytes (3T3-
L1) (Miegueu et al., 2011) and globally (WAT depot) (Churm et al., 2017, Porteiro et 
al., 2013)(Table 4.22).  
In addition to a local versus global effect of acyl-ghrelin, a further 
explanation that may account for the difference is the degree and duration of a 
hyperglycaemic state. Previously reported evidence shows that hyperglycaemia has 
demonstrated a regulatory role in the expression of key lipid retention genes 
including ABCG1 (Mauerer et al., 2009) and LXR (Mitro et al., 2007).  
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Model 
 
Dose Treatment Effect Reference 
3T3-L1 
(Murine 
adipocytes) 
Acyl-ghrelin 
1-100 pmol, 
Desacyl-
ghrelin 1–
100 pmol 
Preadipocytes 
incubated with 
desacyl-ghrelin and 
acyl-ghrelin for 
24 hours 
Desacyl and acyl-
ghrelin-
stimulated 
adipogenesis, 
fatty acid uptake 
and inhibited 
lipolysis 
(Miegueu 
et al., 
2011) 
Perigonadal 
adipose tissue 
(Murine) 
Acyl-ghrelin 
30 μg day 
Daily ip injection 
mRNA levels of 
several 
adipogenic and 
fat-storage-
promoting 
enzymes were 
up-regulated 
(Porteiro 
et al., 
2013) 
THP-1 
(Human 
macrophages) 
1, 10 & 100 
nM Acyl-
ghrelin 
Treated PMA-
differentiated THP-
1 macrophages 
with increasing 
doses of ghrelin 
Increases in 
mRNA levels of 
LXR and ABC 
isoforms 
(Demers 
et al., 
2009) 
Table 4.22. Effects of acyl-ghrelin treatment on adipogenesis in both local and global adipose 
regions, table taken in part from (Churm et al., 2017).  
 
 
 
 
 
 
156 
 
4.5.3 Acyl-ghrelin and the inflammatory state 
Relevant findings within this chapter indicate no overall change in plasma levels of 
pro-inflammatory markers across groups, indicating no correlation to acyl-ghrelin 
levels or GHRL expression. This is counter to the published IL-6 literature which 
indicates that the enhancement of the metabolic state causes an increase in pro-
inflammatory markers such as IL-6 (Maachi et al., 2004, Bastard et al., 2006, Bastard 
et al., 2002, Makki et al., 2013). In addition, TNFα was initially reported 20 years 
ago to be increased within obesity and T2D (Saghizadeh et al., 1996, Löfgren et al., 
2000, Bastard et al., 2006, McLaughlin et al., 2017), however findings differ 
amongst publications with studies often reporting no significant alterations in TNFα 
levels between both disease states and a control cohort (Frittitta et al., 1997, 
Koistinen et al., 2000, Borst, 2004). A lack of association seen within the pro-
inflammatory marker levels during the progression of the metabolic state may not 
be apparent due to variation within samples and the relatively small sample size 
assessed here. Another plausible explanation is the role of prescribed medication 
within the sample cohorts. For instance, meta-analysis data suggests a role for 
metformin in the amelioration of chronic inflammation via a reduction of key 
inflammatory markers such as C-reactive protein, IL-6 and TNFα in vivo in humans 
(Wang et al., 2017) and in vitro in rodents (Jing et al., 2017). 
 Upon exploration of disease effect, it is apparent that both obesity and Type 
2 diabetes caused a marked decline in anti-inflammatory and an increase in 
oxidative stress i.e. plasma IL-10 (van Exel et al., 2002, Esposito et al., 2003) and 
TAOS levels (Fenkci et al., 2003, Prior et al., 2017). Furthermore, within the total 
sample cohort and those within the obese effect cohort, there was a significant 
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association between GHRL expression and IL-10.  However, this association was 
diminished within the diabetes effect cohort. An improvement in IL-10 and TAOS 
(%) data are both associated with the up regulation of GHRL expression, 
corresponding with published studies that indicate a promotion of inflammatory 
health in the presence of ghrelin (Suematsu et al., 2005, Harvey et al., 2017). Even 
though GHRL expression is significantly linked to acyl-ghrelin circulation, whether 
this inflammatory protection is due to an increase in total ghrelin, desacyl-ghrelin or 
acyl-ghrelin is not determined. Acyl-ghrelin has been linked to a plausible role in 
protecting human lens epithelial cells (Bai et al., 2017) and osteoblastic cells (Dieci 
et al., 2014) against ROS accumulation. Furthermore, as discussed in Chapter 3, 
upon acyl-ghrelin dosage of human mature adipocytes there is a promotion in a 
protective inflammatory response and an increase in anti-inflammatory markers. In 
addition to acyl-ghrelin, desacyl-ghrelin treatment has also established a protective 
role from oxidative stress in microvascular endothelial cells via regulation of SIRT1 
catalytic activity (Shimada et al., 2014) and within osteoblastic cells independent of 
GHSR1α (Dieci et al., 2014).  
 
4.6 Conclusion 
Within the data sets, it is evident that acyl-ghrelin associations are only present 
within the total sample cohort, indicating values within the diseased state are too 
extreme or sample size to small too assess and reveal any relationships. mRNA 
levels of GHRL are indicative of a positive association with an increase in plasma 
lipid markers across all study arms. Within both a diabetes and obesity effects there 
is an association of SREBF1 mRNA levels, suggesting the transcription of GHRL gene 
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is associated with an increase in lipid biosynthesis and in turn an increase in 
circulating lipid profiles.  Previous literature and results from this chapter conclude 
that total ghrelin; a combination of both acyl- and desacyl-ghrelin, is associated 
with a protective response to oxidative burden.  
 
4.7 Limitations 
Within this section, TAOS was measured as a marker of antioxidant status. 
However, in addition to this surrogate marker, it would have been beneficial to 
encompass additional analysis including thiobarbituric acid reactive substances 
(TBARS) assay (a measure of lipid peroxidation) and telomere length (a measure of 
DNA damage due to cellular oxidative burden). 
The main limitation within this chapter is the analysis of sub-section data. The use 
of ex vivo samples allowed for the exploration of acyl-ghrelin mediated response, 
however, the analysis of association must be taken with caution. Due to the 
statistical approach used to elucidate disease effect, large amounts of comparisons 
and association analyses within the sub-sections were conducted, therefore there is 
a potential of Type 1 errors and the analysis of a smaller sample number. Increasing 
sample size would allow for the representation of this statistical analysis with 
greater power, however, time restraints did not allow for this to occur. In addition 
to this, upon analysis it is apparent that within the O and OT2D groups, there was a 
significant difference in weight and BMI. Upon further consideration, analysis could 
have benefited from a stricter inclusion criteria specifying a range within weight 
and BMI to ensure continuity within the weight between the two groups.  
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Chapter 5 
The effect of combining metformin and acyl-
ghrelin exposure on lipid retention and 
inflammation 
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5.1 Introduction 
5.1.1 Type 2 diabetes medication 
Early stage T2D can often be managed through an improvement in diet and/or 
exercise. However, as the disease progresses, many individuals also require the use 
of hyperglycaemia medication or insulin therapy. Evaluating pharmacological 
agents as treatment for individuals who have T2D and are obese or overweight 
(OT2D), requires considerations due to the effects that some hyperglycaemic 
agents may have on weight management. Hyperglycaemic therapy can be split into 
three distinct pharmaceutical groupings:- (i) treatments associated with weight 
gain- insulin secretagogues, thiazolidinediones and insulin, (ii) treatments that are 
weight neutral- metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors, (iii) 
treatments linked to weight loss including- amylin mimetics and GLP-1 agonists and 
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) (American Diabetes 
Association, 2017). Most pharmaceutical agents work in a manner to either 
promote insulin secretion or increase insulin sensitivity.  
 
5.1.2 Treatment guidelines 
The National Institute for Health and Care Excellence (NICE) guidelines for the 
management of T2D in adults directs the recommended treatment course based on 
up to date evidence and key developments. The algorithm for blood glucose 
lowering therapy in adults with T2D states initial drug therapy is dependent on 
HbA1c rise when following lifestyle intervention, with the introduction of 
metformin as a first line therapy (National Institute Health and Care Excellence, 
2015). Metformin treatment can either be as monotherapy or in addition to other 
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oral medications as dual or triple therapy (National Institute Health and Care 
Excellence, 2015). Alternatively, insulin therapy is recommended if (i) an individual 
is symptomatically hyperglycaemic, (ii) the dual or triple therapy is ineffective, or 
(iii) contraindications are present to metformin treatment and HbA1c raises above 
58 mmol/mol (7.5%) (National Institute Health and Care Excellence, 2015).    
 
5.1.3 Metformin 
Metformin (1,1-dimethylbiguanide hydrochloride) is the most commonly prescribed 
oral medication worldwide that acts to lower blood glucose (Bailey, 2017, Griffin et 
al., 2017). The therapy is often used as a foundation therapy for individuals with 
newly diagnosed T2D due to a reputation of effective glucose lowering abilities, low 
cost, and good safety profile (Sanchez-Rangel and Inzucchi, 2017, Inzucchi et al., 
2015). 
Reflective of metformin being a first line diabetes therapy that is weight 
neutral, data analysis of individuals recruited within Chapter 4 showed 90% (n=9) of 
the OT2D group were receiving routine metformin treatment with the additional 
10% (n=1) being undisclosed. 
First noted for its lipid lowering abilities post-extraction from the plant 
Galega officinalis or French lilac in the 1920s, it was not until the 1950s that 
metformin was introduced as a treatment of adult onset diabetes in the USA, after 
studies by Jean Sterne in 1957 (Sterne, 1957), then in the UK and other European 
countries in 1958 (Bailey, 2017). Despite metformin’s popularity as a first-line 
therapy, there is still debate as to the exact mechanism of action. Evidence suggests 
a reduction in hepatic glucose production being predominant, but there is 
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fundamental evidence that metformin is also involved in the regulation of incretin 
hormones and can lower insulin resistance (Sanchez-Rangel and Inzucchi, 2017, 
Rena et al., 2017).  
 
5.1.4 Proposed mechanism of metformin action  
Metformin primarily acts to inhibit hepatic gluconeogenesis and increase insulin 
action (or sensitivity) in other organs i.e. fat (Moreno-Navarrete et al., 2011). 
Metformin is known to have a regulatory effect on key lipid metabolic pathways. 
For example metformin administration in rodent cells and in vivo results in the 
activation of AMPK, which supresses the expression of the LXR ligands and SREBF-1 
(Yang et al., 2009, Yap et al., 2011, Hayashi et al., 2014). In addition to regulating 
key lipogenic genes, metformin also demonstrates a relationship with the ghrelin 
axis via AMPK. Gagnon and colleagues reported that administration of metformin in 
rats was associated with lower circulating levels of acyl-ghrelin via diminished 
protein secretion and reduced mRNA transcription (Gagnon et al., 2013). 
Furthermore, both effects were blocked when treated with an AMPK inhibitor 
compound (Gagnon et al., 2013). Independent studies report the intrinsic effect of 
metformin treatment on acyl-ghrelin or lipogenic factors, however further 
exploration is required to understand whether acyl-ghrelin could alter metformin’s 
action, or vice versa, on lipid metabolism and resultant inflammation within 
humans. In addition to the molecular mechanism of metformin, there is also a 
notably defined physiological route. Physiologically it is evident that metformin acts 
both directly and indirectly on the gut to increase glucose utilisation, increase GLP-1 
levels and alter gut microbiome (Rena et al., 2017, McCreight et al., 2016) all of 
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which highlight the vast network of pathways in which metformin plays a key role. 
Furthermore, there are variations in independent studies as the effect is altered 
dependent on cell or tissue type, dosage application and animal model used (Rena 
et al., 2017). Review of published data allows for a summary of the role of 
metformin on various site specific action, however very little published data 
indicates an effect of metformin on adipose tissue within humans (Bailey, 2017, 
Griffin et al., 2017, Rena et al., 2017, McCreight et al., 2016).  
Due to metformin having a pre-defined intrinsic effect on the lipogenesis 
pathway, the interaction between hyperglycaemia, metformin exposure and acyl-
ghrelin needs elucidation within human mature adipocytes. 
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5.2 Aim 
As metformin is the first line treatment and most commonly prescribed treatment 
of T2D, it is vital to understand its interaction with acyl-ghrelin and the resulting 
effect on lipid retention and inflammation. I predict that the evaluation of 
metformin role would elucidate a common pathway between itself and acyl-
ghrelin’s action. Thus ameliorating acyl-ghrelin’s effect on lipid retention genes and 
further promoting inflammatory health. This chapter aimed to:- 
1. Explore the effect of metformin on lipid retention genes in mature 
adipocytes in a hyperglycaemic environment 
2. Explore the effect of metformin on inflammatory markers IL-6 and IL-10, in 
mature adipocytes in a hyperglycaemic environment 
3. Investigate the combined effect of acyl-ghrelin and metformin on lipid 
retention and inflammation  
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5.3 Methods 
5.3.1 SGBS cell treatment 
Human pre-adipocytes (SGBS cells) were revived, cultured, seeded into six well 
plates and differentiated as previously described in Section 2.1.2. Mature 
adipocytes were pre-exposed to a hyperglycaemic environment [25 mM glucose] at 
day 12. The cells were then dosed with metformin [5nM] and/or acyl-ghrelin [100 
nM] or PBS vehicle to act as a control for all treatments on day 14. For dual 
exposure, cells were pre-exposed to acyl-ghrelin, 30 minutes prior to the addition 
of metformin. Due to the novelty of this work, cell treatment dose and timings were 
based on alternative human cell lines or primary adipocyte cultures,  as previously 
described in 3T3-L1 (Barbato et al., 2013) and Poietics™ human visceral adipocytes 
(Fujita et al., 2016). Metformin (Sigma-Aldrich) was dissolved in PBS and added in 
serum-free culture medium at a final concentration of 5 nM. Cell experiments were 
conducted over 17 hours following the addition of metformin, as previous work 
(Chapter 3) indicated this was a sufficient incubation period to report cellular 
changes resulting from the addition of acyl-ghrelin. 
 
5.3.2 Oil Red O staining 
After 17 hours of exposure to metformin, and/or acyl-ghrelin or a PBS vehicle, cells 
underwent Oil red O analysis as described in Section 2.1.6, based on Mehlem and 
colleagues published protocol (Mehlem et al., 2013). All images were analysed 
using ImageJ software (Version 2) using the same procedure as discussed in Section 
3.2.3. 
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5.3.3 Gene expression analysis 
To explore whether metformin altered acyl-ghrelin mediated lipid retention, cell 
treatments underwent relative gene expression analysis. Gene expression data was 
analysed within those treated with metformin and/or acyl-ghrelin or vehicle. 
Analysis was conducted on key lipid retention genes; LXRβ, ABCG1 and SREBF1. RNA 
was extracted from cells (Section 2.1.8) 17 hours post-exposure, then underwent 
Real Time PCR (Section 2.3), and raw Ct values analysed using the 2-ΔΔCT method 
(Section 2.3.4) (Appendix 7).  
 
5.3.4 Adipokine analysis 
As demonstrated in earlier chapters, acyl-ghrelin has a pronounced effect on IL-6 
and IL-10. These were analysed within cell supernatant extracted 17 hours post-
treatment exposure via commercially available ELISA (Quantikine®, R&D systems) as 
described within the manufacturers’ guidelines and Section 2.4.  
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5.4 Results 
5.4.1 Effect of metformin on human mature adipocytes 
5.4.1.1 Lipid area  
Intracellular lipid area was recorded and analysed to elucidate metformin’s effect 
on mature adipocytes in terms of lipid area versus a control. Overall lipid area was 
unaltered with metformin treatment compared to control (Met v Veh; 3870.3 [3177 
– 4463] µm2 v 3592.5 [2491 – 4696] µm2; p=0.35) (Figure 5.1). 
 
 
Figure 5.1. Oil red O imaging of mature SGBS cells in 25 mM (hyperglycaemia) glucose and 
metformin treatment at x50 magnification. Red stain- lipid droplets; purple stain- nuclei. (A) Cells 
grown in presence of metformin for 17 hours. (B) Cells grown in presence of PBS control for 17 
hours.  
 
5.4.1.2 Real Time gene expression  
Analysis of lipid retention genes showed that after 17 hours of metformin exposure, 
mature adipocytes, compared to control, had a significant up regulation of LXRβ, 
ABCG1 and SREBF1. In order of fold change magnitude, results showed an up 
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regulation of; 3.5 (±0.1) fold change for LXRβ (p<0.001), 33.1 (±1.9) fold change for 
ABCG1 (p<0.001) and 3.4 (±0.8) fold change for SREBF1 (p<0.001) (Figure 5.2). 
 
Figure 5.2. Relative fold change values for gene expression data in metformin treated cells in a 
hyperglycaemic environment [25 mM] in comparison to control at 17 hours. Fold change between -
1.5 and 1.5 is classed as no relative gene expression change (grey region). Error bars indicate 
standard deviation between ΔΔCt of experimental repeats (n=6). * indicates a significant (p<0.001) 
difference of ΔCt in metformin treated cells versus control treated cells, determined using an 
independent t-test. 
 
5.4.1.3 Adipokine levels 
Metformin exposure resulted in no significant alteration in IL-10 levels compared to 
a control (Met v Veh; 282.5 [252.0 – 299.5] pg/mL v 258.2 [244.6 – 282.9] pg/mL; 
p=0.44) (Figure 5.3A). However, the amount of IL-6 present was significantly lower 
following metformin exposure (Met v Veh; 23.2 [19.3 – 25.6] pg/mL v 89.5 [87.7 – 
95.5] pg/mL; p<0.01) (Figure 5.3B). 
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Figure 5.3. Box plot of IL-10 and IL-6 levels within metformin and control cells in a hyperglycaemic 
environment. (A) IL-10 [pg/mL]. (B) IL-6 [pg/mL]. Statistical analysis was conducted using non 
parametric measures (n=6 per treatment). The Kruskal Wallis test determined statistical significance 
(p<0.01) between groups which are indicated by *. 
 
5.4.2 Effect of metformin in combination with acyl-ghrelin exposure on human 
mature adipocytes 
Within this results section, acyl-ghrelin only treatment data has been utilised from 
Chapter 3 to allow for the comparison of the effect of metformin in combination or 
as a monotherapy on SGBS cells in relation to acyl-ghrelin mediated lipid retention.  
 
5.4.2.1 Lipid area  
Comparison to vehicle 
The combination of acyl-ghrelin with metformin significantly increased intracellular 
lipid area when compared to a vehicle control (Figure 5.4) (Veh v Met + AG; 3592.5 
[2491 – 4696] µm2 v 4539.5 [3773 - 5501] µm2; p<0.001).  
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Comparison to metformin 
The presence of acyl-ghrelin in combination with metformin caused significant 
increase in cellular lipid area when compared to metformin-only treated cells 
(Figure 5.4) (Met + AG v Met; 4539.5 [3773 - 5501] µm2 v 3870.3 [3177 – 4463] µm2; 
p<0.001). 
Comparison to acyl-ghrelin  
There was a significant decrease in the cellular lipid area of those cells exposed to 
both metformin and acyl-ghrelin in comparison to those treated with only acyl-
ghrelin (Met + AG v AG; 4539.5 [3773 - 5501] µm2 v 4788.7 [4040 – 5976] µm2; 
p<0.05) (Figure 5.4). 
   
  
Figure 5.4. Box plot of interquartile range and median intracellular lipid area within vehicle, acyl-
ghrelin, metformin and metformin plus acyl-ghrelin treated cells in a hyperglycaemic environment. 
Statistical analysis was conducted using non-parametric measures (n=600 per treatment). The 
Kruskal Wallis test determined statistical significance between groups which are indicated by * for 
p<0.001 and ** for p<0.05. Metformin (Met), acyl-ghrelin (AG) and metformin/acyl-ghrelin (Met + 
AG).  
171 
 
5.4.2.2 Real Time gene expression  
Fold change relative to vehicle 
When gene expression data was analysed with respect to combined metformin and 
acyl-ghrelin exposure against a vehicle control there was a significant down 
regulation of LXRβ with a 2.9 (±0.7) fold change (p<0.01), a significant up regulation 
of SREBF1 with a 4.9 (±1.4) fold change (p<0.01) and a non-significant change in 
expression of ABCG1 of 1.1 (±0.02) fold change (p=0.36) (Table 5.1). 
 
Fold change relative to metformin 
Exposure to a combination of metformin and acyl-ghrelin caused a significant down 
regulation of two genes; ABCG1 with 34.2 (±4.0) fold change and LXRβ with 35.1 
(±0.9) fold change, both p<0.01. However, there was no fold change difference for 
SREBF1 between the treatment two treatment groups (p=0.08) (Table 5.1).  
 
Fold change relative to acyl-ghrelin 
Furthermore, when combined metformin and acyl-ghrelin exposure was compared 
to acyl-ghrelin only exposure, data indicated that there was a significant effect of 
metformin with down regulation of 3.5 (±0.4) fold change for LXRβ, a significant up 
regulation of 2.5 (0.2) fold change for ABCG1, and a significant up regulation of 3.5 
(±0.5) fold change for SREBF1 (Table 5.1). 
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Group Gene of interest Fold Change Direction P-value 
V vs 
Met+AG 
LXRβ 10.1 (1.2)  <0.01 
ABCG1 1.1 (0.02)  0.36 
SREBF1 4.9 (1.4)  <0.01 
Met vs 
Met+AG 
LXRβ 34.2 (4.0)  <0.01 
ABCG1 35.1 (0.9)  <0.01 
SREBF1 0.7 (0.2)  0.08 
AG vs 
Met+AG 
LXRβ 3.5 (0.4)  <0.01 
ABCG1 2.5 (0.2)  <0.01 
SREBF1 3.5 (0.5)  <0.01 
Table 5.1. Relative fold change values for gene expression data in vehicle, acyl-ghrelin and dual 
metformin/acyl-ghrelin treated cells in hyperglycaemic environment at 17 hours. Fold change 
between -1.5 and 1.5 is classed as no relative gene expression change. Standard deviation between 
ΔΔCt of experimental repeats are shown in brackets (n=6). Statistical difference of ΔCt in comparison 
group were determined using an independent t-test, statistically significant values shown in bold.  
Vehicle (V), Acyl-ghrelin (AG), Metformin (Met) and Metformin/Acyl-ghrelin (Met + AG). 
        – up regulation.             – down regulation.                      – no fold change, 
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5.4.2.3 Adipokine levels 
The quantity of IL-10 present within the cellular supernatant did not significantly 
change across all four treatment groups (p=0.70) (Table 5.2).  
 IL-10 [pg/mL] 
Treatment No acyl-ghrelin 
(n=6)  
Acyl-ghrelin  
(n=6) 
P-Value 
Vehicle 
(n=6) 
258.2  
[245 – 283] 
282.8 
[224 – 319] 
0.39 
Metformin 
(n=6) 
282.5  
[252 – 300] 
257.4  
[172 – 316] 
1.00 
P-Value 0.44 0.90  
Table 5.2. IL-10 levels for all treated cells in hyperglycaemic environment. Statistical analysis 
conducted using non-parametric parameters using a Kruskal Wallis test.  
 
Compared to vehicle- IL-6 
When combined metformin and acyl-ghrelin treatment was compared to a PBS 
vehicle control there was a significant decline in IL-6 levels (Met+AG v Veh; 12.6 
[9.0 – 16.6] pg/mL v 89.5 [87.7 – 95.5] pg/mL; p<0.05) (Figure 5.5). 
 
Compared to metformin- IL-6 
When compared to only metformin treated cells combined metformin and acyl-
ghrelin treatment caused a significant decline in IL-6 levels. (Met + AG v Met; 12.6 
[9.0 – 16.6] pg/mL v 23.2 [19.3 – 25.6] pg/mL; p<0.05) (Figure 5.5). 
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Compared to acyl-ghrelin- IL-6 
Dual treatment also caused a significant decline in the level of IL-6 within the cell 
supernatants in comparison to acyl-ghrelin only treatment (Met + AG v AG; 12.6 
[9.0 – 16.6] pg/mL v 75.5 [68.9 – 89.5] pg/mL; p<0.05) (Figure 5.5).  
 
 
Figure 5.5. Box plot of IL-6 levels within vehicle, acyl-ghrelin, metformin and metformin/acyl-ghrelin 
treated cells in hyperglycaemic environment. Statistical analysis was conducted using non 
parametric measures (n=6). The Kruskal Wallis test determined statistical significance (p<0.05) 
between groups which are indicated by *. 
Acyl-ghrelin (AG), Metformin (Met) and Metformin/Acyl-ghrelin (Met + AG) 
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5.5 Discussion 
5.5.1 Metformin and lipid retention 
Metformin mono therapy exhibited minimal effect on mature adipocyte 
intracellular lipid area, however there was an increase in the expression of the key 
lipid retention genes ABCG1, LXRβ and SREBF1. This data suggests that metformin 
can act to alleviate lipid retention within cells through promotion of cellular lipid 
export. However 17 hours may not be a long enough duration to exhibit this effect 
on a cell morphological level. In addition to this, metformin is shown to have an 
effect on acyl-ghrelin mediated lipid retention, resulting in the curtailment in acyl-
ghrelin’s promotion of lipid storage within mature adipocytes.  
Previous literature supports this hypothesis, demonstrating that metformin 
treatment of THP-1 macrophages results in the promotion of cholesterol efflux and 
expression of both ABCA1 and ABCG1, this promotion however was deemed to be 
independent of LXR expression (Luo et al., 2017). Metformin stimulation of ABCG1 
is thought to be the result of an increase in the expression of fibroblast growth 
factor (FGF) 21 within adipose tissue and the liver (Luo et al., 2016). Furthermore, 
my data indicate that the action of metformin on ABCG1 is present within cells pre-
treated with acyl-ghrelin or with a vehicle control, indicating that metformin is 
counteracting acyl-ghrelin’s down regulation of ABCG1, resulting in no overall 
change in expression upon dual treatment. In addition to these findings, I 
determined that the effect on ABCG1 expression is independent of LXRβ within 
metformin treated human adipocytes, which is in line with published data that 
indicates that activation of AMPK within mouse macrophages stabilizes the mRNA 
expression of ABCG1 in a LXR-independent manner (Li et al., 2010a).  
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Metformin administration is shown to decrease hepatic lipogenesis via its 
partial mitochondrial uncoupling effect, which activates AMPK and inhibits SREBP-
1c transcriptional activities  (Ferre and Foufelle, 2007, Zhou et al., 2001). However, 
in my data, metformin exposure caused an increase in SREBF1 expression. This 
increase in SREBF1 expression was seen in experimental conditions, whether cells 
were pre-exposed or not to acyl-ghrelin. I hypothesise this paradoxical result is due 
to a depot specific action of SREBF1 within adipocytes, resulting in AMPK regulatory 
action also being depot specific and not true of a hyperglycaemic adipocyte cell 
depot.    
The action of AMPK, described above, on SREBP-1c is due to AMPK directly 
inhibiting ligand-induced LXR activity in addition to blocking the production of 
endogenous LXR ligands within hepatic loci (Yap et al., 2011). This chapter indicates 
a marked increase in LXRβ and SREBF1 expression within an adipose depot, 
signifying alternative actions dependant on experimental depot. However, previous 
studies have shown that metformin administration coincides with an increase in 
GLUT4 expression within human skeletal muscle cells (Al-Khalili et al., 2005), and 
within subcutaneous adipose tissue of women with polycystic ovary syndrome 
(Jensterle et al., 2008). GLUT4 and LXR share an intrinsic pathway with GLUT4 being 
up regulated by LXR agonists (Calkin and Tontonoz, 2012). One possible explanation 
may be that within a hyperglycaemic state, metformin action on mature adipocytes 
increases GLUT4 expression via LXR up regulation.   
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5.5.2 Metformin and inflammation 
Metformin exposure had no effect on the anti-inflammatory marker IL-10, alone or 
in combination with acyl-ghrelin. Previously published data in murine macrophages 
reports that metformin induces an anti-inflammatory response under LPS immune-
challenge (Hyun et al., 2013, Kelly et al., 2015, Zhou et al., 2016). However, previous 
work was conducted within murine models and could account for variation in 
findings that may be the result of a species-specific effect.  
In contrast to IL-10, our IL-6 data are supported by previously published 
work showing that metformin supresses the expression and release of IL-6 (Zhou et 
al., 2016, Kelly et al., 2015). This protective effect in the inflammatory state, via a 
decline in IL-6, is also present when mature human adipocytes are pre-exposed to 
acyl-ghrelin, indicating metformin further enhances the suppression of pro-
inflammatory cytokines that are present following exposure to acyl-ghrelin.   
Metformin exposure was shown to supress the expression of pro-
inflammatory cytokines through cellular regulation via AMPK signalling in rodents, 
resulting in induced NFκB inhibition and enhanced expression of anti-inflammatory 
cytokines via AMPK activation. This response was shown to also occur in the 
presence of AGEs, indicating metformin also inhibits AGE-induced inflammatory 
response (Zhou et al., 2016). In addition to cellular mechanisms, circulatory markers 
of inflammation are also shown to be reduced when humans are treated with 
metformin, including the suppression of neutrophil to lymphocyte ratio (Cameron 
et al., 2016), indicating that metformin acts to reduce the inflammatory state in 
those with or without T2D, an action that is accentuated in the presence of acyl–
ghrelin.  
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5.6 Conclusion 
Published studies show an increased level of acyl-ghrelin present within obesity and 
T2D which may have a detrimental effect on cellular lipid retention, this effect 
could be diminished via metformin administration. With respects to an 
inflammatory response, it is clear that co-administration of metformin and acyl-
ghrelin could have therapeutic advantages in reducing the presence of pro-
inflammatory adipokine levels in hyperglycaemia. Expansion and investigation into 
this interlinked modulation of the inflammatory state could reveal key therapeutic 
pathways.  
 
5.7 Limitations 
The experimental design within this chapter was based on that of previous chapter 
findings, however, it was limited to only one time point at 17 hours. Within future 
work, an expansion on this chapter could include the analysis of treatment 
exposure at a greater frequency i.e. baseline to 17 hours with hour intervals to 
establish a response curve over time. In addition to this, dosage concentrations 
were based on previous literature rather than the physiological range present 
within circulation, therefore, a dose response curve would also have been 
beneficial. However, due to time constraints this was not conducted within this 
chapter, as the aim was to establish whether cell dosage could contribute to a 
change and if this change could be sufficient to allow for further exploration. 
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Chapter 6  
General Discussion 
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The aim of this project was to translate previous findings present within murine 
models for an intrinsic role played by acyl-ghrelin on lipid retention within adipose 
tissue, and whether this acyl-ghrelin associated lipid retention could alter the 
inflammatory state within those that are obese and/or have T2D (Davies et al., 
2009, Miegueu et al., 2011). This thesis on the based analysis of expression levels of 
specific lipid retention genes and inflammatory markers within an adipocyte cell 
line and ex vivo hVAT samples from individuals that are obese and/or have T2D, to 
identify whether acyl-ghrelin has a mediatory role that can be explored as a 
possible therapeutic target for T2D and related comorbidities. Furthermore, to 
expand on in vitro and ex vivo data collected in Chapter 3 and 4, application of acyl-
ghrelin in response to the first line drug therapy of T2D, metformin was also 
investigated.  
 Within Chapter 3, exposure to acyl-ghrelin in a normoglycaemic state 
resulted in an increase in lipid retention via the initial down regulation of ABCG1. 
Over time, this effect was eliminated via a compensatory increase in LXRβ 
expression, leading to an up regulation of ABCG1, returning it to a level seen within 
vehicle treated cells (Figure 6.1). In Chapter 4, circulating acyl-ghrelin 
concentrations were at their highest in non-obese individuals, however acyl-ghrelin 
mediated lipid retention shown in vitro was not mirrored in lipid retention markers 
of the ex vivo samples. This may indicate that lipid retention within visceral adipose 
tissue of non-obese individuals is independent of circulatory acyl-ghrelin levels. In 
vitro experiments required the exposure of mature adipocytes directly to acyl-
ghrelin, whereas circulatory levels present within individuals may not be 
representative of the physiological level of acyl-ghrelin present within adipose 
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tissue. Thus a comparison between the two must be under taken with caution as 
acyl-ghrelin’s action may be depot/cell specific (Miegueu et al., 2011, Porteiro et al., 
2013, Churm et al., 2017, Demers et al., 2009).  
 Over the time span of the initial experiments SREBF1 also showed an 
increase in expression levels within acyl-ghrelin treated mature adipocytes in a 
normoglycaemic state. This is in line with previous literature that shows SREBF1 is a 
target for LXRα/β ligands (Repa et al., 2000). Therefore, these data suggest that 
SREBF1 regulation is dependent on LXR up regulation rather than a direct effect of 
acyl-ghrelin. My results suggest that the intracellular lipid area increase was due to 
the depot specific action of acyl-ghrelin on the down regulated ABCG1 expression, 
and that over time, within a normoglycaemic state the cell aims to counteract this 
effect via up regulation of LXR and the resultant up regulation of ABCG1. However, 
this counteraction also results in the up regulation of SREBF1 independent of acyl-
ghrelin exposure. This hypothesis corresponds with results from the ex vivo 
samples, which showed no association within the total sample cohort between 
LXRβ or SREBF1 expression and GHRL expression or circulating acyl-ghrelin levels.  
 
 
Figure 6.1. Gene expression profile over time (17 and 34 hours) of SGBS cells within normoglycaemic 
environment treated with either acyl-ghrelin (effect shown in red) or vehicle (effect shown in blue).  
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Upon evaluation of acyl-ghrelin mediation of the lipid retention pathway 
within mature adipocytes in a hyperglycaemic environment there was deviation in 
the established pathway compared to that shown for normoglycaemia (Figure 6.2). 
Within human adipocytes an immediate effect was evident when exposed to acyl-
ghrelin, producing a significant increase in lipid area, via the down regulation of 
both LXRβ and ABCG1. Therefore, one hypothesis is that in addition to acyl-ghrelin’s 
effect on the down regulation of ABCG1,  the cumulative effect of a hyperglycaemic 
environment resulted in the further down regulation of ABCG1 and an impingement 
of the cells counter measure via LXRβ by causing its down regulation instead (Xue et 
al., 2009), producing a dual mediation of lipid retention via an inhibition of the 
cholesterol export mechanism.  
 
 
Figure 6.2. Gene expression profile over time (17 and 34 hours) of SGBS cells within hyperglycaemic 
environment treated with either acyl-ghrelin (effect shown in red) or vehicle (effect shown in blue).  
 
Furthermore, ex vivo experiments in Chapter 4 also demonstrated an 
association with hyperglycaemic environment with LXRβ within the hVAT of those 
with T2D. Due to circulating acyl-ghrelin levels being significantly reduced in 
individuals with T2D, I hypothesise that acyl-ghrelin action on T2D adipose tissue is 
183 
 
minimal, suggesting that the down regulation of ABCG1 and SREBF1 in the OT2D 
group was the result of diminished LXR promotion via the presence of an elevated 
blood glucose rather than acyl-ghrelin itself (Mitro et al., 2007, Mauerer et al., 
2009). Further evidence of acyl-ghrelins’ diminished action within T2D is the 
negative correlation between plasma fasting glucose, GHRL mRNA expression and 
acyl-ghrelin levels, indicating that ghrelin levels within T2D are under glucose 
regulation. As previously discussed in Chapter 4, the ratio of acyl-ghrelin, total 
ghrelin and desacyl-ghrelin within the metabolic state is controversial across 
published study cohorts (Rodríguez et al., 2012, Dardzińska et al., 2014, Supák et al., 
2016). This ex vivo investigation of the ghrelin axis suggest that acyl-ghrelin 
concentrations may be dependent on GHRL expression only, and not its post-
translational modification, accounting for a lower plasma acyl-ghrelin level seen in 
this cohort, and reduced desacyl-ghrelin level often reported within the metabolic 
state (Rodríguez et al., 2012).  
 VAT samples from OT2D group showed an alternative relationship between 
hyperglycaemia and lipid biosynthesis gene expression. SREBF1 was down regulated 
in ex vivo samples, but had no fold change in mature adipocytes. This could be due 
to two hypothesies: (i) depot-specific action and/or (ii) interaction with anti-
diabetic therapeutic agents. A depot-specific effect would allow for variability to 
stem from the vast cellular make up of adipose tissue in contrast to the pure 
mature adipocytes culture. Adipose tissue has been reported to be affected by the 
presence of a hyperglycaemic environment and acyl-ghrelin by impacting 
macrophages (Liu et al., 2012), monocytes (Dixit et al., 2004) and T cells (Dixit et al., 
2004). As these cell types were not investigated in co-culture with adipocytes we 
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are unable to determine whether there is an alternative effect occurring within ex 
vivo samples resulting in a variation in data. The second theory has been discussed 
in detail within Chapter 5, where metformin was prescribed and taken by 90% of 
the individuals recruited for this study with T2D, therefore impact on adipocyte lipid 
retention was examined. In contrary to published data within murine models (Zhou 
et al., 2001, Lin et al., 2000), metformin caused an increase in SREBF1 transcription 
within mature adipocytes, therefore this variation within a hyperglycaemic state 
could be due to the use of a homogeneous cell source (mature adipocytes) rather 
than a heterogeneous animal model. 
 Furthermore, combined treatment with both acyl-ghrelin and metformin 
suggested that metformin altered the expression of both LXRβ and SREBF1; 
increasing expression of SREBF1, whilst down regulating LXRβ. This demonstrates 
that metformin’s action is independent of LXR stimulation, diminishing its action on 
LXR expression in the presence of both hyperglycaemia and high acyl-ghrelin. 
Additionally, metformin treatment produced a significant up regulation of ABCG1, 
however upon administration of combined acyl-ghrelin and metformin there was 
no change in ABCG1 expression compared to vehicle treated cells, indicating that 
metformin up regulation of ABCG1 counteracts the effects of acyl-ghrelin exposure. 
 Obesity is often characterised by an increase in the prevalence of 
dyslipidaemia, with the main factor often being uncontrolled fatty acid lipolysis 
from VAT, which is dependent upon adipocyte size and number of ATM (Gutierrez 
et al., 2009). This study demonstrates an association between acyl-ghrelin with 
both lipid retention genes and plasma lipid markers, indicating that acyl-ghrelin 
levels are a risk factor associated with dyslipidaemia.    
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 Acyl-ghrelin’s ability to mediate lipid retention led to the hypothesis that it 
would also result in the promotion of a pro-inflammatory state. Acyl-ghrelin 
exposure in vitro caused a significant decline in IL-6 in both normo- and 
hyperglycaemic environments, which coincides with findings in murine models 
(Baatar et al., 2011, Chorny et al., 2008, Wu et al., 2008) and an increase in the anti-
inflammatory marker IL-10 in a normoglycaemic environment. However, within a 
hyperglycaemic environment this anti-inflammatory IL-10 promotion via acyl-
ghrelin was diminished. Complementary to in vitro work, analysis of ex vivo samples 
showed that mRNA levels of GHRL were significantly positively associated with IL-10 
within the total sample cohort and TAOS (%) within an obese cohort. This 
association was lost within the T2D cohort indicating that, as the in vitro arm of the 
experiments, glucose may be diminishing acyl-ghrelin’s effect on oxidative burden 
and anti-inflammatory state. IL-10 levels across the chapters provided contradictory 
findings with respect to ghrelin association, however it is important to note that an 
association of GHRL expression within ex vivo sample may indicate two alternative 
theories. Firstly, acyl-ghrelin does promote anti-inflammatory state markers 
(Waseem et al., 2008), however this effect does not take place within adipocytes, 
instead being from an alternative cell source. Within the immune system, acyl-
ghrelin has been shown to induce an anti-inflammatory state through M2 
macrophage polarization and inhibiting Th1 cells and increasing the polarization of 
both Th2 and T cells (Pereira et al., 2017). Secondly, as previously discussed, 
increases in GHRL mRNA levels could indicate an increase in either or both acyl-and 
desacyl-ghrelin.  Desacyl-ghrelin, which was once considered biologically inactive, is 
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now known to play a role in various metabolic pathways, including that of 
macrophage polarization (Pereira et al., 2017, Au et al., 2017)  
Obesity and T2D are associated with an increase in IL-6 as well as a decline 
in both plasma IL-10 (van Exel et al., 2002, Esposito et al., 2003) and TAOS levels 
(Fenkci et al., 2003, Prior et al., 2017). The combination of both in vitro and ex vivo 
data presented within the previous chapters indicate that acyl-ghrelin may play a 
beneficial role abrogating inflammation, and that exploration of this novel pathway 
within human adipocytes could elucidate key therapeutic targets for the 
management of low-grade inflammation.  
When metformin treatment was analysed in Chapter 5, it was shown to 
have no effect on the pro-inflammatory marker IL-10, nor when used in 
combination with acyl-ghrelin. However, the combination of the two did cause a 
significant decrease in IL-6 compared to either treatment alone. In addition to this, 
combination of metformin and acyl-ghrelin alleviated the detrimental effect of acyl-
ghrelin on lipid retention. Therefore, co-administration within adipocytes resulted 
in the promotion of inflammatory health, but with no effect on cellular lipid 
retention.   
 I hypothesise that the mode in which acyl-ghrelin acts on both lipid 
retention and inflammatory response is similar to that of metformin, acting via 
AMPK. Acyl-ghrelin has been shown to directly activate neuropeptide Y (NPY) 
neurons in the ARC via an increase in AMPK-mediated signalling (Kohno et al., 2008, 
Kang et al., 2015), with AMPK induction inhibiting the release of IL-6 and other pro-
inflammatory cytokines via the attenuation of NFκB (Lihn et al., 2008). 
Furthermore, due to metformin’s well described action on AMPK (Phoenix et al., 
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2009), combination treatment may exhibit a dual activation of AMPK activity which 
would amplify this effect.  
However, contradictory to this theory is acyl-ghrelin’s action on lipid 
retention. In contrast to the AMPK-inflammation relationship, this does not fit the 
project’s findings, as AMPK activation results in the alleviation of lipid retention and 
promotion of cholesterol efflux due to the up regulation of ABCG1 (Li et al., 2010b) 
and the inhibition of SREBF1 (Pedram et al., 2013). Therefore, further work is 
required to elucidate the cellular mechanisms in which acyl-ghrelin acts to mediate 
lipid retention within adipocytes.  
This work translated previous murine findings that acyl-ghrelin and 
glycaemic levels are detrimental to lipid retention causing an increase in 
intracellular lipid area via alterations within the LXR-ABC pathway and the 
independent action acyl-ghrelin has on the inflammatory state. However, acyl-
ghrelin was also shown to be beneficial to inflammatory health via a reduction in 
pro-inflammatory marker IL-6. Therefore, the combination of acyl-ghrelin and 
metformin treatment could allow for a reduction in low-grade inflammation 
present within the adipocytes of individuals with T2D, thus ameliorating insulin 
resistance and improving insulin sensitivity. 
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Limitations & future work 
The main methodological limitations are set out and discussed in each chapter 
(sections 3.7, 4.7 and 5.7). However, in expansion to these the project design as a 
whole was also restricted by general methodology limitations that could have 
enhanced analysis. For example, relative mRNA changes provided crucial 
understanding of acyl-ghrelin’s effect at a gene level, deducing significant fold 
changes present when comparing groups or treatments. However, this does not 
allow for the quantification of mRNA transcript, nor whether this is translated at a 
protein level. Further analysis via Western blot could allow for greater insight into 
cellular changes and the degree in which acyl-ghrelin exhibits a mediatory role.  
 As noted within Chapter 4, exploratory analysis associated the expression of 
GHRL with key inflammatory markers, yet this encompasses acyl-ghrelin in addition 
to desacyl-ghrelin. This project would have benefitted if time allowed, for the 
further analysis of desacyl-ghrelin dosing within in vitro experiments to act as a 
comparator to the cellular responses to acyl-ghrelin.  
Within the project proposal, an adequate power calculation deemed that 30 
ex vivo samples would suffice to elucidate any statistical significance within the 
data.  However, in reality the analysis of small numbers of samples proved difficult, 
especially to elucidate significance within the study data. Due to sample collections 
being from routine non-emergency abdominal surgeries, often the collection of 
samples would be delayed due to surgery cancellations. Another minor limitation 
within this study was the ability to only look at the interaction of acyl-ghrelin with 
one type of T2D therapy. Further information on acyl-ghrelin’s potential to 
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ameliorate the inflammatory response may have been yielded from exposure to 
further combinations, such as insulin analogues or GLP-1 agonist therapies. 
 Despite the limitation of sample size, the data provide a novel insight into an 
area of expertise that still has several knowledge gaps. Even though this thesis 
pinpoints specific pathways in which acyl-ghrelin interacts with cellular energy 
balance, an expansion should aim to yield the exact pathway in which acyl-ghrelin 
results in alterations in lipid retention and inflammation. This project demonstrates 
that under the correct circumstances acyl-ghrelin can be used as a therapeutic 
target for T2D, however the way this is optimised for maximum impact and 
minimum consequence requires investigating.  
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Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation. 
 
Sponsors are not required to notify the Committee of approvals from host organisations.  
 
Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be registered 
on a publically accessible database within 6 weeks of recruitment of the first participant (for 
medical device studies, within the timeline determined by the current registration and publication 
trees).   
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as part of 
the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered but 
for non-clinical trials this is not currently mandatory. 
 
If a sponsor wishes to contest the need for registration they should contact  
, the HRA does not, however, expect exceptions to be made. 
Guidance on where to register is provided within IRAS. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
Ethical review of research sites 
 
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
“Conditions of the favourable opinion” above). 
 
Approved documents 
 
The documents reviewed and approved by the Committee are: 
 
Document   Version   Date   
GP/consultant information sheets or letters [GP letter, V1, 
20th Aug 2014 (if needed)]  
Version 1  20 August 2014  
IRAS Checklist XML [Checklist_17092014]    17 September 2014  
Other [Email with contact number ]    04 September 2014  
Other [Reply to panel comments]  Version 1  16 September 2014  
Participant consent form [Consent form, V2, 16th Sept 2014 
highlighted]  
Version 2  16 September 2014  
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Participant consent form [Consent form, V2, 16th Sept 2014]  Version 2  16 September 2014  
Participant information sheet (PIS) [PIS, V2, 16th Sept 2014]  Version 2  16 September 2014  
Participant information sheet (PIS) [PIS, V2, 16th Sept 2014 
highlighted]  
Version 2  16 September 2014  
REC Application Form    01 September 2014  
Research protocol or project proposal [NISCHR Successful 
application including proposal]  
Version 1  20 August 2014  
Summary CV for Chief Investigator (CI) [CV Jeffrey Stephens, 
August 2014]  
Version 1  20 August 2014  
Summary CV for student [CV Rachel Churm, PhD Student]  Version 1  20 August 2014  
Summary CV for supervisor (student research) [CV Sarah 
Prior, Academic supervisor]  
Version 1  20 August 2014  
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
 Notifying substantial amendments 
 Adding new sites and investigators 
 Notification of serious breaches of the protocol 
 Progress and safety reports 
 Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
 
Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views known 
please use the feedback form available on the HRA website: http://www.hra.nhs.uk/about-the-
hra/governance/quality-assurance  
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/  
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Department of Diabetes and Endocrinology 
Morriston Hospital, Morriston, Swansea, SA6 6NL 
 
 
 
Tel: 01792 704078 
 
Fat and its role in obesity and diabetes 
Patient Information Sheet 
 
 
You are being invited to take part in a research study that is being undertaken as part of an 
educational qualification, with the goal of improving our knowledge of why human fat is important in 
obesity and diabetes. The purpose is to improve our knowledge of hormones and chemicals made 
in the fat within the abdomen and how these might be important in ill-health related to diabetes. 
 
Before you decide, it is important to understand why the research is being done and what it will 
involve. Please take time to read the information carefully. Talk to others about the study if you wish. 
Ask us if there is anything that is not clear or if you would like to know more. Part 1 tells you the 
purpose of this study and what will happen to you if you take part. Part 2 gives you more information 
about the conduct of the study. Take time to decide whether or not you wish to take part. 
 
 
Part 1 
 
What is the purpose of this study? 
Obesity (carrying too much weight) and type 2 diabetes are major health concerns and contribute to 
heart disease and general ill health. Fat from inside the abdomen (visceral fat) appears to be 
important in causing these conditions. This research looks at the differences between abdominal fat 
from people who are lean, obese or have type 2 diabetes. We will look at differences in the size and 
development of fat cells and also on proteins and hormones that are produced by fat from people 
who are lean, obese or have type 2 diabetes. We will also examine how genes within fat might 
influence various chemicals produced in fat. The blood sample will be used to measure levels of 
molecules with the body that help reduce oxidative stress. Eventually the work may lead to a better 
understanding of why too much fat causes diabetes and heart disease. This might lead to newer 
treatments to prevent and treat these common conditions. 
 
Why have I been invited to take part? 
You have been asked to take part in this study because you are due to have an operation on your 
abdomen. As part of the operation the surgeon will routinely remove or move around abdominal fat. 
We are asking if you would be happy to donate a small piece of this fat, along with a blood sample, 
for the research study. We are asking patients who are lean, obese or have type 2 diabetes to be 
involved. 
 
Do I have to take part? 
Your participation in this study is entirely voluntary. It is up to you to decide whether or not to take 
part. We will describe the study and go through this information sheet which you will keep. We will 
then ask you to sign a consent form to show you have agreed to take part. The original signed and 
dated copy will remain at the hospital and you will be given a copy to take home. You are free to 
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stop the research at any time without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
At the start, the study will be explained to you by the study doctor. The surgeon looking after your 
routine care may telephone or during clinic ask your permission to receive a telephone call from 
Professor Stephens or his team to provide more information on the research. If you agree to take 
part we ask that you sign the consent form. Any treatments which you usually take will not change. 
Before your scheduled operation we will collect a blood sample from you. During the scheduled 
operation, the surgeon will remove a small piece of fat from inside the abdomen (about the size of a 
sugar cube) and underneath the skin. This should not cause any problems and will not have an 
effect on the planned operation. After the scheduled operation there will be no need for any further 
samples or action.  
 
Expenses and payments? 
There are no payments for taking part in this study. 
 
What do I have to do? 
If you agree to take part you will then be asked to complete the consent form, give a blood sample 
and then the surgeon will remove the samples of fat during the operation. Before the operation you 
should just follow the routine advice given. There is nothing else you need to do. 
 
What are the benefits of taking part? 
There is no direct benefit to you of taking part in the research but the information we get from this 
study might help improve the treatment of people with obesity and diabetes.  
 
What are the risks of taking part? 
There are no extra risks in taking part in this study as your routine medical care is not changed. 
There will be risks related to the main operation which your doctor will discuss with you beforehand. 
For the research, taking the small piece of fat does not affect the procedure being performed. The 
fat biopsy might cause a small amount of bleeding but this can be stopped immediately and the risk 
of internal scarring if extremely minimal. 
 
What happens when the study stops? 
No further samples will be necessary. We will dispose of all samples (fat and blood) after the study 
has completed. 
 
What if there is a problem? 
Participating in the study should not put you at any increased risk of anything going wrong. Part 2 of 
this sheet provides information on how to deal with any problems which arise.  
 
Will my taking part be kept confidential? 
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2. 
 
 
 
 
 
 
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in 
 Part 2 before making any decision. 
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Part 2 
 
What will happen if I don’t want to carry on with the study? 
Your participation in this study is completely voluntary and you may refuse to participate and are 
free to withdraw from the study at any time. Your decision to withdraw from the study will not affect 
the relationship between you and your study doctor, nor affect any future medical treatment 
provided for you. If you withdraw from the study, we will dispose of the samples and withdraw them 
from the research. 
 
What if there is a problem? 
Participating in the study should not put you at any increased risk of anything going wrong. If you 
have a concern about any aspect of this study, you should ask to speak to the researchers who will 
do their best to answer your questions (Telephone: 01792 704078). If you remain unhappy and wish 
to complain formally, you can do this through the ABMU Complaints Procedure (Website: 
http://www.wales.nhs.uk/sitesplus/863/page/39350; email: ABM.Complaints@wales.nhs.uk). If 
taking part in this research project harms you there are no special compensation arrangements. If 
you are harmed due to someone's negligence then you may have grounds for legal action but you 
may have to pay for it.  
 
Will my taking part in this study be kept confidential? 
Yes. Any information and samples which are collected during this research will be kept strictly 
confidential. You will be given a unique identifying number and any information about you which 
leaves the hospital will have your name and address removed so that you cannot be recognised. 
Some parts of your medical records and the data collected for the study may be looked at by 
authorised hospital staff to check that the study is being carried out correctly. All will have a duty of 
confidentiality to you as a research participant and we will do our best to meet this duty. 
  
Involvement of the General Practitioner/Family doctor (GP) 
If you agree to take part in this study, your study doctor will contact your GP to let him/her know if 
you so wish. You will be asked to consent for your GP to be informed of your participation on the 
consent form.  
 
What will happen to any samples I give and will genetic tests be done? 
We consider the fat sample you donate for the research to be a gift. This sample will be used to look 
how changes regulation within fat influences proteins and hormones. No genetic tests for disease 
risk will take place. Samples will be stored by the investigators in a locked freezer within a locked 
laboratory in Swansea University. The samples may be kept for the duration of the research. All 
samples will be anonymised. 
 
What will happen to the results of the research study? 
The results of the study may be published in a medical journal and might be presented to other 
doctors and scientists with an interest in diabetes. If reports or publications are generated from the 
study you will not be identified in these. The results will also be used to look at the possibility of a 
larger more focused study involving fat. 
 
Who is organising and funding the research? 
This work is being organised between Abertawe Bro Morgannwg University Health Board and 
Swansea University College of Medicine. The work is being supported by funds from the Welsh 
Government.  
 
Who has reviewed the study? 
The East of Scotland Research Ethics Committee REC 1 has examined the proposal and has raised 
no objections from the point of view of research ethics. It is a requirement that your records in this 
research, together with any relevant medical records, be made available for scrutiny by monitors 
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from the Abertawe Bro Morgannwg University Health Board, whose role is to check that research is 
properly conducted and the interests of those taking part are adequately protected. 
 
 
Who can I contact for further information? 
This Patient Information Sheet and the Informed Consent Form contain important facts which you 
should consider when deciding whether you are willing to take part in this study. If at any time you 
have any questions about the study, your rights as a research participant, a study related injury or 
side effects you should contact either of the two research doctors below or the Director of Research 
and Development within the local Health Board: 
 
  
     
  
 
  
   
  
 
  
  
  
     
 
 
  
 
  
  
  
 
 
Thank you for reading this information sheet. 
 
  
 
 
 
 
 
 
 
 
 
 
 
Appendix 2 
Primer sequences & programmes 
 
 
 
 
 
 
 
 
 
Primer Sequences 
 
Primer Forward Primer Reverse Primer Source 
Β-actin 
GATGGCCACGGCTG
CTTC 
TGCCTCAGGGCAGC
GGAA 
Eurofins MWG 
operon 
GHRL 
TGAGCCCTGAACAC
CAGAGAG 
AAAGCCAGATGAG
CGCTTCTA 
Eurofins MWG 
operon 
PPARγ 
ACAGCGACTTGGCA
ATATTTATTG 
AGCTCCAGGGCTTG
TAGCA 
Eurofins MWG 
operon 
ABCG1 
TCCTATGTCAGGTA
TGGGTTCG 
GTCCAGGTACAGCT
TGGCAT 
Eurofins MWG 
operon 
LXRβ 
CCTGCAGGTGGAGT
TCATCA 
CAGCTGGTCCTGCG
GC 
Eurofins MWG 
operon 
LYPLA1 
GGTCCTATCGGTGG
TGCTAA 
ACATCCATCATTTCC
TGTTGACAC 
Eurofins MWG 
operon 
SREBF1 
CTTAGAGCGAGCAC
TGAACTG 
CCGAGGGCATCCGA
GAATT 
PrimerDesign 
mBOAT4 
TCTTTGTCTGAGCA
TGTGTGTAA 
AAGCACTGGACCCT
TGAACA 
PrimerDesign 
 
Table 1. Primer sequences generated through NCBI primer tools and PrimerDesign 
 
 
 
 
Primer Cycling Conditions 
Programme Primer Sets 
95⁰C for 3 min 
35 cycles of 
95⁰C for 30 sec 
60⁰C for 30 sec 
72⁰C for 30 sec 
Β-actin 
LYPLA1 
PPARγ 
95⁰C for 3 min 
35 cycles of 
95⁰C for 30 sec 
59.5⁰C for 30 sec 
72⁰C for 30 sec 
ABCG1 
LXRβ 
95⁰C for 3 min 
35 cycles of 
95⁰C for 30 sec 
58.5⁰C for 30 sec 
72⁰C for 30 sec 
GHRL 
95⁰C for 2 min 
40 cycles of 
95⁰C for 15 sec 
60⁰C for 60 sec 
SREBF1 
mBOAT4 
 
 
Table 2. Cycling conditions with optimal annealing temperature in bold for primer 
sequences.  
  
 
 
 
 
 
 
 
 
 
 
Appendix 3 
Primer optimisation & validation 
 
 
 
 
 
 
 
 
 
 
Β-actin 
 
Figure 1. β actin standard curve 10-fold dilution over 4 points. Log starting quantity vs cycle 
threshold (Ct). y = -3.202x + 18.822, R² = 0.99. Efficiency= 105%. Error bars indicate standard 
deviation. 
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Figure 2. Ghrelin standard curve 10-fold dilution over 3 points. Log starting quantity vs cycle 
threshold (Ct). y = -3.1894x + 27.852, R² = 0.99. Efficiency= 106%. Error bars indicate standard 
deviation. 
 
 
Figure 3. Ghrelin primer set validation semi-regression plot over 3 points. Log starting quantity vs 
delta cycle threshold (Δ Ct). y = 0.011x + 9.186, R² = 0.0058. 
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Figure 4. PPARγ standard curve 10-fold dilution over 4 points. Log starting quantity vs cycle 
threshold (Ct). y = -3.1742x + 20.31, R² = 0.99. Efficiency= 107%. Error bars indicate standard 
deviation. 
 
Figure 5. PPARγ primer set validation semi-regression plot over 4 points. Log starting quantity vs 
delta cycle threshold (Δ Ct). y = 0.0808x + 1.5533, R² = 0.4929. 
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Figure 6. ABCG1 standard curve 10-fold dilution over 3 points. Log starting quantity vs cycle 
threshold (Ct). y = -3.305x + 27.255, R² = 0.9926. Efficiency= 101%. Error bars indicate standard 
deviation. 
 
Figure 7. ABCG1 primer set validation semi-regression plot over 3 points. Log starting quantity vs 
delta cycle threshold (Δ Ct). y= -0.0933x + 8.6211, R² = 0.1445. 
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Figure 8. LXRβ standard curve 10-fold dilution over 3 points. Log starting quantity vs cycle threshold 
(Ct). y = -3.28x + 25.843, R² = 0.994. Efficiency= 102%. Error bars indicate standard deviation. 
 
Figure 9. LXRβ primer set validation semi-regression plot over 3 points. Log starting quantity vs delta 
cycle threshold (Δ Ct). y = -0.0983x + 6.8272, R² = 0.2543. 
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Figure 10. LXRβ standard curve 10-fold dilution over 3 points. Log starting quantity vs cycle threshold 
(Ct). y = -3.2233x + 27.739, R² = 0.9928. Efficiency= 104%. Error bars indicate standard deviation 
 
Figure 11. LYPLA1 primer set validation semi-regression plot over 3 points. Log starting quantity vs 
delta cycle threshold (Δ Ct). y = -0.0783x + 8.2472, R² = 0.1195. 
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Figure 12. SREBF1 standard curve 1 in 4 dilution series over 3 points. Log starting quantity vs cycle 
threshold (Ct). y = -3.3053x + 24.27, R² = 0.9963. Efficiency= 101%. Error bars indicate standard 
deviation. 
 
Figure 13. SREBF1 primer set validation semi-regression plot over 3 points. Log starting quantity vs 
delta cycle threshold (Δ Ct). y = -0.0396x + 5.8708, R² = 0.6805. 
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Figure 14. mBOAT4 standard curve 1 in 4 dilution series over 3 points. Log starting quantity vs cycle 
threshold (Ct). y = -3.4853x + 28.457, R² = 0.99. Efficiency= 94%. Error bars indicate standard 
deviation. 
 
Figure 15. mBOAT4 primer set validation semi-regression plot over 3 points. Log starting quantity vs 
delta cycle threshold (Δ Ct). y = 0.0489x + 10.102, R² = 0.1058. 
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Appendix 4  
Real Time PCR validation 
(Raw data) 
 
 
 
 
 
 
 
 
Primer Set Replicate Intra assay 
Variation 
Inter assay 
variation 
 
PPARγ 
1 22.0 25.5 19.2 22.0 25.5 19.2 
22.0 24.4 19.2 22.0 24.4 19.2 
22.2 24.8 19.1 22.2 24.8 19.1 
2 22.1 24.9 NA 23.0 24.0 18.9 
22.1 24.3 19.7 23.1 24.4 18.8 
22.0 24.3 19.9 22.9 24.2 18.9 
3 22.2 25.2 19.9 22.5 25.1 19.5 
22.2 25.2 19.9 22.7 25.4 19.7 
21.8 25.6 19.5 22.9 25.0 19.2 
4 21.8 24.9 20.1 23.1 24.8 19.6 
21.8 24.9 20.1 22.8 24.6 19.9 
21.6 24.3 19.8 22.4 24.6 20.2 
5 22.4 25.3 19.7 22.6 24.1 19.3 
22.2 25.3 19.7 22.6 24.2 19.3 
22.5 25.5 19.9 22.7 23.9 19.4 
 
GHRL 
1 27.6 29.8 31.5 27.6 29.8 31.5 
27.7 30.2 32.0 27.7 30.2 32.0 
27.6 30.4 32.0 27.6 30.4 32.0 
2 27.6 29.9 32.2 27.6 29.6 32.1 
27.6 30.0 32.4 28.0 30.1 32.9 
27.7 30.0 32.2 27.2 30.0 32.1 
3 28.0 29.7 31.8 27.7 29.7 31.4 
28.1 29.8 31.1 27.7 29.7 31.5 
27.2 29.8 30.9 28.1 30.1 31.3 
4 28.2 29.3 31.5 27.5 28.9 31.9 
28.5 29.9 32.0 27.3 29.3 32.3 
27.9 30.0 32.0 27.5 29.4 32.4 
5 27.2 30.3 32.4 28.1 29.9 32.9 
27.4 29.9 32.1 28.5 30.1 32.6 
27.6 29.8 32.0 27.9 30.2 32.6 
 
mBOAT4 
1 21.7 30.2 27.8 21.7 30.2 27.8 
22.0 29.8 27.5 22.0 29.8 27.5 
21.2 30.2 27.8 21.2 30.2 27.8 
2 21.6 29.6 27.5 22.1 30.5 27.8 
21.7 29.7 27.8 22.3 30.6 27.9 
21.4 29.4 27.8 22.3 30.5 28.0 
3 21.7 29.4 27.1 21.5 29.6 28.1 
21.7 29.5 27.0 21.5 29.9 27.9 
21.8 29.4 28.0 21.6 30.3 27.9 
4 21.7 30.0 27.4 22.4 30.9 27.1 
21.7 30.1 27.6 22.3 31.0 28.0 
22.0 29.8 27.8 22.6 31.3 27.4 
5 21.8 29.7 27.1 21.2 29.7 27.6 
21.8 29.7 27.7 21.8 29.8 28.6 
21.8 30.2 27.6 21.9 29.8 28.4 
 
Primer Set Replicate Intra assay 
Variation 
Inter assay 
variation 
 
ABCG1 
1 27.2 26.7 23.7 27.2 26.7 23.7 
27.3 26.7 23.7 27.3 26.7 23.7 
27.2 26.6 23.9 27.2 26.6 23.9 
2 27.2 26.3 23.9 27.7 26.1 24.1 
27.2 26.4 23.9 27.8 26.1 24.3 
27.7 26.8 23.8 27.7 26.2 24.4 
3 27.2 26.6 24.4 27.4 26.7 23.6 
27.5 26.7 23.7 27.5 26.7 24.5 
27.5 26.7 24.5 27.3 26.9 24.1 
4 27.8 26.4 23.9 26.9 26.2 23.8 
27.7 26.7 24 27 26.3 24.3 
27.4 26.3 23.7 26.9 26.6 24.2 
5 27.4 27.1 23.8 27 26.9 24.3 
27.3 26.8 23.6 27.2 26.9 24.4 
27.4 26.8 24.2 27.3 26.7 23.8 
 
LXRβ 
1 23.2 24.9 28.7 23.2 24.9 28.7 
23.2 24.6 29.1 23.2 24.6 29.1 
23 24.6 28.7 23 24.6 28.7 
2 23.3 24.6 28.9 23.8 25 29.7 
23.1 24.9 29.1 23.9 24.9 30.1 
22.9 25 28.8 23.9 24.6 29.5 
3 23.1 24.3 28.9 23.7 24.9 29.8 
23.3 25.1 28.9 23.4 24.6 29.5 
23.5 24.5 28.7 23.3 24.6 29.4 
4 23.7 25.1 28.5 23 23.2 28.7 
23.6 24.8 28.5 22.7 23.2 29.1 
23.9 24.6 29.1 22.4 23.9 29.2 
5 22.8 24.7 29 NA 24.3 30.4 
22.9 24.7 28.4 22.9 24.3 29.7 
23 24.5 28.5 22.9 24.9 29.9 
 
SREBF1 
1 23.6 21.3 23.5 23.6 21.3 23.5 
23.3 21.4 23.8 23.3 21.4 23.8 
23.2 21.3 23.6 23.2 21.3 23.6 
2 23.5 21.9 23.8 24.2 20.9 24.0 
23.4 21.2 23.8 24.1 20.9 24.0 
23.4 21.4 23.8 NA 21.0 23.9 
3 23.6 21.8 23.9 23.2 21.0 23.8 
24.0 20.8 23.7 23.4 21.2 23.8 
23.8 21.3 24.0 23.4 21.2 23.7 
4 23.5 21.5 23.1 23.8 21.6 23.9 
23.2 21.2 23.7 23.8 21.6 23.8 
23.7 21.3 23.7 23.9 21.4 23.9 
5 23.3 21.1 23.7 24.0 NA 23.7 
23.8 21.1 23.6 23.4 20.9 23.4 
23.3 21.3 24.2 23.5 20.9 23.4 
 
Primer Set Replicate Intra assay 
Variation 
Inter assay 
variation 
 
LYPLA1 
1 22.5 25.5 21.4 22.5 25.5 21.4 
22.5 25.4 21.2 22.5 25.4 21.2 
22.5 25.3 21.2 22.5 25.3 21.2 
2 22.6 25.3 21.1 22.1 24.9 21.0 
22.6 25.5 21.1 22.1 25.0 21.0 
22.5 24.9 21.2 22.2 25.0 21.1 
3 22.4 25.3 21.5 22.3 25.4 21.2 
22.5 25.6 21.4 22.3 25.4 21.2 
22.4 25.6 21.3 22.5 25.3 21.3 
4 22.7 25.3 21.4 21.9 25.6 21.5 
22.5 25.1 21.3 21.9 25.5 21.4 
22.7 25.1 21.2 22.0 25.5 21.4 
5 22.6 25.6 21.5 22.5 25.5 21.0 
22.5 25.4 21.4 22.4 25.4 21.2 
22.4 25.6 21.3 22.4 25.4 21.2 
 
Β-actin 
1 20.3 19.1 15.4 20.3 19.1 15.4 
20.2 18.7 15.5 20.2 18.7 15.5 
20.3 18.7 15.4 20.3 18.7 15.4 
2 20.4 18.9 15.5 20.0 19.0 15.1 
20.6 18.9 15.5 19.9 19.1 15.0 
20.6 19.2 15.4 20.0 19.0 14.9 
3 20.3 19.2 15.3 20.4 18.8 15.4 
20.3 19.2 15.4 20.3 18.6 15.6 
20.2 19.1 15.5 20.2 18.6 15.6 
4 20.2 18.9 15.2 20.5 18.2 15.4 
20.4 18.9 15.6 20.2 18.5 15.2 
20.4 19.0 15.5 20.0 18.7 15.6 
5 20.7 19.0 15.3 19.8 19.1 15.1 
20.5 18.9 15.4 19.8 19.1 15.5 
20.4 19.0 15.4 20.2 19.0 15.3 
 
Table to represent intra- and inter- variation of all primer sets as discussed in Chapter 2 
section 2.3.5. 
  
 
 
 
 
Appendix 5 
Raw ΔΔCT data for SGBS cells  
Data used in Chapter 3 
 
  
Β-actin referred to as Act throughout 
ΔΔCt Values for LXRβ 
Hyperglycaemic environment at 17 hours 
Vehicle v Acyl-ghrelin (AG) 
Round 1 
ΔCt (Vehicle)= Average LXR Ct- Average Act Ct ΔCt(AG)= Average LXR Ct- AverageActCt 
ΔCt (Vehicle)= 25.68 – 20.39 = 5.28                        ΔCt(AG)= 26.45 – 19.91 = 6.54   
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= 1.26 
             X = 2-ΔΔCt 
             X = 0.41 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -2.39  
 
Round 2 
ΔCt (Vehicle)= Average LXR Ct- Average Act Ct   ΔCt(AG)= Average LXR Ct- AverageActCt 
ΔCt (Vehicle)= 26.79 – 21.16 = 5.63                          ΔCt(AG)= 29.43 – 22.03 = 7.40 
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= 1.78 
             X = 2-ΔΔCt 
             X = 0.29 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -3.42  
Average Fold change and variation 
Fold Change = - 2.39 (±0.7) 
 
 
Hyperglycaemic environment at 34 hours 
Vehicle v Acyl-ghrelin (AG) 
Round 1 
ΔCt (Vehicle)= Average LXR Ct- Average Act Ct   ΔCt(AG)= Average LXR Ct- AverageActCt 
ΔCt (Vehicle)= 25.49 – 19.72 = 5.76                          ΔCt(AG)= 27.39 – 17.90 = 9.49   
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= 3.72 
             X = 2-ΔΔCt 
             X = 0.08 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -13.2  
 
Round 2 
ΔCt (Vehicle)= Average LXR Ct- Average Act Ct ΔCt(AG)= Average LXR Ct- AverageActCt 
ΔCt (Vehicle)= 25.26 – 17.64 = 7.61                        ΔCt(AG)= 29.31– 18.61 = 10.70  
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= 3.09 
             X = 2-ΔΔCt 
             X = 0.29 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -8.5 
Average Fold change and variation 
Fold Change = - 10.84 (±3.4) 
 
 
 
 
Normoglycaemic environment at 17 hours 
Vehicle v Acyl-ghrelin (AG) 
Round 1 
ΔCt (Vehicle)= Average LXR Ct- Average Act Ct  ΔCt(AG)= Average LXR Ct- AverageActCt 
ΔCt (Vehicle)= 25.70 – 24.50 = 1.20                         ΔCt(AG)= 22.41 – 21.08 = 1.33 
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= -0.13 
             X = 2-ΔΔCt 
             X = 1.10 (No change) 
 
Round 2 
ΔCt (Vehicle)= Average LXR Ct- Average Act Ct  ΔCt(AG)= Average LXR Ct- AverageActCt 
ΔCt (Vehicle)= 22.82 – 20.86 = 1.96                         ΔCt(AG)= 23.93– 22.52 = 1.41  
             ΔΔCt= ΔCt (acylG) – ΔCt (vehicle) 
             ΔΔCt= 0.55 
             X = 2-ΔΔCt 
             X = 0.68 (No change) 
Average Fold change and variation 
Fold Change = 0.89 (±0.29) 
 
 
 
 
 
 
 
 
Normoglycaemic environment at 34 hours 
Vehicle v Acyl-ghrelin (AG) 
Round 1 
ΔCt (Vehicle)= Average LXR Ct- Average Act Ct ΔCt(AG)= Average LXR Ct- AverageActCt 
ΔCt (Vehicle)= 24.76 – 21.32 = 3.43                        ΔCt(AG)= 25.60 – 24.07 = 1.53 
             ΔΔCt= ΔCt (acylG) – ΔCt (vehicle) 
             ΔΔCt= -1.90 
             X = 2-ΔΔCt 
             X = 3.74 (Up regulation) 
 
Round 2 
ΔCt (Vehicle)= Average LXR Ct- Average Act Ct     ΔCt(AG)= Average LXR Ct- AverageActCt 
ΔCt (Vehicle)= 25.14 – 21.32 = 3.82                         ΔCt(AG)= 27.04 – 25.29 = 1.75  
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= -1.75 
             X = 2-ΔΔCt 
             X = 3.36 (Up regulation) 
Average Fold change and variation 
Fold Change = +3.55 (±0.27) 
 
 
 
 
 
 
 
 
ΔΔCt Values for ABCG1 
Hyperglycaemic environment at 17 hours 
Vehicle v Acyl-ghrelin (AG) 
Round 1 
ΔCt (Vehicle)= Average ABC Ct- Average Act Ct  ΔCt(AG)= Average ABC Ct- AverageActCt 
ΔCt (Vehicle)= 27.63 – 20.39 = 7.24                         ΔCt(AG)= 28.23 – 19.91 = 8.32   
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= 1.09 
             X = 2-ΔΔCt 
             X = 0.47 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -2.12 
 
Round 2 
ΔCt (Vehicle)= Average ABC Ct- Average Act Ct  ΔCt(AG)= Average ABC Ct- AverageActCt 
ΔCt (Vehicle)= 28.73 – 21.16 = 7.56                         ΔCt(AG)= 31.06 – 22.03 = 9.04 
             ΔΔCt= ΔCt (acylG) – ΔCt (vehicle) 
             ΔΔCt= 1.48 
             X = 2-ΔΔCt 
             X = 0.36 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -2.78  
Average Fold change and variation 
Fold Change = - 2.45 (±0.5) 
 
 
 
Hyperglycaemic environment at 34 hours 
Vehicle v Acyl-ghrelin (AG) 
Round 1 
ΔCt (Vehicle)= Average ABC Ct- Average Act Ct     ΔCt(AG)= Average ABC Ct- AverageActCt 
ΔCt (Vehicle)= 28.84 – 19.72 = 9.12                         ΔCt(AG)= 29.98 – 17.90 = 12.08   
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= 2.96 
             X = 2-ΔΔCt 
             X = 0.13 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = - 7.80 
 
Round 2 
ΔCt (Vehicle)= Average ABC Ct- Average Act Ct  ΔCt(AG)= Average ABC Ct- AverageActCt 
ΔCt (Vehicle)= 25.80 – 17.64 = 8.16                          ΔCt(AG)= 28.98 – 18.61 = 10.37  
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= 2.21 
             X = 2-ΔΔCt 
             X = 0.22 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = - 4.64 
Average Fold change and variation 
Fold Change = - 6.22 (±2.2) 
 
 
 
 
Normoglycaemic environment at 17 hours 
Vehicle v Acyl-ghrelin (AG) 
Round 1 
ΔCt (Vehicle)= Average ABC Ct- Average Act Ct    ΔCt(AG)= Average ABC Ct- Average ActCt 
ΔCt (Vehicle)= 27.73 – 24.50 = 3.23                        ΔCt(AG)= 27.58 – 21.08 = 6.50 
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= 3.27 
             X = 2-ΔΔCt 
             X = 0.10 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = - 9.64 
 
 
Round 2 
ΔCt (Vehicle)= Average ABC Ct- Average Act Ct ΔCt(AG)= Average ABC Ct- Average ActCt 
ΔCt (Vehicle)= 24.82 – 20.86 = 3.96                        ΔCt(AG)= 29.20– 22.52 = 6.68  
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= 2.72 
             X = 2-ΔΔCt 
             X = 0.15 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = - 6.60 
 
Average Fold change and variation 
Fold Change = -8.12 (±2.1) 
 
 
Normoglycaemic environment at 34 hours 
Vehicle v Acyl-ghrelin (AG) 
Round 1 
ΔCt (Vehicle)= Average ABC Ct- Average Act Ct ΔCt(AG)= Average ABC Ct- Average ActCt 
ΔCt (Vehicle)= 27.31 – 21.32 = 5.99                        ΔCt(AG)= 29.49 – 24.07 = 5.42 
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= 0.57 
             X = 2-ΔΔCt 
             X = 0.67 (No change) 
 
Round 2 
ΔCt (Vehicle)= Average ABC Ct- Average Act Ct ΔCt(AG)= Average ABC Ct- Average ActCt 
ΔCt (Vehicle)= 27.62 – 21.32 = 6.30                        ΔCt(AG)= 31.33 – 25.29 = 6.04  
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= -0.3 
             X = 2-ΔΔCt 
             X = 1.20 (No change) 
Average Fold change and variation 
Fold Change = 0.94 (±0.4) 
 
 
 
 
 
 
 
 
ΔΔCt Values for SREBF1 
Hyperglycaemic environment at 17 hours 
Vehicle v Acyl-ghrelin (AG) 
Round 1 
ΔCt (Vehicle)= Average SRB Ct- Average Act Ct ΔCt(AG)= Average SRB Ct- Average ActCt 
ΔCt (Vehicle)= 35.12 – 20.39 = 14.72                      ΔCt(AG)= 34.21 – 19.91 = 14.30  
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= -0.42 
             X = 2-ΔΔCt 
             X = 1.34 (No change) 
 
Round 2 
ΔCt (Vehicle)= Average SRB Ct- Average Act Ct ΔCt(AG)= Average SRB Ct- Average ActCt 
ΔCt (Vehicle)= 35.09 – 21.16 = 13.92                      ΔCt(AG)= 35.35 – 22.03 = 13.33 
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= -0.59 
             X = 2-ΔΔCt 
             X = 1.50 (No change) 
Average Fold change and variation 
Fold Change = 1.42 (±0.1) 
 
 
 
 
 
 
 
Hyperglycaemic environment at 34 hours 
Vehicle v Acyl-ghrelin (AG) 
Round 1 
ΔCt (Vehicle)= Average SRB Ct- Average Act Ct ΔCt(AG)= Average SRB Ct- Average ActCt 
ΔCt (Vehicle)= 33.93 – 19.72 = 14.20                      ΔCt(AG)= 32.47 – 17.90 = 14.57  
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= 0.37 
             X = 2-ΔΔCt 
             X = 0.77 (No change) 
 
Round 2 
ΔCt (Vehicle)= Average SRB Ct- Average Act Ct ΔCt(AG)= Average SRB Ct- Average ActCt 
ΔCt (Vehicle)= 32.38 – 17.64 = 14.74                      ΔCt(AG)= 33.62 – 18.61 = 15.01  
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= -0.27 
             X = 2-ΔΔCt 
             X = 1.20 (No change) 
 
Average Fold change and variation 
Fold Change = 1.0 (±0.3) 
 
 
 
 
 
 
 
Normoglycaemic environment at 17 hours 
Vehicle v Acyl-ghrelin (AG) 
Round 1 
ΔCt (Vehicle)= Average SRB Ct- Average Act Ct ΔCt(AG)= Average SRB Ct- Average ActCt 
ΔCt (Vehicle)= 34.99 – 24.50 = 10.49                      ΔCt(AG)= 32.51 – 21.08 = 11.44             
ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= -0.95 
             X = 2-ΔΔCt 
             X = 1.93 (Up regulated) 
 
Round 2 
ΔCt (Vehicle)= Average SRB Ct- Average Act Ct     ΔCt(AG)= Average SRB Ct- Average ActCt 
ΔCt (Vehicle)= 31.55 – 20.86 = 10.69                       ΔCt(AG)= 33.98 – 22.52 = 11.46  
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= -0.77 
             X = 2-ΔΔCt 
             X = 1.71 (Up regulated) 
 
Average Fold change and variation 
Fold Change = +1.82 (±0.2) 
 
 
 
 
 
 
 
 
Normoglycaemic environment at 34 hours 
Vehicle v Acyl-ghrelin (AG) 
Round 1 
ΔCt (Vehicle)= Average SRB Ct- Average Act Ct ΔCt(AG)= Average SRB Ct- Average ActCt 
ΔCt (Vehicle)= 33.68 – 21.32 = 12.35                      ΔCt(AG)= 32.51 – 24.07 = 11.44 
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= -2.22 
             X = 2-ΔΔCt 
             X = 4.65 (Up regulated) 
 
Round 2 
ΔCt (Vehicle)= Average SRB Ct- Average Act Ct     ΔCt(AG)= Average SRB Ct- Average ActCt 
ΔCt (Vehicle)= 33.78 – 21.32 = 12.46                       ΔCt(AG)= 34.91 – 25.29 = 9.62  
             ΔΔCt= ΔCt (AG) – ΔCt (vehicle) 
             ΔΔCt= -2.84 
             X = 2-ΔΔCt 
             X = 7.14 (Up regulated) 
Average Fold change and variation 
Fold Change = +5.90 (±1.8) 
 
 
  
 
 
 
 
 
 
 
Appendix 6 
Raw ΔΔCT data for hVAT  
Data used in Chapter 4 
  
Β-actin referred to as Act throughout 
ABCG1 
Non-obese v Obese 
ΔCt (NO)= AverageABCG1Ct- AverageActCt   ΔCt(O)= AverageABCG1Ct- AverageActCt 
ΔCt (NO)= 26.49-18.79= 7.70                            ΔCt(O)= 26.70 – 19.04 =7.95 
            ΔΔCt= ΔCt (O) – ΔCt (NO) 
             ΔΔCt= 0.25 
             X = 2-ΔΔCt 
             X = 0.84 (no change) 
Non-obese v OT2D 
ΔCt (NO)= AverageABCG1Ct-AverageActCt  ΔCt(OT2D)= AverageABCG1Ct-AverageActCt 
ΔCt (NO)= 26.49-18.79= 7.70                           ΔCt(OT2D)= 27.80 -18.83 =8.97 
             ΔΔCt= ΔCt (OT2DM) – ΔCt (NO) 
             ΔΔCt= 1.27 
             X = 2-ΔΔCt 
             X = 0.41 (down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -2.44 
Obese (O) v OT2DM 
ΔCt (O)= AverageABCG1Ct-AverageActCt       ΔCt(OT2D)= AverageABCG1Ct- AverageActCt                                            
ΔCt(O)= 26.70 – 19.04 =7.95                             ΔCt(OT2D)= 27.80 -18.83 =8.97 
             ΔΔCt= ΔCt (OT2D) – ΔCt (O) 
             ΔΔCt= 1.02 
             X = 2-ΔΔCt 
             X = 0.49 (down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -2.04 
Obesity effect 
NO v Obese (O+OT2D) 
ΔCt (NO)= AverageABCG1Ct- AverageActCt    ΔCt(O+OT2D)= AverageABCG1Ct-AverageActCt 
ΔCt (NO)= 26.49-18.79= 7.70                              ΔCt= 8.36 
            ΔΔCt= ΔCt (O+OT2D) – ΔCt (NO) 
             ΔΔCt= 0.66 
             X = 2-ΔΔCt 
             X = 0.63 (no change) 
 
Diabetes effect 
No Diabetes (NO+O) v OT2D 
ΔCt (NO=O)= AverageABCG1Ct- AverageActCt    ΔCt(OT2D)= AverageABCG1Ct-AverageActCt 
Ct = 7.82                               ΔCt= 8.96 
            ΔΔCt= ΔCt (OT2D) – ΔCt (NO+O) 
             ΔΔCt= 1.14 
             X = 2-ΔΔCt 
             X = 0.45 (down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -2.22 
 
 
 
 
 
 
 
 
LXRβ 
Non-obese v Obese 
ΔCt (NO)= AverageLXRβCt- AverageActCt ΔCt(O)= AverageLXRβCt- AverageActCt 
ΔCt (NO)= 25.89 – 18.79 = 7.10                            ΔCt(O)= 26.59 -19.04 = 7.55   
             ΔΔCt= ΔCt (O) – ΔCt (NO) 
             ΔΔCt= 0.45 
             X = 2-ΔΔCt 
             X = 0.73 (no change) 
Non-obese v OT2D 
ΔCt (NO)= AverageLXRβCt- AverageActCt       ΔCt(OT2D)= AverageLXRβCt- AverageActCt 
ΔCt (NO)= 25.89 – 18.79 = 7.10                         ΔCt(OT2D)= 27.72-19.15 = 8.57 
             ΔΔCt= ΔCt (OT2D) – ΔCt (NO) 
             ΔΔCt= 1.47 
             X = 2-ΔΔCt 
             X = 0.36 (down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -2.78 
 
Obese v OT2D 
ΔCt (O)= AverageLXRβCt- AverageActCt      ΔCt(OT2D)= AverageLXRβCt- AverageActCt 
ΔCt(O)= 26.59 -19.04 = 7.55                           ΔCt(OT2D)= 27.72-19.15 = 8.57 
             ΔΔCt= ΔCt (OT2D) – ΔCt (O) 
             ΔΔCt= 1.02 
             X = 2-ΔΔCt 
             X = 0.49 (down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -2.04 
Obesity effect 
Non-obese v Obese (O+OT2D) 
ΔCt (NO)= AverageLXRβCt- AverageActCt       ΔCt(O+OT2D)= AverageLXRβCt- AverageActCt 
ΔCt (leans)= 7.14                                                   ΔCt(O+OT2D)= 26.59 -19.04 = 8.13 
             ΔΔCt= ΔCt (O+OT2D) – ΔCt (NO) 
             ΔΔCt= 0.99 
             X = 2-ΔΔCt 
             X = 0.50 (no change) 
 
Diabetes effect 
(NO+O) v OT2D 
ΔCt (NO+O)= AverageLXRβCt- AverageActCt        ΔCt(OT2D)= AverageLXRβCt- AverageActCt 
ΔCt(NO+O)= 7.42                                            ΔCt(OT2D)= 27.72-19.15 = 8.57 
             ΔΔCt= ΔCt (OT2D) – ΔCt (NO+O) 
             ΔΔCt= 1.15 
             X = 2-ΔΔCt 
             X = 0.45 (down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -2.22 
 
 
 
 
 
 
 
 
PPARγ 
Non-obese v Obese 
ΔCt (NO)= AveragePPARγCt-AverageActCt      ΔCt(O)= AveragePPARγCt- AverageActCt 
ΔCt (NO)= 2.84                                                     ΔCt(O)= 3.30 
             ΔΔCt ΔCt (O) – ΔCt (NO) 
             ΔΔCt= 0.46 
             X = 2-ΔΔCt 
             X = 0.73 (no change) 
Non-obese v OT2DM 
ΔCt (NO)= AveragePPARγCt-AverageActCt    ΔCt(OT2D)= AveragePPARγCt-AverageActCt 
ΔCt (NO)= 2.84                                      ΔCt(OT2D)= 3.44 
             ΔΔCt= ΔCt (OT2D) – ΔCt (NO) 
             ΔΔCt= 0.6 
             X = 2-ΔΔCt 
             X = 0.66 (no change) 
 
Obese v OT2D 
ΔCt (O)= AveragePPARγCt-AverageActCt   ΔCt(OT2D)= AveragePPARγCt-AverageActCt 
ΔCt (O)= 3.30                                                    ΔCt(OT2D)= 3.44 
             ΔΔCt= ΔCt (OT2DM) – ΔCt (obese) 
             ΔΔCt= 0.14 
             X = 2-ΔΔCt 
             X = 0.91 (no change) 
 
 
 
 
Obesity effect 
Non-obese v Obese (O+OT2D) 
ΔCt (NO)= AveragePPARγCt-AverageActCt     ΔCt(O+OT2D)= AveragePPARγCt- AverageActCt 
ΔCt (NO)= 2.84                                                 ΔCt(O+OT2D)= 3.37 
             ΔΔCt ΔCt (O+OT2D) – ΔCt (NO) 
             ΔΔCt= 0.53 
             X = 2-ΔΔCt 
             X = 0.69 (no change) 
 
 
Diabetes effect 
(NO+O) v OT2DM 
ΔCt (NO+O)= AveragePPARγCt- AverageActCt    ΔCt(OT2D)= AveragePPARγCt- AverageActCt 
ΔCt (NO+O)= 3.07                                                      ΔCt(OT2D)= 3.44 
             ΔΔCt= ΔCt (OT2D) – ΔCt (NO+O) 
             ΔΔCt= 0.37 
             X = 2-ΔΔCt 
             X = 0.77 (no change) 
 
 
 
 
 
 
 
 
 
SREBF1 
Non-obese v Obese 
ΔCt (NO)= AverageSREBF1Ct- AverageActCt     ΔCt(O)= AverageSREBF1Ct- AerageActCt 
ΔCt (NO)= 27.61 – 18.79 =  8.82                           ΔCt(O)= 27.70 – 19.04 = 8.66 
             ΔΔCt= ΔCt (O) – ΔCt (NO) 
             ΔΔCt= -0.16 
             X = 2-ΔΔCt 
             X = 1.12 (no change) 
Non-obese v OT2D 
ΔCt (NO)= AverageSREBF1Ct-AverageActCt    ΔCt(OT2D)= AverageSREBF1Ct-averageActCt 
ΔCt (lNO)= 27.61 – 18.79 =  8.82                       ΔCt(OT2D )= 29.40 – 19.15 = 10.25 
             ΔΔCt= ΔCt (OT2D) – ΔCt (NO) 
             ΔΔCt= 1.43 
             X = 2-ΔΔCt 
             X = 0.37 (down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -2.70  
 
Obese v OT2DM 
ΔCt(O)= AverageSREBF1Ct-AverageActCt    ΔCt(OT2D)= AverageSREBF1Ct- AverageActCt                                                                                            
ΔCt(O)= 27.70 – 19.04 = 8.66                    ΔCt(OT2D )= 29.40 – 19.15 = 10.25 
             ΔΔCt= ΔCt (OT2D) – ΔCt (O) 
             ΔΔCt= 1.59 
             X = 2-ΔΔCt 
X = 0.33 (down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -3.03  
Obesity effect 
Non-obese v Obese (O+OT2DM) 
ΔCt (leans)= AverageSREBF1Ct-AverageActCt   ΔCt(Obese)= AverageSREBF1Ct-AverageActCt 
ΔCt (leans)= 27.61 – 18.79 =  8.82                       ΔCt(Obese)= 27.70 – 19.04 = 9.46 
             ΔΔCt= ΔCt (Obese) – ΔCt (lean) 
             ΔΔCt= 0.64 
             X = 2-ΔΔCt 
             X = 0.64 (no change) 
 
 
(NO+O) v OT2DM 
ΔCt (NO+O)= AverageSREBF1Ct-AverageActCt   ΔCt(OT2D)= AverageSREBF1Ct-AverageActCt 
ΔCt(NO+O)=8.74                                                       ΔCt(OT2D)= 29.40 – 19.15 = 10.26 
             ΔΔCt= ΔCt (OT2D) – ΔCt (NO+O) 
             ΔΔCt= 1.52 
             X = 2-ΔΔCt 
X = 0.35 (down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = -2.86  
 
 
 
 
 
 
 
 
Ghrelin 
Non-obese v Obese 
ΔCt (NO)= Average Ghrel Ct- Average Act Ct     ΔCt(O)= AverageGhrelCt- AverageActCt 
ΔCt (NO)= 30.29 – 18.50 = 11.38                                 ΔCt(O)= 29.77 – 19.04= 10.72 
             ΔΔCt= ΔCt (O) – ΔCt (NO) 
             ΔΔCt= -0.66 
             X = 2-ΔΔCt          
             X = 1.58 (up regulation) 
             Fold change = 1.58 
 
Non-obese v OT2D 
ΔCt (NO)= AverageGhrelCt-AverageActCt      ΔCt(OT2D) = AverageGhrelCt-AverageActCt 
ΔCt (NO)= 30.29 – 18.50 = 11.38                      ΔCt(OT2D) = 31.14 – 19.10= 12.13 
             ΔΔCt= ΔCt (OT2D) – ΔCt (NO) 
             ΔΔCt= 0.78 
             X = 2-ΔΔCt 
             X = 0.58 (no change) 
 
Obese v OT2D 
ΔCt (O)= AverageGhrelCt-AverageActCt      ΔCt(OT2D)= AverageGhrelCt-AverageActCt 
ΔCt(O)= 29.77 – 19.04= 10.72                        ΔCt(OT2D)= 31.14 – 19.10= 12.13 
             ΔΔCt= ΔCt (OT2D) – ΔCt (O) 
             ΔΔCt= 1.41 
             X = 2-ΔΔCt 
             X = 0.38 (down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change= - 2.6  
Obesity effect 
Non-obese v Obese (O+OT2D) 
ΔCt (NO)= AverageGhrelCt- AverageActCt        ΔCt(O+OT2D)= AverageGhrelCt-AverageActCt 
ΔCt (NO)= 30.29 – 18.50 = 11.38                         ΔCt(O+OT2D)= 11.43 
             ΔΔCt= ΔCt (O) – ΔCt (lean) 
             ΔΔCt= 0.05 
             X = 2-ΔΔCt 
             X = 0.97 (no change) 
 
Diabetes effect 
(NO+O) v OT2D 
ΔCt(NO+O)= AverageGhrelCt-AverageActCt      ΔCt(OT2D) = AverageGhrelCt-AverageActCt 
ΔCt (NO+O)= 11.05                           ΔCt(OT2D) = 31.14 – 19.10= 12.13 
             ΔΔCt= ΔCt (OT2D) – ΔCt (NO+O) 
             ΔΔCt= 1.08 
             X = 2-ΔΔCt 
             X = 0.47 (down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change= -2.1  
 
 
 
 
 
 
 
 
mBOAT4 (GOAT) 
Non-obese v Obese 
ΔCt (NO)= AverageGOATCt-AverageActCt      ΔCt(O)=AverageGOATCt-AverageActCt 
ΔCt (NO)= 10.05                                                   ΔCt(O)= 10.23 
             ΔΔCt= ΔCt (O) – ΔCt (NO) 
             ΔΔCt= 0.18 
             X = 2-ΔΔCt 
             X = 0.88 (no change) 
 
Non-obese v OT2D 
ΔCt (NO)= AverageGOATCt-AverageActCt      ΔCt(OT2D)=AverageGOATCt-AverageActCt 
ΔCt (NO)= 10.05                        ΔCt(OT2D)= 10.64 
             ΔΔCt= ΔCt (OT2D) – ΔCt (NO) 
             ΔΔCt= 0.59 
             X = 2-ΔΔCt 
             X = 0.66 (no change) 
 
Obese v OT2D 
ΔCt (O)= AverageGOATCt-AverageActCt     ΔCt(OT2D)=AverageGOATCt-AverageActCt 
ΔCt (O)= 10.23                                                   ΔCt(OT2D)= 10.64 
             ΔΔCt= ΔCt (OT2D) – ΔCt (O) 
             ΔΔCt= 0.41 
             X = 2-ΔΔCt 
             X = 0.75 (no change) 
 
 
 
Obesity effect 
Non-obese v Obese (O+OT2D) 
ΔCt (NO)= AverageGOATCt-AverageActCt         ΔCt(O+OT2D)=AverageGOATCt-AverageActCt 
ΔCt (NO)= 10.05                                                      ΔCt(O+OT2D)= 10.44 
             ΔΔCt= ΔCt (O+OT2D) – ΔCt (NO) 
             ΔΔCt= 0.39 
             X = 2-ΔΔCt 
             X = 0.76 (no change) 
 
Diabetes effect 
(NO+O) v OT2D 
ΔCt (NO+O)= AverageGOATCt-AverageActCt        ΔCt(OT2D)= AverageGOATCt-AverageActCt 
ΔCt(NO+O)= 10.15                                                      ΔCt(OT2D)= 10.64 
             ΔΔCt= ΔCt (OT2D) – ΔCt (NO+O) 
             ΔΔCt= 0.49 
             X = 2-ΔΔCt 
             X = 0.71 (no change) 
 
 
 
 
 
 
 
 
 
 
Lypla 
Non-obese v Obese 
ΔCt (NO)= AverageLyplaCt - AverageActCt        ΔCt(O)= AverageLyplaCt- AverageActCt 
ΔCt (NO)= 24.40 – 18.79 = 5.61                           ΔCt(O)= 18.79 – 19.04 = 5.07 
             ΔΔCt= ΔCt (O) – ΔCt (NO) 
             ΔΔCt= -0.54 
             X = 2-ΔΔCt 
             X = 1.45 (no change) 
 
Non-obese v OT2D 
ΔCt (NO)= AverageLyplaCt- AverageActCt       ΔCt(OT2D) =AverageLyplaCt-AverageActCt 
ΔCt (NO)= 24.40 – 18.79 = 5.61                         ΔCt(OT2D)= 24.58 – 19.15 = 5.43 
             ΔΔCt= ΔCt (OT2D) – ΔCt (NO) 
             ΔΔCt= -0.18 
             X = 2-ΔΔCt 
             X = 1.13 (no change) 
 
Obese v OT2D 
ΔCt (O)= AverageLyplaCt-AverageActCt       ΔCt(OT2D)= AverageLyplaCt-AverageActCt 
ΔCt(O)= 18.79 – 19.04 = 5.07                         ΔCt(OT2D)= 24.58 – 19.15 = 5.43 
             ΔΔCt= ΔCt (OT2D) – ΔCt (O) 
             ΔΔCt= 0.36 
             X = 2-ΔΔCt 
             X = 0.78 (no change) 
 
 
 
Obesity effect 
Non-obese v Obese (O+OT2D) 
ΔCt (NO)= AverageLyplaCt- AverageActCt         ΔCt(O+OT2D)= AverageLyplaCt-AverageActCt 
ΔCt (NO)= 24.40 – 18.79 = 5.61                           ΔCt(O+OT2D)= 5.25 
             ΔΔCt= ΔCt (O+OT2D) – ΔCt (NO) 
             ΔΔCt= -0.36 
             X = 2-ΔΔCt 
             X = 1.28 (no change) 
 
Diabetes effect 
(NO+O) v OT2D 
ΔCt (NO+O)= AverageLyplaCt- AverageActCt      ΔCt(OT2D)= AverageLyplaCt- AverageActCt 
ΔCt (NO+O)= 5.34                                                     ΔCt(OT2D)= 24.58 – 19.15 = 5.43 
             ΔΔCt= ΔCt (OT2D) – ΔCt (NO+O) 
             ΔΔCt= 0.09 
             X = 2-ΔΔCt 
             X = 0.94 (no change) 
 
 
  
 
 
 
 
 
 
 
 
Appendix 7 
Raw ΔΔCT data for SGBS cells with 
metformin treatment 
Data used in Chapter 5 
 
ΔΔCt Values for Metformin 
Vehicle (V) V Metformin (Met) treatment 
ΔΔCt Values for LXRβ 
Round 1 
ΔCt (V) = Average LXR Ct- Average Act Ct   ΔCt(Met) = Average LXR Ct- AverageActCt 
ΔCt (V) = 25.68 – 20.39 = 5.28                                    ΔCt(Met) = 26.11 – 22.59 = 3.52 
             ΔΔCt = ΔCt (Met) – ΔCt (V) 
             ΔΔCt = -1.76 
             X = 2-ΔΔCt 
             X = 3.39 (Up regulated) 
 
Round 2 
ΔCt (V) = Average LXR Ct- Average Act Ct   ΔCt(Met) = Average LXR Ct- AverageActCt 
ΔCt (V) = 26.79 – 21.16 = 5.63                                    ΔCt(Met) =25.61 – 21.81 = 3.80 
             ΔΔCt = ΔCt (Met) – ΔCt (V) 
             ΔΔCt = -1.83 
             X = 2-ΔΔCt 
             X = 3.56 (Up regulated) 
 
Average Fold change and variation 
Fold Change = 3.47 (±0.1) 
 
 
 
 
 
 
ΔΔCt Values for ABCG1 
Round 1 
ΔCt (V) = Average ABC Ct- Average Act Ct   ΔCt(Met) = Average ABC Ct- AverageActCt 
ΔCt (V) = 27.63 – 20.39 = 7.24                                    ΔCt(Met) =24.53 – 22.59 = 1.94  
             ΔΔCt = ΔCt (Met) – ΔCt (V) 
             ΔΔCt = - 5.3 
             X = 2-ΔΔCt 
             X = 39.40 (Up regulated)  
 
Round 2 
ΔCt (V)= Average ABC Ct- Average Act Ct   ΔCt(Met)= Average ABC Ct- AverageActCt 
ΔCt (V)= 28.73 – 21.16 = 7.57                                     ΔCt(Met)= 24.18 – 21.81 = 2.37 
             ΔΔCt= ΔCt (Met) – ΔCt (V) 
             ΔΔCt= -5.2 
             X = 2-ΔΔCt  
             X = 36.76 (Up regulated) 
     
Average Fold change and variation 
Fold Change = 38.08 (±1.9) 
 
 
 
 
 
 
 
 
ΔΔCt Values for SREBF1 
Round 1 
ΔCt (V) = Average SRB Ct- Average Act Ct   ΔCt(Met) = Average SRB Ct- AverageActCt 
ΔCt (V) = 35.21 – 20.39 = 14.82                                  ΔCt(Met) = 35.45 – 22.59 = 12.86  
             ΔΔCt = ΔCt (Met) – ΔCt (V) 
             ΔΔCt = -1.96 
             X = 2-ΔΔCt 
             X = 3.89 (Up regulated) 
Round 2 
ΔCt (V)= Average SRB Ct- Average Act Ct                  ΔCt(Met)= Average SRB Ct- AverageActCt 
ΔCt (V)= 35.09 – 21.16 = 13.92                                   ΔCt(Met)= 34.24 – 21.82 = 12.43 
             ΔΔCt= ΔCt (Met) – ΔCt (V) 
             ΔΔCt= -1.49 
             X = 2-ΔΔCt 
             X = 2.81 (Up regulated) 
 
Average Fold change and variation 
Fold Change = 3.35 (±0.8) 
 
 
 
 
 
 
 
 
 
Metfromin (Met) V Met and AG treatment 
ΔΔCt Values for LXRβ 
Round 1 
ΔCt (Met) = Average LXR Ct- Average Act Ct     ΔCt(Met+AG) = Average LXR Ct- AverageActCt 
ΔCt (Met) = 26.11 – 22.59 = 3.52                           ΔCt(Met+AG) = 28.20 – 19.71 = 8.49  
             ΔΔCt = ΔCt (Met+&AG) – ΔCt (Met) 
             ΔΔCt = 4.97 
             X = 2-ΔΔCt 
             X = 0.03 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = - 31.3 
 
Round 2 
ΔCt (AG)= Average LXR Ct- Average Act C         ΔCt(Met+AG)= Average LXR Ct- AverageActCt 
ΔCt (AG)= 25.61 – 21.81 = 3.80                           ΔCt(Met+AG)= 32.95 – 23.88 = 9.07  
             ΔΔCt= ΔCt (Met+AG) – ΔCt (Met) 
             ΔΔCt= 5.27 
             X = 2-ΔΔCt 
             X = 0.03 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = - 38.6 
 
Average Fold change and variation 
Fold Change = - 34.2 (±4.0) 
 
 
 
ΔΔCt Values for ABCG1 
Round 1 
ΔCt (Met) = Average ABC Ct- Average Act Ct   ΔCt(Met+AG) = Average ABC Ct- AverageActCt 
ΔCt (Met) = 24.53 – 22.59 = 1.94                       ΔCt(Met+AG) = 26.82 – 19.71 = 7.11  
             ΔΔCt = ΔCt (Met+AG) – ΔCt (Met) 
             ΔΔCt = 5.17 
             X = 2-ΔΔCt 
             X = 0.03 (Downregulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = - 36.0 
 
Round 2 
ΔCt (Met)= Average ABC Ct- Average Act Ct    ΔCt(Met+AG)= Average ABC Ct- AverageActCt 
ΔCt (Met)= 24.18 – 21.81 = 2.37                         ΔCt(Met+AG)= 31.36 – 23.88 = 7.48  
             ΔΔCt= ΔCt (Met+AG) – ΔCt (Met) 
             ΔΔCt= 5.11 
             X = 2-ΔΔCt 
             X = 0.03 (Downregulated) 
As down regulated (x <0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = - 34.5 
 
Average Fold change and variation 
Fold Change = -35.1 (±0.9) 
 
 
 
 
ΔΔCt Values for SREBF1 
Round 1 
ΔCt (Met) = Average SRB Ct- Average Act C     ΔCt(Met+AG) = Average SRB Ct- AverageActCt 
ΔCt (Met) = 35.45 – 22.59 = 12.86                       ΔCt(Met+AG) = 32.10 – 19.71 = 12.39 
             ΔΔCt = ΔCt (Met+AG) – ΔCt (Met) 
             ΔΔCt = -0.47 
             X = 2-ΔΔCt 
             X = 0.72 (No change) 
Round 2 
ΔCt (Met)= Average SRB Ct- Average Act Ct      ΔCt(Met+AG)= Average SRB Ct- AverageActCt 
ΔCt (Met)= 34.24 – 21.82 = 12.43                        ΔCt(Met+AG)= 35.54 – 23.88 = 11.66 
             ΔΔCt= ΔCt (Met+AG) – ΔCt (Met) 
             ΔΔCt= -0.77 
             X = 2-ΔΔCt 
             X = 0.59 (No change) 
 
Average Fold change and variation 
Fold Change = 0.65 (±0.2) 
 
 
 
 
 
 
 
 
 
Acyl Ghrelin (AG) V Met and AG treatment 
ΔΔCt Values for LXRβ 
Round 1 
ΔCt (AG) = Average LXR Ct- Average Act Ct       ΔCt(Met+AG) = Average LXR Ct- AverageActCt 
ΔCt (AG) = 26.45 – 19.91 = 6.54                           ΔCt(Met+AG) = 28.20 – 19.71 = 8.49  
             ΔΔCt = ΔCt (Met+&AG) – ΔCt (AG) 
             ΔΔCt = 1.95 
             X = 2-ΔΔCt 
             X = 0.26 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = - 3.85 
 
Round 2 
ΔCt (AG)= Average LXR Ct- Average Act C         ΔCt(Met+AG)= Average LXR Ct- AverageActCt 
ΔCt (AG)= 29.43 – 22.03 = 7.4                              ΔCt(Met+AG)= 32.95 – 23.88 = 9.07  
             ΔΔCt= ΔCt (Met+AG) – ΔCt (AG) 
             ΔΔCt= 1.67 
             X = 2-ΔΔCt 
             X = 0.31 (Down regulated) 
As down regulated (x < 0.5); 𝐹𝑜𝑙𝑑 𝑐ℎ𝑎𝑛𝑔𝑒 =
1
𝑋
 
Fold change = - 3.23 
 
Average Fold change and variation 
Fold Change = - 3.54 (±0.4) 
 
 
 
ΔΔCt Values for ABCG1 
Round 1 
ΔCt (AG) = Average ABC Ct- Average Act Ct   ΔCt(Met+AG) = Average ABC Ct- AverageActCt 
ΔCt (AG) = 28.24 – 19.91 = 8.33                       ΔCt(Met+AG) = 26.82 – 19.71 = 7.11  
             ΔΔCt = ΔCt (Met+AG) – ΔCt (AG) 
             ΔΔCt = - 1.22 
             X = 2-ΔΔCt 
             X = 2.33 (Up regulated) 
 
Round 2 
ΔCt (AG)= Average ABC Ct- Average Act Ct       ΔCt(Met+AG)= Average ABC Ct- AverageActCt 
ΔCt (AG)= 30.89 – 22.03 = 8.86                           ΔCt(Met+AG)= 31.36 – 23.88 = 7.48  
             ΔΔCt= ΔCt (Met+AG) – ΔCt (AG) 
             ΔΔCt= -1.38 
             X = 2-ΔΔCt 
             X = 2.60 (Up regulated) 
 
Average Fold change and variation 
Fold Change = 2.47 (±0.2) 
 
 
 
 
 
 
 
 
ΔΔCt Values for SREBF1 
Round 1 
ΔCt (AG) = Average SRB Ct- Average Act C        ΔCt(Met+AG) = Average SRB Ct- AverageActCt 
ΔCt (AG) = 34.25 – 19.91 = 14.34                        ΔCt(Met+AG) = 32.10 – 19.71 = 12.39 
             ΔΔCt = ΔCt (Met+AG) – ΔCt (AG) 
             ΔΔCt = -1.95 
             X = 2-ΔΔCt 
             X = 3.86 (Up regulated) 
Round 2 
ΔCt (AG)= Average SRB Ct- Average Act Ct        ΔCt(Met+AG)= Average SRB Ct- AverageActCt 
ΔCt (AG)= 25.36 – 22.03 = 13.33                          ΔCt(Met+AG)= 35.54 – 23.88 = 11.66 
             ΔΔCt= ΔCt (Met+AG) – ΔCt (AG) 
             ΔΔCt= -1.67 
             X = 2-ΔΔCt 
             X = 3.18 (Up regulated) 
 
Average Fold change and variation 
Fold Change = 3.52 (±0.5) 
 
 
 
 
 
 
 
 
 
Appendix 8 
Publications 
Publication redacted due to copyright 
restrictions
  
 
 
 
 
 
 
 
 
 
Appendix 9 
Conference lists 
 
 
 
 
 
 
 
 
 
 
British Obesity & Metabolism Surgery Society January 2016- oral presentation  
Churm R, Barry JD, Caplin S, Eyre N, Davies JS, Stephens JW & Prior SL.  
Cholesterol efflux in obesity related type 2 diabetes: Effects of glucose and ghrelin. 
 
Diabetes UK March 2016- poster presentation 
Churm R, Barry JD, Davies JS, Stephens JW & Prior SL.  
The effect of glucose on cholesterol efflux in obesity related Type 2 diabetes. 
In Diabetic Medicine (Vol. 33, pp. 82-82)  
 
WEDS May 2016- poster presentation 
Churm R, Barry JD, Davies JS, Stephens JW & Prior SL.  
The effect of glucose on cholesterol efflux in obesity related Type 2 diabetes. 
 
Diabetes UK March 2017- poster presentation 
Churm R, Barry JD, Davies JS, Stephens JW & Prior SL.  
Effect of increased endogenous glucose levels within Type 2 diabetes on cellular 
lipid profiles 
In Endocrine Abstracts (2017) 48 P2. 
European Association of the Study of Diabetes (EASD) September 2017- poster 
presentation 
Churm R, Caplin S, Barry J, Davies JS, Stephens JW, Prior SL 
The role of acyl ghrelin in human visceral adipose tissue in relation to the LXR-ABC 
pathway and the metabolic state. 
In DIABETOLOGIA (Vol. 60, pp. S270-S271). 
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